BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, Van Assche G, Axler J, Kim HJ, Danese S, Fox I, Milch C, Sankoh S, Wyant T, Xu J, Parikh A; GEMINI 1 Study Group. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369:699-710. [PMID: 23964932 DOI: 10.1056/nejmoa1215734] [Cited by in Crossref: 1251] [Cited by in F6Publishing: 1286] [Article Influence: 139.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhang Z, Zheng CQ. Vedolizumab in the treatment of immune checkpoint inhibitor-induced colitis: Two case reports. World J Clin Cases 2022; 10(29): 10550-10558 [DOI: 10.12998/wjcc.v10.i29.10550] [Reference Citation Analysis]
2 Pavlidis P, Tsakmaki A, Treveil A, Li K, Cozzetto D, Yang F, Niazi U, Hayee BH, Saqi M, Friedman J, Korcsmaros T, Bewick G, Powell N. Cytokine responsive networks in human colonic epithelial organoids unveil a molecular classification of inflammatory bowel disease. Cell Rep 2022;40:111439. [PMID: 36170836 DOI: 10.1016/j.celrep.2022.111439] [Reference Citation Analysis]
3 Choi S, Kim ES, Kwon Y, Kim MJ, Choe YH, Choe BH, Kang B. Vedolizumab Is Safe and Efficacious for the Treatment of Pediatric-Onset Inflammatory Bowel Disease Patients Who Fail a Primary Biologic Agent. J Korean Med Sci 2022;37:e282. [PMID: 36163478 DOI: 10.3346/jkms.2022.37.e282] [Reference Citation Analysis]
4 Burdge G, Hardman A, Carbery I, Broglio G, Greer D, Selinger CP. Uptake of a Switching Program for Patients Receiving Intravenous Infliximab and Vedolizumab to Subcutaneous Preparations. JCM 2022;11:5669. [DOI: 10.3390/jcm11195669] [Reference Citation Analysis]
5 Vieujean S, D’amico F, Netter P, Danese S, Peyrin‐biroulet L. Landscape of new drugs and targets in inflammatory bowel disease. UEG Journal. [DOI: 10.1002/ueg2.12305] [Reference Citation Analysis]
6 Iizuka M, Etou T, Sagara S. Efficacy of cytapheresis in patients with ulcerative colitis showing insufficient or lost response to biologic therapy. World J Gastroenterol 2022; 28(34): 4959-4972 [DOI: 10.3748/wjg.v28.i34.4959] [Reference Citation Analysis]
7 Lin SN, Musso A, Wang J, Mukherjee PK, West GA, Mao R, Lyu R, Li J, Zhao S, Elias M, Haberman Y, Denson LA, Kugathasan S, Chen MH, Czarnecki D, Dejanovic D, Le HT, Chandra J, Lipman J, Steele SR, Nguyen QT, Fiocchi C, Rieder F. Human Intestinal Myofibroblasts DepositED COLLAGEN VI EnhanceS Adhesiveness for T cells - A Novel Mechanism for Maintenance of Intestinal Inflammation. Matrix Biol 2022:S0945-053X(22)00113-5. [PMID: 36108990 DOI: 10.1016/j.matbio.2022.09.001] [Reference Citation Analysis]
8 Zhang T, Zhang B, Tian W, Wang F, Zhang J, Ma X, Wei Y, Tang X. Research trends in ulcerative colitis: A bibliometric and visualized study from 2011 to 2021. Front Pharmacol 2022;13:951004. [DOI: 10.3389/fphar.2022.951004] [Reference Citation Analysis]
9 Hahn GD, LeBlanc JF, Golovics PA, Wetwittayakhlang P, Qatomah A, Wang A, Boodaghians L, Liu Chen Kiow J, Al Ali M, Wild G, Afif W, Bitton A, Lakatos PL, Bessissow T. Effectiveness, safety, and drug sustainability of biologics in elderly patients with inflammatory bowel disease: A retrospective study. World J Gastroenterol 2022; 28(33): 4823-4833 [DOI: 10.3748/wjg.v28.i33.4823] [Reference Citation Analysis]
10 Nielsen DL, Juhl CB, Chen IM, Kellermann L, Nielsen OH. Immune checkpoint Inhibitor–Induced diarrhea and Colitis: Incidence and Management. A systematic review and Meta-analysis. Cancer Treatment Reviews 2022;109:102440. [DOI: 10.1016/j.ctrv.2022.102440] [Reference Citation Analysis]
11 Cogan RC, El-Matary BW, El-Matary WM. Therapeutic drug monitoring for biological medications in inflammatory bowel disease. Saudi J Gastroenterol 2022;28:322-31. [PMID: 35343213 DOI: 10.4103/sjg.sjg_3_22] [Reference Citation Analysis]
12 Massironi S, Pirola L, Mulinacci G, Ciaccio A, Viganò C, Palermo A, Zilli A, Invernizzi P, Danese S. Use of IBD Drugs in Patients With Hepatobiliary Comorbidities: Tips and Tricks. Inflamm Bowel Dis 2022:izac189. [PMID: 36040402 DOI: 10.1093/ibd/izac189] [Reference Citation Analysis]
13 Zhu Y, Qin H, Sun C, Shao B, Li G, Qin Y, Kong D, Ren S, Wang H, Wang Z, Zhang J, Wang H, Li XK. Endometrial Regenerative Cell-Derived Exosomes Attenuate Experimental Colitis through Downregulation of Intestine Ferroptosis. Stem Cells International 2022;2022:1-15. [DOI: 10.1155/2022/3014123] [Reference Citation Analysis]
14 Abreu MT, Davies JM, Quintero MA, Delmas A, Diaz S, Martinez CD, Venables T, Reich A, Crynen G, Deshpande AR, Kerman DH, Damas OM, Fernandez I, Santander AM, Pignac-Kobinger J, Burgueno JF, Sundrud MS. Transcriptional Behavior of Regulatory T Cells Predicts IBD Patient Responses to Vedolizumab Therapy. Inflamm Bowel Dis 2022:izac151. [PMID: 35993552 DOI: 10.1093/ibd/izac151] [Reference Citation Analysis]
15 Zundler S, Günther C, Kremer AE, Zaiss MM, Rothhammer V, Neurath MF. Gut immune cell trafficking: inter-organ communication and immune-mediated inflammation. Nat Rev Gastroenterol Hepatol 2022. [PMID: 35945456 DOI: 10.1038/s41575-022-00663-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Sood A, Singh A, Mahajan R, Midha V, Bernstein CN, Rubin DT. (Re)Appraising Remission in Ulcerative Colitis. Inflamm Bowel Dis 2022:izac170. [PMID: 35917172 DOI: 10.1093/ibd/izac170] [Reference Citation Analysis]
17 Cantarelli L, Carrillo Palau M, Hernandez Guerra M, Nazco Casariego GJ, Gutierrez Nicolás F. Definition of a therapeutic range for predicting long-term infliximab response in patients with inflammatory bowel disease. Med Clin (Barc) 2022:S0025-7753(22)00312-8. [PMID: 35931568 DOI: 10.1016/j.medcli.2022.05.008] [Reference Citation Analysis]
18 Lee HS, Sun H, Lagarrigue F, Kim SHJ, Fox JW, Sherman NE, Gingras AR, Ginsberg MH. Phostensin enables lymphocyte integrin activation and population of peripheral lymphoid organs. J Exp Med 2022;219:e20211637. [PMID: 35766979 DOI: 10.1084/jem.20211637] [Reference Citation Analysis]
19 Lee H, Khan N. Editorial: effectiveness and safety of vedolizumab in a matched cohort of elderly and non-elderly patients with inflammatory bowel disease - the IG-IBD LIVE study. Aliment Pharmacol Ther 2022;56:731-2. [PMID: 35879894 DOI: 10.1111/apt.16957] [Reference Citation Analysis]
20 Bylsma S, Yun K, Patel S, Dennis MJ. Immune Checkpoint Inhibitor Rechallenge After Prior Immune Toxicity. Curr Treat Options Oncol 2022. [PMID: 35876957 DOI: 10.1007/s11864-022-00995-9] [Reference Citation Analysis]
21 Liu Z, Tang H, Liang H, Bai X, Zhang H, Yang H, Wang H, Wang L, Qian J. Dyslipidaemia Is Associated with Severe Disease Activity and Poor Prognosis in Ulcerative Colitis: A Retrospective Cohort Study in China. Nutrients 2022;14:3040. [DOI: 10.3390/nu14153040] [Reference Citation Analysis]
22 Volkers A, Straatmijer T, Duijvestein M, Sales A, Levran A, van Schaik F, Maljaars J, Gecse K, Ponsioen C, Grootjans J, Hanzel J, Tack G, Jansen J, Hoentjen F, de Boer N, van der Marel S, Dijkstra G, Oldenburg B, Löwenberg M, van der Meulen A, D′haens G; IBD center Amsterdam and the Dutch Initiative on Crohn and Colitis. Real‐world experience of switching from intravenous to subcutaneous vedolizumab maintenance treatment for inflammatory bowel diseases. Aliment Pharmacol Ther. [DOI: 10.1111/apt.17153] [Reference Citation Analysis]
23 Gabriëls RY, Bourgonje AR, von Martels JZH, Blokzijl T, Weersma RK, Galinsky K, Juarez J, Faber KN, Kats-Ugurlu G, Dijkstra G. Mucosal Eosinophil Abundance in Non-Inflamed Colonic Tissue Is Associated with Response to Vedolizumab Induction Therapy in Inflammatory Bowel Disease. J Clin Med 2022;11:4141. [PMID: 35887905 DOI: 10.3390/jcm11144141] [Reference Citation Analysis]
24 Schweda A, Becker E, Wiendl M, Atreya R, Atreya I, Müller TM, Neurath MF, Zundler S. Etrolizumab-s Does Not Induce Residual Trafficking of Regulatory T Cells. Inflamm Bowel Dis 2022:izac137. [PMID: 35815779 DOI: 10.1093/ibd/izac137] [Reference Citation Analysis]
25 Besendorf L, Müller TM, Geppert CI, Schneider I, Mühl L, Atreya I, Vitali F, Atreya R, Neurath MF, Zundler S. Vedolizumab blocks α4β7 integrin-mediated T cell adhesion to MAdCAM-1 in microscopic colitis. Therap Adv Gastroenterol 2022;15:17562848221098899. [PMID: 35784193 DOI: 10.1177/17562848221098899] [Reference Citation Analysis]
26 Li Y, Sheng L, Jena PK, Gilbert MC, Wan YY, Mao H. Retinoic Acid Signaling Is Compromised in DSS-Induced Dysbiosis. Nutrients 2022;14:2788. [DOI: 10.3390/nu14142788] [Reference Citation Analysis]
27 Fehily SR, Al-Ani AH, Abdelmalak J, Rentch C, Zhang E, Denholm JT, Johnson D, Ng SC, Sharma V, Rubin DT, Gibson PR, Christensen B. Review article: latent tuberculosis in patients with inflammatory bowel diseases receiving immunosuppression-risks, screening, diagnosis and management. Aliment Pharmacol Ther 2022;56:6-27. [PMID: 35596242 DOI: 10.1111/apt.16952] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
28 Bergqvist V, Holmgren J, Klintman D, Marsal J. Editorial: intravenous to subcutaneous vedolizumab-switch without glitch! Authors' reply. Aliment Pharmacol Ther 2022;56:351-2. [PMID: 35748834 DOI: 10.1111/apt.17073] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
29 Gonzalez-vivo M, Lund Tiirikainen MK, Andreu M, Fernandez-clotet A, López-garcía A, Murciano Gonzalo F, Abril Rodriguez L, de Jesús-gil C, Ruiz-romeu E, Sans-de San Nicolàs L, Santamaria-babí LF, Márquez-mosquera L. Memory T Cell Subpopulations as Early Predictors of Remission to Vedolizumab in Ulcerative Colitis. Front Med 2022;9:837294. [DOI: 10.3389/fmed.2022.837294] [Reference Citation Analysis]
30 Peyrin-Biroulet L, Arkkila P, Armuzzi A, Danese S, Guardiola J, Jahnsen J, Lees C, Louis E, Lukáš M, Reinisch W, Roblin X, Jang M, Byun HG, Kim DH, Lee SJ, Atreya R. Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis. BMC Gastroenterol 2022;22:291. [PMID: 35676620 DOI: 10.1186/s12876-022-02347-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Lodhia N, Rao S. Updates in therapeutic drug monitoring in inflammatory bowel disease. World J Gastroenterol 2022; 28(21): 2282-2290 [DOI: 10.3748/wjg.v28.i21.2282] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 . Stellungnahme der DGVS zur Nutzenbewertung des GBA zum Wirkstoff Filgotinib (Anwendungsgebiet: Colitis Ulcerosa, vorbehandelte Patient*innen). Z Gastroenterol 2022;60:1047-50. [DOI: 10.1055/a-1851-7777] [Reference Citation Analysis]
33 Pu D, Zhang Z, Feng B. Alterations and Potential Applications of Gut Microbiota in Biological Therapy for Inflammatory Bowel Diseases. Front Pharmacol 2022;13:906419. [DOI: 10.3389/fphar.2022.906419] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
34 Hernandez Santana YE, Irwin N, Walsh PT. IL-36: a therapeutic target for ulcerative colitis? Expert Opin Ther Targets 2022;:1-6. [PMID: 35634891 DOI: 10.1080/14728222.2022.2084381] [Reference Citation Analysis]
35 Townsend CM, Lovegrove F, Khanna R, Wilson AS. Review article: paradoxical psoriasis as a consequence of tumour necrosis factor antagonists in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2022;55:1379-88. [PMID: 35312094 DOI: 10.1111/apt.16883] [Reference Citation Analysis]
36 Smith RL, Taylor KM, Friedman AB, Gibson DJ, Con D, Gibson PR. Early sonographic response to a new medical therapy is associated with future treatment response or failure in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2022;34:613-21. [PMID: 35352696 DOI: 10.1097/MEG.0000000000002367] [Reference Citation Analysis]
37 Schubert S, Picker N, Cavlar T, Knop J, Kahraman A, Mohl W. Inflammatory Bowel Disease Patients' Treatment Preferences Using a Discrete Choice Experiment Technique: The InPuT Study. Adv Ther 2022;39:2889-905. [PMID: 35451740 DOI: 10.1007/s12325-022-02143-z] [Reference Citation Analysis]
38 Uchiyama K, Takagi T, Mizushima K, Asaeda K, Kajiwara M, Kashiwagi S, Minagawa Y, Hotta Y, Tanaka M, Inoue K, Dohi O, Okayama T, Yoshida N, Katada K, Kamada K, Ishikawa T, Yasuda H, Konishi H, Kishimoto M, Naito Y, Itoh Y. Investigation on the Inhibitory Effect of Wnt-5a on Colonic Mucosal Inflammation in Patients with Ulcerative Colitis. Dig Dis Sci 2022. [PMID: 35590045 DOI: 10.1007/s10620-022-07537-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Pugliese D, Privitera G, Crispino F, Mezzina N, Castiglione F, Fiorino G, Laterza L, Viola A, Bertani L, Caprioli F, Cappello M, Barberio B, Ricci C, Balestrieri P, Daperno M, Pluchino D, Rizzello F, Scribano ML, Sablich R, Pastorelli L, Manguso F, Variola A, Di Sario A, Grossi L, Armuzzi A, Ribaldone DG, Biscaglia G, Buda A, Mocci G, Viscido A, Di Paolo MC, Onali S, Rodino S, Coletta M, Principi M, Miranda A, Amato A, Bezzio C, Petruzzellis C, Mazzuoli S, Festa S, Sartini A, Checchin D, Fanigliulo L, Gallina S, Cesarini M, Bodini G, Stradella D, Spagnuolo R, Guidi L, Savarino E, Scrivo B, Soru P, Costa F, Fries W, Scaldaferri F, Allocca M, Pellegrini L, Massari A, Orlando A; IG‐IBD LIVE Study Group. Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG‐IBD LIVE study. Aliment Pharmacol Ther 2022;56:95-109. [DOI: 10.1111/apt.16923] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
40 Singh A, Fenton CG, Anderssen E, Paulssen RH. Identifying predictive signalling networks for Vedolizumab response in ulcerative colitis. Int J Colorectal Dis 2022. [PMID: 35543875 DOI: 10.1007/s00384-022-04176-w] [Reference Citation Analysis]
41 Rowan C, Ungaro R, Mehandru S, Colombel JF. An overview of ozanimod as a therapeutic option for adults with moderate-to-severe active ulcerative colitis. Expert Opin Pharmacother 2022. [PMID: 35503955 DOI: 10.1080/14656566.2022.2071605] [Reference Citation Analysis]
42 Khushal S, Oliva-Hemker M. Diagnosis and Management of Microscopic Colitis in Pediatric Patients. Paediatr Drugs 2022;24:217-33. [PMID: 35501559 DOI: 10.1007/s40272-022-00504-3] [Reference Citation Analysis]
43 Aoun R, Hanauer S. A critical review of ozanimod for the treatment of adults with moderately to severely active ulcerative colitis. Expert Rev Gastroenterol Hepatol 2022;16:411-23. [PMID: 35400292 DOI: 10.1080/17474124.2022.2065258] [Reference Citation Analysis]
44 Danese S, Vermeire S, Zhou W, Pangan AL, Siffledeen J, Greenbloom S, Hébuterne X, D'haens G, Nakase H, Panés J, Higgins PDR, Juillerat P, Lindsay JO, Loftus EV, Sandborn WJ, Reinisch W, Chen M, Sanchez Gonzalez Y, Huang B, Xie W, Liu J, Weinreich MA, Panaccione R. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. The Lancet 2022. [DOI: 10.1016/s0140-6736(22)00581-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
45 Klonarakis M, Andrews CN, Raman M, Panaccione R, Ma C. Review article: therapeutic targets for the pharmacologic management of coeliac disease-the future beyond a gluten-free diet. Aliment Pharmacol Ther 2022;55:1277-96. [PMID: 35229332 DOI: 10.1111/apt.16846] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Hanzel J, Hulshoff MS, Grootjans J, D'Haens G. Emerging therapies for ulcerative colitis. Expert Rev Clin Immunol 2022. [PMID: 35477319 DOI: 10.1080/1744666X.2022.2069562] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Vande Casteele N, Sandborn WJ, Feagan BG, Vermeire S, Dulai PS, Yarur A, Roblin X, Ben-Horin S, Dotan I, Osterman MT, Rosario M, Osborn TM, Panes J, Lindner D, Agboton C. Real-world multicentre observational study including population pharmacokinetic modelling to evaluate the exposure-response relationship of vedolizumab in inflammatory bowel disease: ERELATE Study. Aliment Pharmacol Ther 2022. [PMID: 35474325 DOI: 10.1111/apt.16937] [Reference Citation Analysis]
48 Fenu E, Lukyanov V, Acs A, Radu X, Stypa S, Fischer A, Marshall JK, Oppe M. Cost Effectiveness of Subcutaneous Vedolizumab for Maintenance Treatment of Ulcerative Colitis in Canada. PharmacoEconomics Open. [DOI: 10.1007/s41669-022-00331-9] [Reference Citation Analysis]
49 Poto R, Troiani T, Criscuolo G, Marone G, Ciardiello F, Tocchetti CG, Varricchi G. Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events. Front Immunol 2022;13:804597. [PMID: 35432346 DOI: 10.3389/fimmu.2022.804597] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
50 Ferretti F, Cannatelli R, Monico MC, Maconi G, Ardizzone S. An Update on Current Pharmacotherapeutic Options for the Treatment of Ulcerative Colitis. J Clin Med 2022;11:2302. [PMID: 35566428 DOI: 10.3390/jcm11092302] [Reference Citation Analysis]
51 Gordon M, Sinopoulou V, Akobeng AK, Pana M, Gasiea R, Moran GW. Tacrolimus (FK506) for induction of remission in corticosteroid-refractory ulcerative colitis. Cochrane Database Syst Rev 2022;4:CD007216. [PMID: 35388476 DOI: 10.1002/14651858.CD007216.pub2] [Reference Citation Analysis]
52 Kirchgesner J, Desai RJ, Schneeweiss MC, Beaugerie L, Schneeweiss S, Kim SC. Decreased risk of treatment failure with vedolizumab and thiopurines combined compared with vedolizumab monotherapy in Crohn's disease. Gut 2022:gutjnl-2022-327002. [PMID: 35387877 DOI: 10.1136/gutjnl-2022-327002] [Reference Citation Analysis]
53 Fang S, Song Y, Zhang C, Wang L. Efficacy and safety of vedolizumab for pediatrics with inflammatory bowel disease: a systematic review. BMC Pediatr 2022;22:175. [PMID: 35379216 DOI: 10.1186/s12887-022-03229-x] [Reference Citation Analysis]
54 Kaazan P, Tan Z, Maiyani P, Mickenbecker M, Edwards S, Mcivor C, Andrews JM. Weight and BMI Patterns in a Biologicals-Treated IBD Cohort. Dig Dis Sci. [DOI: 10.1007/s10620-022-07488-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
55 Hong SJ, Galati J, Katz S. Crohn's Disease of the Elderly. Gastroenterology Clinics of North America 2022. [DOI: 10.1016/j.gtc.2021.12.014] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
56 Zhao Z, Zhu H, Li Q, Liao W, Chen K, Yang M, Long D, He Z, Zhao M, Wu H, Lu Q. Skin CD4+ Trm cells distinguish acute cutaneous lupus erythematosus from localized discoid lupus erythematosus/subacute cutaneous lupus erythematosus and other skin diseases. Journal of Autoimmunity 2022;128:102811. [DOI: 10.1016/j.jaut.2022.102811] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
57 Rydell N, Ekoff H, Hellström PM, Movérare R. Measurement of Serum IgG Anti-Integrin αvβ6 Autoantibodies Is a Promising Tool in the Diagnosis of Ulcerative Colitis. J Clin Med 2022;11:1881. [PMID: 35407486 DOI: 10.3390/jcm11071881] [Reference Citation Analysis]
58 Hyun HK, Zhang H, Yu J, Kang EA, Park J, Park SJ, Park JJ, Kim TI, Kim WH, Cheon JH. Comparative effectiveness of second-line biological therapies for ulcerative colitis and Crohn’s disease in patients with prior failure of anti-tumour necrosis factor treatment. BMC Gastroenterol 2022;22. [DOI: 10.1186/s12876-022-02225-w] [Reference Citation Analysis]
59 Zakerska-banaszak O, Łykowska-szuber L, Walczak M, Żuraszek J, Zielińska A, Skrzypczak-zielińska M. Cytotoxicity of Thiopurine Drugs in Patients with Inflammatory Bowel Disease. Toxics 2022;10:151. [DOI: 10.3390/toxics10040151] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
60 Akbar A, Orchard T, Powell N, Selinger C, tibbatts C. Influence of comorbidities on treatment considerations for first-line biologic prescribing in patients with inflammatory bowel disease in the UK. Frontline Gastroenterol. [DOI: 10.1136/flgastro-2021-101995] [Reference Citation Analysis]
61 Lyons M, Derikx LAAP, Fulforth J, McCall S, Plevris N, Jenkinson PW, Kirkwood K, Siakavellas S, Lucaciu L, Constantine-Cooke N, Arnott ID, Henderson P, Russell RK, Wilson DC, Lees CW, Jones GR. Patterns of emergency admission for IBD patients over the last 10 years in Lothian, Scotland: A retrospective prevalent cohort analysis. Aliment Pharmacol Ther 2022. [PMID: 35301734 DOI: 10.1111/apt.16867] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
62 Kundu K, Tardaguila M, Mann AL, Watt S, Ponstingl H, Vasquez L, Von Schiller D, Morrell NW, Stegle O, Pastinen T, Sawcer SJ, Anderson CA, Walter K, Soranzo N. Genetic associations at regulatory phenotypes improve fine-mapping of causal variants for 12 immune-mediated diseases. Nat Genet 2022;54:251-62. [PMID: 35288711 DOI: 10.1038/s41588-022-01025-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
63 Hong SJ, Zenger C, Pecoriello J, Pang A, Vallely M, Hudesman DP, Chang S, Axelrad JE. Ustekinumab and Vedolizumab Are Not Associated With Subsequent Cancer in IBD Patients with Prior Malignancy. Inflamm Bowel Dis 2022:izac035. [PMID: 35262671 DOI: 10.1093/ibd/izac035] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
64 Kishi M, Hirai F, Takatsu N, Hisabe T, Takada Y, Beppu T, Takeuchi K, Naganuma M, Ohtsuka K, Watanabe K, Matsumoto T, Esaki M, Koganei K, Sugita A, Hata K, Futami K, Ajioka Y, Tanabe H, Iwashita A, Shimizu H, Arai K, Suzuki Y, Hisamatsu T. A review on the current status and definitions of activity indices in inflammatory bowel disease: how to use indices for precise evaluation. J Gastroenterol 2022. [PMID: 35235037 DOI: 10.1007/s00535-022-01862-y] [Reference Citation Analysis]
65 Spiewak TA, Patel A. User's Guide to JAK Inhibitors in Inflammatory Bowel Disease. Current Research in Pharmacology and Drug Discovery 2022. [DOI: 10.1016/j.crphar.2022.100096] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
66 Lechner K, Zeeshana M, Noack M, Ali H, Neurath M, Weigmanna B. Small but powerful: Will nanoparticles be the future state‐of‐the‐art therapy for IBD? Expert Opinion on Drug Delivery. [DOI: 10.1080/17425247.2022.2043847] [Reference Citation Analysis]
67 Bonovas S, Pansieri C, Piovani D, Macaluso FS, Orlando A, Festa S, Papi C, Pugliese D, Armuzzi A. Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD technical review based on the GRADE methodology. Dig Liver Dis 2022:S1590-8658(22)00134-7. [PMID: 35183439 DOI: 10.1016/j.dld.2022.01.123] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
68 Kumar A, Cole A, Segal J, Smith P, Limdi JK. A review of the therapeutic management of Crohn’s disease. Therap Adv Gastroenterol 2022;15:175628482210784. [DOI: 10.1177/17562848221078456] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
69 Zhang J, Liu MH, Gao X, Dong C, Li YX. Vedolizumab-associated diffuse interstitial lung disease in patients with ulcerative colitis: A case report. World J Clin Cases 2022; 10(5): 1716-1722 [DOI: 10.12998/wjcc.v10.i5.1716] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
70 Grossberg LB, Papamichael K, Cheifetz AS. Review: emerging drug therapies in inflammatory bowel disease. Aliment Pharmacol Ther 2022. [PMID: 35166398 DOI: 10.1111/apt.16785] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
71 Kaneoka A, Okada E, Sugino H, Saito-sasaki N, Omoto D, Nakamura M. Vedolizumab Attenuates Immune-Checkpoint-Therapy-Induced Infliximab-Refractory Colitis. Diagnostics 2022;12:480. [DOI: 10.3390/diagnostics12020480] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
72 Jung JH, Choi S, Kang Y, Cho D, Lee SM, Park TI, Choe B, Kim D, Kang B. Development of Spinal Tuberculosis in an Adolescent With Crohn's Disease After Infliximab Therapy: A Case Report With Literature Review. Front Pediatr 2022;9:802298. [DOI: 10.3389/fped.2021.802298] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
73 Gupta S, Shyamsundar K, Agrawal M, Vichare N, Biswas J. Current Knowledge of Biologics in Treatment of Noninfectious Uveitis. Journal of Ocular Pharmacology and Therapeutics. [DOI: 10.1089/jop.2021.0098] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
74 Chen X, Jiang L, Han W, Bai X, Ruan G, Guo M, Zhou R, Liang H, Yang H, Qian J. Artificial Neural Network Analysis-Based Immune-Related Signatures of Primary Non-Response to Infliximab in Patients With Ulcerative Colitis. Front Immunol 2021;12:742080. [PMID: 34992592 DOI: 10.3389/fimmu.2021.742080] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
75 Schreiber S, Irving PM, Sharara AI, Martín-Arranz MD, Hébuterne X, Penchev P, Danese S, Anthopoulos P, Akhundova-Unadkat G, Baert F. Review: randomised controlled trials in inflammatory bowel disease-common challenges and potential solutions. Aliment Pharmacol Ther 2022. [PMID: 35132657 DOI: 10.1111/apt.16781] [Reference Citation Analysis]
76 Norton B, Sullivan A, Senior J, Candela N, Jason M, Weyant K. Vedolizumab for Moderate to Severe Ulcerative Colitis: A Review for Nurse Practitioners. The Journal for Nurse Practitioners 2022. [DOI: 10.1016/j.nurpra.2021.12.001] [Reference Citation Analysis]
77 Kaiser R, Escaig R, Erber J, Nicolai L. Neutrophil-Platelet Interactions as Novel Treatment Targets in Cardiovascular Disease. Front Cardiovasc Med 2022;8:824112. [DOI: 10.3389/fcvm.2021.824112] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
78 Sieber A, Aberra FN, Bonhomme B, Mckeever L, Lewis JD. Influence of Corticosteroid Use on Short- and Long-Term Outcomes of Biologic Therapy for Inflammatory Bowel Diseases. Dig Dis Sci. [DOI: 10.1007/s10620-021-07361-z] [Reference Citation Analysis]
79 Cleveland NK, Torres J, Rubin DT. What Does Disease Progression Look Like in Ulcerative Colitis, and How Might It Be Prevented? Gastroenterology 2022:S0016-5085(22)00077-4. [PMID: 35101421 DOI: 10.1053/j.gastro.2022.01.023] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
80 Sun C, Hao J, Qin H, Zhu Y, Li X, Zhang B, Qin Y, Li G, Wang H, Wang H, Paspaliaris V. Endometrial Regenerative Cell-Derived Conditioned Medium Alleviates Experimental Colitis. Stem Cells International 2022;2022:1-13. [DOI: 10.1155/2022/7842296] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
81 Tarabar D, El Jurdi K, Traboulsi C, Yvellez O, Milenkovic Z, Petrovic S, Subotic B, Gils A, Brocic T, Brcerevic I, Latinovic O, Jocic T, Rubin DT. A Prospective Trial with Long Term Follow-up of Patients With Severe, Steroid-Resistant Ulcerative Colitis Who Received Induction Therapy With Cyclosporine and Were Maintained With Vedolizumab. Inflammatory Bowel Diseases 2022. [DOI: 10.1093/ibd/izab328] [Reference Citation Analysis]
82 Nassar IO, Cheesbrough J, Quraishi MN, Sharma N. Proposed pathway for therapeutic drug monitoring and dose escalation of vedolizumab. Frontline Gastroenterol. [DOI: 10.1136/flgastro-2021-102032] [Reference Citation Analysis]
83 Knyazev OV, Kagramanova AV, Parfenov AI. Ulcerative colitis. To the 180th anniversary of the description by Karl Rokytansky. Terapevticheskii arkhiv 2022;93:1564-8. [DOI: 10.26442/00403660.2021.12.201219] [Reference Citation Analysis]
84 Damião AOMC, Queiroz NSF. Medical Therapy in Chronic Refractory Ulcerative Colitis: When Enough Is Enough. Clin Colon Rectal Surg 2022;35:032-43. [DOI: 10.1055/s-0041-1740036] [Reference Citation Analysis]
85 Risto A, Abdalla M, Myrelid P. Staging Pouch Surgery in Ulcerative Colitis in the Biological Era. Clin Colon Rectal Surg 2022;35:058-65. [DOI: 10.1055/s-0041-1740039] [Reference Citation Analysis]
86 Moreau JM, Gouirand V, Rosenblum MD. T-Cell Adhesion in Healthy and Inflamed Skin. JID Innov 2021;1:100014. [PMID: 35024681 DOI: 10.1016/j.xjidi.2021.100014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
87 Lamb CA, Saifuddin A, Powell N, Rieder F. The Future of Precision Medicine to Predict Outcomes and Control Tissue Remodeling in Inflammatory Bowel Disease. Gastroenterology 2022;162:1525-42. [PMID: 34995532 DOI: 10.1053/j.gastro.2021.09.077] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
88 Cai Z, Wang S, Li J. Treatment of Inflammatory Bowel Disease: A Comprehensive Review. Front Med (Lausanne) 2021;8:765474. [PMID: 34988090 DOI: 10.3389/fmed.2021.765474] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
89 Michalopoulos G, Karmiris K. When disease extent is not always a key parameter: Management of refractory ulcerative proctitis. Curr Res Pharmacol Drug Discov 2022;3:100071. [PMID: 34988432 DOI: 10.1016/j.crphar.2021.100071] [Reference Citation Analysis]
90 Kanauchi Y, Yamamoto T, Yoshida M, Zhang Y, Lee J, Hayashi S, Kadowaki M. Cholinergic anti-inflammatory pathway ameliorates murine experimental Th2-type colitis by suppressing the migration of plasmacytoid dendritic cells. Sci Rep 2022;12:54. [PMID: 34997096 DOI: 10.1038/s41598-021-04154-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
91 Miller C, Kwok H, Harrow P, Vega R, Seward E, Mehta S, Rahman F, Mccartney S, Parisi I, Lim SH, Sharma E, Samaan MA, Bancil A, Kok KB, Shalabi A, Johnston EL, Katarey D, Taherzadeh N, Murray C, Sharip MT, Carter MJ, Radhakrishnan ST, Peake S, Khakoo I, Wahed M, Povlsen S, Patel M, Dubois P, Finkel J, Onnie C, Bloom S. Comparative effectiveness of a second-line biologic in patients with ulcerative colitis: vedolizumab followed by an anti-TNF versus anti-TNF followed by vedolizumab. Frontline Gastroenterol. [DOI: 10.1136/flgastro-2021-101906] [Reference Citation Analysis]
92 Bhattacharya S, Cross RK. Medical treatment of ulcerative colitis. Seminars in Colon and Rectal Surgery 2022. [DOI: 10.1016/j.scrs.2022.100863] [Reference Citation Analysis]
93 Li F, Liu H, Fu J, Fan L, Lu S, Zhang H, Liu Z. Knockdown of long non-coding RNA NEAT1 relieves inflammation of ulcerative colitis by regulating the miR-603/FGF9 pathway. Exp Ther Med 2022;23:131. [PMID: 34970354 DOI: 10.3892/etm.2021.11054] [Reference Citation Analysis]
94 Falloon K, Padival R, Kurada S, Ouali SE, Rieder F. BIOLOGIC AGENTS AND SMALL MOLECULES – MECHANISM OF ACTION. Seminars in Colon and Rectal Surgery 2022. [DOI: 10.1016/j.scrs.2022.100861] [Reference Citation Analysis]
95 Fukuchi T, Kawashima K, Koga H, Utsunomiya R, Sugiyama K, Shimazu K, Eguchi T, Ishihara S. Induction of mucosal healing by intensive granulocyte/monocyte adsorptive apheresis (GMA) without use of corticosteroids in patients with ulcerative colitis: long-term remission maintenance after induction by GMA and efficacy of GMA re-treatment upon relapse. J Clin Biochem Nutr . [DOI: 10.3164/jcbn.21-112] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
96 Kim JE, Won H, Kim YH, Kim ER, Hong SN, Chang DK. Specificity of clinical decision support tools for vedolizumab and ustekinumab in biologically naïve patients with Crohn's disease. Scand J Gastroenterol 2021;:1-3. [PMID: 34967701 DOI: 10.1080/00365521.2021.2020332] [Reference Citation Analysis]
97 Sandborn WJ, Armuzzi A, Liguori G, Irving PM, Sharara AI, Mundayat R, Lawendy N, Woolcott JC, Danese S. Predictors of Sustained Response With Tofacitinib Therapy in Patients With Ulcerative Colitis. Inflamm Bowel Dis 2021:izab278. [PMID: 34958359 DOI: 10.1093/ibd/izab278] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
98 Mazza S, Soro S, Verga MC, Elvo B, Ferretti F, Cereatti F, Drago A, Grassia R. Liver-side of inflammatory bowel diseases: Hepatobiliary and drug-induced disorders. World J Hepatol 2021; 13(12): 1828-1849 [DOI: 10.4254/wjh.v13.i12.1828] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
99 Shimizu H, Fujii T, Kinoshita K, Kawamoto A, Hibiya S, Takenaka K, Saito E, Nagahori M, Ohtsuka K, Watanabe M, Okamoto R. Intravenous tacrolimus is a superior induction therapy for acute severe ulcerative colitis compared to oral tacrolimus. BMC Gastroenterol 2021;21:494. [PMID: 34949172 DOI: 10.1186/s12876-021-02043-6] [Reference Citation Analysis]
100 Burr NE, Gracie DJ, Black CJ, Ford AC. Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis. Gut 2021:gutjnl-2021-326390. [PMID: 34937767 DOI: 10.1136/gutjnl-2021-326390] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
101 Privitera G, Pugliese D, Lopetuso LR, Scaldaferri F, Papa A, Rapaccini GL, Gasbarrini A, Armuzzi A. Orphan patients with inflammatory bowel disease - when we treat beyond evidence. World J Gastroenterol 2021; 27(47): 8047-8057 [DOI: 10.3748/wjg.v27.i47.8047] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
102 Shouval DS. α4β7 expression guides B cells to front lines of defense in the gut. Mucosal Immunol 2021. [PMID: 34931001 DOI: 10.1038/s41385-021-00476-6] [Reference Citation Analysis]
103 Suarez-Lopez L, Shui B, Brubaker DK, Hill M, Bergendorf A, Changelian PS, Laguna A, Starchenko A, Lauffenburger DA, Haigis KM. Cross-species transcriptomic signatures predict response to MK2 inhibition in mouse models of chronic inflammation. iScience 2021;24:103406. [PMID: 34849469 DOI: 10.1016/j.isci.2021.103406] [Reference Citation Analysis]
104 Kuo CJ, Le PH, Tai WC, Wu KL, Yen HH, Yen CW, Tung SY, Chung CS, Su MY, Chiu CT. The effectiveness and safety of vedolizumab induction for moderate to severe ulcerative colitis for Asia patient: A real practice observational study. J Formos Med Assoc 2021:S0929-6646(21)00532-5. [PMID: 34924273 DOI: 10.1016/j.jfma.2021.11.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
105 Sattler L, Hanauer SB, Malter L. Immunomodulatory Agents for Treatment of Patients with Inflammatory Bowel Disease (Review safety of anti-TNF, Anti-Integrin, Anti IL-12/23, JAK Inhibition, Sphingosine 1-Phosphate Receptor Modulator, Azathioprine / 6-MP and Methotrexate). Curr Gastroenterol Rep 2021;23:30. [PMID: 34913108 DOI: 10.1007/s11894-021-00829-y] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
106 Attauabi M, Madsen GR, Bendtsen F, Seidelin JB, Burisch J. Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn's disease - a systematic review with meta-analysis. Dig Liver Dis 2021:S1590-8658(21)00856-2. [PMID: 34903497 DOI: 10.1016/j.dld.2021.11.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
107 Nakase H, Sato N, Mizuno N, Ikawa Y. The influence of cytokines on the complex pathology of ulcerative colitis. Autoimmun Rev 2021;:103017. [PMID: 34902606 DOI: 10.1016/j.autrev.2021.103017] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
108 Chen J, Girard M, Wang S, Kisfalvi K, Lirio R. Using supervised machine learning approach to predict treatment outcomes of vedolizumab in ulcerative colitis patients. J Biopharm Stat 2021;:1-16. [PMID: 34882518 DOI: 10.1080/10543406.2021.2009500] [Reference Citation Analysis]
109 Venkateswaran N, Weismiller S, Clarke K. Indeterminate Colitis - Update on Treatment Options. J Inflamm Res 2021;14:6383-95. [PMID: 34876831 DOI: 10.2147/JIR.S268262] [Reference Citation Analysis]
110 Melde M, Müller TM, Schneider I, Geppert CI, Mühl L, Besendorf L, Allner C, Becker E, Atreya I, Vitali F, Atreya R, Neurath MF, Zundler S. α4β7 integrin-dependent adhesion of T cells to MAdCAM-1 is blocked by vedolizumab in patients with chronic refractory pouchitis. Therap Adv Gastroenterol 2021;14:17562848211054707. [PMID: 34868349 DOI: 10.1177/17562848211054707] [Reference Citation Analysis]
111 Avni-Biron I, Bar-Gil Shitrit A, Koslowsky B, Levartovsky A, Kopylov U, Weisshof R, Aviv Cohen N, Maharshak N, Hovel D, Israeli E, Naftali T, Goren I, Snir Y, Ollech JE, Banai-Eran H, Broitman Y, Sharar-Fischler T, Dotan I, Yanai H. Short-term effectiveness and safety of tofacitinib in ulcerative colitis - real world data from tertiary medical centers in Israel. Dig Liver Dis 2021:S1590-8658(21)00849-5. [PMID: 34887214 DOI: 10.1016/j.dld.2021.11.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
112 Toyonaga T, Saruta M. Role of microRNAs in the Pathophysiology of Ulcerative Colitis. Immuno 2021;1:558-73. [DOI: 10.3390/immuno1040039] [Reference Citation Analysis]
113 Caron B, Sandborn WJ, Panaccione R, Schreiber S, Hart A, Solitano V, Danese S, Peyrin-Biroulet L. Efficacy of pharmacological agents for ulcerative proctitis: a systematic literature review. J Crohns Colitis 2021:jjab218. [PMID: 34850857 DOI: 10.1093/ecco-jcc/jjab218] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
114 Lasa JS, Olivera PA, Danese S, Peyrin-Biroulet L. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol 2021:S2468-1253(21)00377-0. [PMID: 34856198 DOI: 10.1016/S2468-1253(21)00377-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 16.0] [Reference Citation Analysis]
115 Papaefthymiou A, Potamianos S, Goulas A, Doulberis M, Kountouras J, Polyzos SA. Inflammatory Bowel Disease-associated Fatty Liver Disease: the Potential Effect of Biologic Agents. J Crohns Colitis 2021:jjab212. [PMID: 34972203 DOI: 10.1093/ecco-jcc/jjab212] [Reference Citation Analysis]
116 Bots SJ, Parker CE, Brandse JF, Löwenberg M, Feagan BG, Sandborn WJ, Jairath V, D'Haens G, Vande Casteele N. Anti-Drug Antibody Formation Against Biologic Agents in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. BioDrugs 2021;35:715-33. [PMID: 34797516 DOI: 10.1007/s40259-021-00507-5] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
117 Shah P, McDonald D. Vedolizumab: An Emerging Treatment Option for Pediatric Inflammatory Bowel Disease. J Pediatr Pharmacol Ther 2021;26:795-801. [PMID: 34790068 DOI: 10.5863/1551-6776-26.8.795] [Reference Citation Analysis]
118 Zundler S. Zellmigration als therapeutischer Zielprozess. Drug Res (Stuttg) 2021;71:S26-7. [PMID: 34788886 DOI: 10.1055/a-1606-5983] [Reference Citation Analysis]
119 Neurath MF. Arzneimitteltherapie in der Gastroenterologie: Molekulare Grundlagen der CED. Drug Res (Stuttg) 2021;71:S15. [PMID: 34788880 DOI: 10.1055/a-1606-5844] [Reference Citation Analysis]
120 Gisbert JP, Chaparro M. Primary Failure to an Anti-TNF Agent in Inflammatory Bowel Disease: Switch (to a Second Anti-TNF Agent) or Swap (for Another Mechanism of Action)? J Clin Med 2021;10:5318. [PMID: 34830595 DOI: 10.3390/jcm10225318] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
121 Arbrile M, Radin M, Rossi D, Menegatti E, Baldovino S, Sciascia S, Roccatello D. Vedolizumab for the Management of Refractory Behçet's Disease: From a Case Report to New Pieces of Mosaic in a Complex Disease. Front Immunol 2021;12:769785. [PMID: 34759935 DOI: 10.3389/fimmu.2021.769785] [Reference Citation Analysis]
122 Cader MZ, Kaser A. Finding the right target for drug-resistant inflammatory bowel disease. Nat Med 2021;27:1870-1. [PMID: 34750554 DOI: 10.1038/s41591-021-01551-y] [Reference Citation Analysis]
123 Moens A, Verstockt B, Alsoud D, Sabino J, Ferrante M, Vermeire S. Translating Results from VARSITY to Real World: Adalimumab vs Vedolizumab as First-line Biological in Moderate to Severe IBD. Inflamm Bowel Dis 2021:izab257. [PMID: 34751766 DOI: 10.1093/ibd/izab257] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
124 Hishinuma K, Moroi R, Okamoto D, Shimoyama Y, Kuroha M, Shiga H, Kakuta Y, Kinouchi Y, Masamune A. Analysis of the Long-Term Prognosis in Japanese Patients with Ulcerative Colitis Treated with New Therapeutic Agents and the Correlation between Prognosis and Disease Susceptibility Loci. Inflamm Intest Dis 2021;6:154-64. [PMID: 34722645 DOI: 10.1159/000518371] [Reference Citation Analysis]
125 Sutter M, Hruz P, Niess JH. High Serum Creatine Kinase Levels in Infliximab and Vedolizumab-Treated Inflammatory Bowel Disease Patients. Inflamm Intest Dis 2021;6:165-74. [PMID: 34722646 DOI: 10.1159/000518264] [Reference Citation Analysis]
126 Keir ME, Fuh F, Ichikawa R, Acres M, Hackney JA, Hulme G, Carey CD, Palmer J, Jones CJ, Long AK, Jiang J, Klabunde S, Mansfield JC, Looney CM, Faubion WA, Filby A, Kirby JA, McBride J, Lamb CA. Regulation and Role of αE Integrin and Gut Homing Integrins in Migration and Retention of Intestinal Lymphocytes during Inflammatory Bowel Disease. J Immunol 2021;207:2245-54. [PMID: 34561227 DOI: 10.4049/jimmunol.2100220] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
127 Salvador-Martín S, Melgarejo-Ortuño A, López-Fernández LA. Biomarkers for Optimization and Personalization of Anti-TNFs in Pediatric Inflammatory Bowel Disease. Pharmaceutics 2021;13:1786. [PMID: 34834201 DOI: 10.3390/pharmaceutics13111786] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
128 Lubrano E, Luchetti MM, Benfaremo D, Mauro D, Ciccia F, Perrotta FM. Inflammatory bowel disease manifestations in spondyloarthritis: considerations for the clinician. Expert Rev Clin Immunol 2021;17:1199-209. [PMID: 34622735 DOI: 10.1080/1744666X.2021.1991315] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
129 Meredith J, Henderson P, Wilson DC, Russell RK. Combination Immunotherapy Use and Withdrawal in Pediatric Inflammatory Bowel Disease-A Review of the Evidence. Front Pediatr 2021;9:708310. [PMID: 34621712 DOI: 10.3389/fped.2021.708310] [Reference Citation Analysis]
130 Romero RK, Magro DO, Queiroz NSF, Damião AOMC, Teixeira FV, Nones RB, Sassaki LY, Saad-Hossne R, Kotze PG. Perception and clinical decisions from inflammatory bowel diseases' specialists towards positioning of new therapies in Crohn's disease and ulcerative colitis: A national web-based survey from the Brazilian IBD study group (GEDIIB). Gastroenterol Hepatol 2021:S0210-5705(21)00296-X. [PMID: 34634427 DOI: 10.1016/j.gastrohep.2021.09.005] [Reference Citation Analysis]
131 Wyatt NJ, Speight RA, Stewart CJ, Kirby JA, Lamb CA. Targeting Leukocyte Trafficking in Inflammatory Bowel Disease. BioDrugs 2021;35:473-503. [PMID: 34613592 DOI: 10.1007/s40259-021-00496-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
132 Chia AYT, Ang GWX, Chan ASY, Chan W, Chong TKY, Leung YY. Managing Psoriatic Arthritis With Inflammatory Bowel Disease and/or Uveitis. Front Med (Lausanne) 2021;8:737256. [PMID: 34604268 DOI: 10.3389/fmed.2021.737256] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
133 Krugliak Cleveland N, Rai V, El Jurdi K, Rao SS, Giurcanu MC, Rubin DT. Ulcerative Colitis Patients Have Reduced Rectal Compliance Compared With Non-Inflammatory Bowel Disease Controls. Gastroenterology 2022;162:331-333.e1. [PMID: 34597674 DOI: 10.1053/j.gastro.2021.09.052] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
134 Vuyyuru SK, Kedia S, Kalaivani M, Sahu P, Kante B, Kumar P, Ranjan MK, Makharia G, Ananthakrishnan A, Ahuja V. Efficacy and safety of fecal transplantation versus targeted therapies in ulcerative colitis: network meta-analysis. Future Microbiol 2021;16:1215-27. [PMID: 34590904 DOI: 10.2217/fmb-2020-0242] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
135 Saito D, Matsuura M, Ozaki R, Tokunaga S, Minowa S, Mitsui T, Miura M, Sakuraba A, Hayashida M, Miyoshi J, Hisamatsu T. Clinical response of vedolizumab at week 6 predicted endoscopic remission at week 24 in ulcerative colitis. JGH Open 2021;5:1056-62. [PMID: 34584975 DOI: 10.1002/jgh3.12630] [Reference Citation Analysis]
136 Chen M, Tian S, Li S, Pang X, Sun J, Zhu X, Lv F, Lu Z, Li X. β-Glucan Extracted from Highland Barley Alleviates Dextran Sulfate Sodium-Induced Ulcerative Colitis in C57BL/6J Mice. Molecules 2021;26:5812. [PMID: 34641356 DOI: 10.3390/molecules26195812] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
137 Ho GT, Cartwright JA, Thompson EJ, Bain CC, Rossi AG. Resolution of Inflammation and Gut Repair in IBD: Translational Steps Towards Complete Mucosal Healing. Inflamm Bowel Dis 2020;26:1131-43. [PMID: 32232386 DOI: 10.1093/ibd/izaa045] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 23.0] [Reference Citation Analysis]
138 Kim EM, Randall C, Betancourt R, Keene S, Lilly A, Fowler M, Dellon ES, Herfarth HH. Mucosal Eosinophilia Is an Independent Predictor of Vedolizumab Efficacy in Inflammatory Bowel Diseases. Inflamm Bowel Dis 2020;26:1232-8. [PMID: 31633167 DOI: 10.1093/ibd/izz251] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 13.0] [Reference Citation Analysis]
139 Veisman I, Barzilay O, Bruckmayer L, Haj-Natour O, Kopylov U, Eliakim R, Ben-Horin S, Ungar B. Association of Infliximab and Vedolizumab Trough Levels with Reported Rates of Adverse Events: A Cross-Sectional Study. J Clin Med 2021;10:4265. [PMID: 34575376 DOI: 10.3390/jcm10184265] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
140 Panés J. Integrin Inhibitors in Inflammatory Bowel Disease: From Therapeutic Antibodies to Small-Molecule Drugs. Gastroenterology 2021;161:1791-3. [PMID: 34529992 DOI: 10.1053/j.gastro.2021.09.016] [Reference Citation Analysis]
141 Pinton P. Combination of vedolizumab and immunomodulators in ulcerative colitis. J Gastroenterol Hepatol 2021;36:3556. [PMID: 34519096 DOI: 10.1111/jgh.15686] [Reference Citation Analysis]
142 Bozward AG, Ronca V, Osei-Bordom D, Oo YH. Gut-Liver Immune Traffic: Deciphering Immune-Pathogenesis to Underpin Translational Therapy. Front Immunol 2021;12:711217. [PMID: 34512631 DOI: 10.3389/fimmu.2021.711217] [Reference Citation Analysis]
143 Sun H, Lagarrigue F, Wang H, Fan Z, Lopez-Ramirez MA, Chang JT, Ginsberg MH. Distinct integrin activation pathways for effector and regulatory T cell trafficking and function. J Exp Med 2021;218:e20201524. [PMID: 33104169 DOI: 10.1084/jem.20201524] [Cited by in Crossref: 5] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
144 Adolph TE, Siegmund B. Deciphering the vedolizumab dosing conundrum in IBD: when less is more. Gut 2021:gutjnl-2021-325893. [PMID: 34497148 DOI: 10.1136/gutjnl-2021-325893] [Reference Citation Analysis]
145 Zhou T, Sheng Y, Guan H, Meng R, Wang Z. Cost-Effectiveness Analysis of Vedolizumab Compared With Infliximab in Anti-TNF-α-Naïve Patients With Moderate-to-Severe Ulcerative Colitis in China. Front Public Health 2021;9:704889. [PMID: 34490187 DOI: 10.3389/fpubh.2021.704889] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
146 Cichoż-Lach H, Michalak A, Kopertowska-Majchrzak M, Eder P, Stawczyk-Eder K, Waszak K, Talar-Wojnarowska R, Zatorski H, Solarska-Półchłopek A, Chmielnicki J, Filip R, Pękala A, Janiak M, Skrobot K, Kasińska E, Krogulecki M, Królikowski P, Kłopocka M, Liebert A, Poniewierka E, Smoła I, Gąsiorowska A, Kaczka A, Wypych J, Wojciechowski K, Drygała S, Zagórowicz E. Characteristics of patients with moderate-to-severe ulcerative colitis treated with vedolizumab: results from a Polish multicenter, prospective, observational real-life study (the POLONEZ study). Therap Adv Gastroenterol 2021;14:17562848211036456. [PMID: 34484422 DOI: 10.1177/17562848211036456] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
147 van Hoeve K, Seyed Tabib NS, Dreesen E, Tops S, Hoffman I, Gils A, Ferrante M, Vermeire S. Infliximab Concentrations during Induction Are Predictive for Endoscopic Remission in Pediatric Patients with Inflammatory Bowel Disease under Combination Therapy. J Pediatr 2022;240:150-157.e4. [PMID: 34481805 DOI: 10.1016/j.jpeds.2021.08.079] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
148 Gubatan J, Keyashian K, Rubin SJS, Wang J, Buckman CA, Sinha S. Anti-Integrins for the Treatment of Inflammatory Bowel Disease: Current Evidence and Perspectives. Clin Exp Gastroenterol 2021;14:333-42. [PMID: 34466013 DOI: 10.2147/CEG.S293272] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
149 Becker E, Dedden M, Gall C, Wiendl M, Ekici AB, Schulz-Kuhnt A, Schweda A, Voskens C, Hegazy A, Vitali F, Atreya R, Müller TM, Atreya I, Neurath MF, Zundler S. Residual homing of α4β7-expressing β1+PI16+ regulatory T cells with potent suppressive activity correlates with exposure-efficacy of vedolizumab. Gut 2021:gutjnl-2021-324868. [PMID: 34462337 DOI: 10.1136/gutjnl-2021-324868] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
150 Tyler CJ, Guzman M, Lundborg LR, Yeasmin S, Zgajnar N, Jedlicka P, Bamias G, Rivera-Nieves J. Antibody secreting cells are critically dependent on integrin α4β7/MAdCAM-1 for intestinal recruitment and control of the microbiota during chronic colitis. Mucosal Immunol 2021. [PMID: 34433904 DOI: 10.1038/s41385-021-00445-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
151 Dulaney D, Dave P, Walsh S, Mehandru S, Colombel JF, Agrawal M. Noninfectious Pulmonary Complications Associated With Anti-Integrin Therapy: A Case Report and Systematic Review of the Literature. Inflamm Bowel Dis 2021:izab212. [PMID: 34427639 DOI: 10.1093/ibd/izab212] [Reference Citation Analysis]
152 Guzman M, Lundborg LR, Yeasmin S, Tyler CJ, Zgajnar NR, Taupin V, Dobaczewska K, Mikulski Z, Bamias G, Rivera-Nieves J. An integrin αEβ7-dependent mechanism of IgA transcytosis requires direct plasma cell contact with intestinal epithelium. Mucosal Immunol 2021;14:1347-57. [PMID: 34417548 DOI: 10.1038/s41385-021-00439-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
153 Choi D, Stewart AP, Bhat S. Ozanimod: A First-in-Class Sphingosine 1-Phosphate Receptor Modulator for the Treatment of Ulcerative Colitis. Ann Pharmacother 2021;:10600280211041907. [PMID: 34423657 DOI: 10.1177/10600280211041907] [Reference Citation Analysis]
154 Dai B, Hackney JA, Ichikawa R, Nguyen A, Elstrott J, Orozco LD, Sun KH, Modrusan Z, Gogineni A, Scherl A, Gubatan J, Habtezion A, Deswal M, Somsouk M, Faubion WA, Chai A, Sharafali Z, Hassanali A, Oh YS, Tole S, McBride J, Keir ME, Yi T. Dual targeting of lymphocyte homing and retention through α4β7 and αEβ7 inhibition in inflammatory bowel disease. Cell Rep Med 2021;2:100381. [PMID: 34467254 DOI: 10.1016/j.xcrm.2021.100381] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
155 Miyoshi J, Maeda T, Matsuoka K, Saito D, Miyoshi S, Matsuura M, Okamoto S, Tamura S, Hisamatsu T. Machine learning using clinical data at baseline predicts the efficacy of vedolizumab at week 22 in patients with ulcerative colitis. Sci Rep 2021;11:16440. [PMID: 34385588 DOI: 10.1038/s41598-021-96019-x] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
156 Slevin SM, Garner LC, Lahiff C, Tan M, Wang LM, Ferry H, Greenaway B, Lynch K, Geremia A, Hughes S, Leavens K, Krull D, Marks DJB, Nevin K, Page K, Srinivasan N, Tarzi R, Klenerman P, Travis S, Arancibia-Cárcamo CV, Keshav S. Lymphocyte Activation Gene (LAG)-3 Is Associated With Mucosal Inflammation and Disease Activity in Ulcerative Colitis. J Crohns Colitis 2020;14:1446-61. [PMID: 32179884 DOI: 10.1093/ecco-jcc/jjaa054] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
157 Rong JM, Luo J, Huang Q, Miao YL. Individualized selection of biological agents in treatment of inflammatory bowel disease. Shijie Huaren Xiaohua Zazhi 2021; 29(15): 893-900 [DOI: 10.11569/wcjd.v29.i15.893] [Reference Citation Analysis]
158 Alipour O, Gualti A, Shao L, Zhang B. Systematic review and meta-analysis: real-world data rates of deep remission with anti-TNFα in inflammatory bowel disease. BMC Gastroenterol 2021;21:312. [PMID: 34344314 DOI: 10.1186/s12876-021-01883-6] [Reference Citation Analysis]
159 Barreto de Albuquerque J, Mueller C, Gungor B. Tissue-Resident T Cells in Chronic Relapsing-Remitting Intestinal Disorders. Cells 2021;10:1882. [PMID: 34440651 DOI: 10.3390/cells10081882] [Reference Citation Analysis]
160 Negi S, Saini S, Tandel N, Sahu K, Mishra RPN, Tyagi RK. Translating Treg Therapy for Inflammatory Bowel Disease in Humanized Mice. Cells 2021;10:1847. [PMID: 34440615 DOI: 10.3390/cells10081847] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 9.0] [Reference Citation Analysis]
161 Pabla BS, Alex Wiles C, Slaughter JC, Scoville EA, Dalal RL, Beaulieu DB, Schwartz DA, Horst SN. Safety and Efficacy of Vedolizumab Versus Tumor Necrosis Factor α Antagonists in an Elderly IBD Population: A Single Institution Retrospective Experience. Dig Dis Sci 2021. [PMID: 34268660 DOI: 10.1007/s10620-021-07129-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
162 Vermeire S, Lukáš M, Magro F, Adsul S, Lindner D, Rosario M, Roth J, Danese S. Vedolizumab Efficacy, Safety, and Pharmacokinetics With Reduced Frequency of Dosing From Every 4 Weeks to Every 8 Weeks in Patients With Crohn's Disease or Ulcerative Colitis. J Crohns Colitis 2020;14:1066-73. [PMID: 32060515 DOI: 10.1093/ecco-jcc/jjaa027] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
163 Siegmund B. Janus Kinase inhibitors in the New Treatment Paradigms of Inflammatory Bowel Disease. J Crohns Colitis 2020;14:S761-6. [PMID: 31922534 DOI: 10.1093/ecco-jcc/jjaa003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
164 Fabiszewska S, Derda E, Szymanska E, Osiecki M, Kierkus J. Safety and Effectiveness of Vedolizumab for the Treatment of Pediatric Patients with Very Early Onset Inflammatory Bowel Diseases. J Clin Med 2021;10:2997. [PMID: 34279480 DOI: 10.3390/jcm10132997] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
165 Ye BD, Cheon JH, Song KH, Kim JS, Kim YH, Yoon H, Lee KM, Kang SB, Jang BI, Park JJ, Kim TO, Lee DW, Foo CY, Shin JE, Park DI. The real-world outcomes of vedolizumab in patients with ulcerative colitis in Korea: a multicenter retrospective study. Therap Adv Gastroenterol 2021;14:17562848211024769. [PMID: 34285716 DOI: 10.1177/17562848211024769] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
166 Ito N, Takeuchi I, Kyodo R, Hirano Y, Sato T, Usami M, Shimizu H, Shimizu T, Arai K. Features and Outcomes of Children with Ulcerative Colitis who Undergo a Diagnostic Change: A Single-Center Experience. Pediatr Gastroenterol Hepatol Nutr 2021;24:357-65. [PMID: 34316470 DOI: 10.5223/pghn.2021.24.4.357] [Reference Citation Analysis]
167 Hong SJ, Katz S. The elderly IBD patient in the modern era: changing paradigms in risk stratification and therapeutic management. Therap Adv Gastroenterol 2021;14:17562848211023399. [PMID: 34276809 DOI: 10.1177/17562848211023399] [Reference Citation Analysis]
168 Eriksson C, Rundquist S, Lykiardopoulos V, Udumyan R, Karlén P, Grip O, Söderman C, Almer S, Hertervig E, Marsal J, Gunnarsson J, Malmgren C, Delin J, Strid H, Sjöberg M, Öberg D, Bergemalm D, Hjortswang H, Halfvarson J; SWIBREG SVEAH Study Group. Real-world effectiveness of vedolizumab in inflammatory bowel disease: week 52 results from the Swedish prospective multicentre SVEAH study. Therap Adv Gastroenterol 2021;14:17562848211023386. [PMID: 34276808 DOI: 10.1177/17562848211023386] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
169 Caron B, Sandborn WJ, Schreiber S, Panaccione R, Danese S, Peyrin-Biroulet L. Drug development for ulcerative proctitis: current concepts. Gut 2021;70:1203-9. [PMID: 33789968 DOI: 10.1136/gutjnl-2021-324108] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
170 Neurath MF. COVID-19: biologic and immunosuppressive therapy in gastroenterology and hepatology. Nat Rev Gastroenterol Hepatol 2021. [PMID: 34188251 DOI: 10.1038/s41575-021-00480-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
171 Sicilia B, Arias L, Hontoria G, García N, Badia E, Gomollón F. Are Steroids Still Useful in Immunosuppressed Patients With Inflammatory Bowel Disease? A Retrospective, Population-Based Study. Front Med (Lausanne) 2021;8:651685. [PMID: 34249960 DOI: 10.3389/fmed.2021.651685] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
172 Kyriakos N, Papaefthymiou A, Giakoumis M, Iatropoulos G, Mantzaris G, Liatsos C. Informed consent in inflammatory bowel disease: a necessity in real-world clinical practice. Ann Gastroenterol 2021;34:466-75. [PMID: 34276184 DOI: 10.20524/aog.2021.0635] [Reference Citation Analysis]
173 Kapoor A, Crowley E. Advances in Therapeutic Drug Monitoring in Biologic Therapies for Pediatric Inflammatory Bowel Disease. Front Pediatr 2021;9:661536. [PMID: 34123968 DOI: 10.3389/fped.2021.661536] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
174 Haanen J, Ernstoff M, Wang Y, Menzies A, Puzanov I, Grivas P, Larkin J, Peters S, Thompson J, Obeid M. Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy. J Immunother Cancer 2020;8:e000604. [PMID: 32532839 DOI: 10.1136/jitc-2020-000604] [Cited by in Crossref: 26] [Cited by in F6Publishing: 44] [Article Influence: 26.0] [Reference Citation Analysis]
175 Kim K, Jo KW, Shim TS, Park JH, Hwang SW, Park SH, Yang DH, Byeon JS, Myung SJ, Yang SK, Ye BD. Frequency of Positive Conversion of Interferon-Gamma Release Assay Results Among Patients With Inflammatory Bowel Disease Treated With Non-tumor Necrosis Factor Inhibitors. Front Med (Lausanne) 2021;8:670242. [PMID: 34095175 DOI: 10.3389/fmed.2021.670242] [Reference Citation Analysis]
176 Ahmed W, Scott FI. Closing the Gap: the Real-World Risk of Serious Infections With Vedolizumab in Comparison With Anti-TNF Therapy in Inflammatory Bowel Disease. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00564-4. [PMID: 34022455 DOI: 10.1016/j.cgh.2021.05.026] [Reference Citation Analysis]
177 Segal JP, LeBlanc JF, Hart AL. Ulcerative colitis: an update. Clin Med (Lond) 2021;21:135-9. [PMID: 33762374 DOI: 10.7861/clinmed.2021-0080] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
178 Noviello D, Mager R, Roda G, Borroni RG, Fiorino G, Vetrano S. The IL23-IL17 Immune Axis in the Treatment of Ulcerative Colitis: Successes, Defeats, and Ongoing Challenges. Front Immunol 2021;12:611256. [PMID: 34079536 DOI: 10.3389/fimmu.2021.611256] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
179 di Giuseppe R, Plachta-Danielzik S, Mohl W, Hoffstadt M, Krause T, Bokemeyer B, Schreiber S. Profile of patients with inflammatory bowel disease in conjunction with unmet needs and decision-making for choosing a new biologic therapy: a baseline analysis of the VEDOIBD-Study. Int J Colorectal Dis 2021. [PMID: 33963913 DOI: 10.1007/s00384-021-03943-5] [Reference Citation Analysis]
180 Matsumoto K, Kurasawa T, Yoshimoto K, Suzuki K, Takeuchi T. Identification of neutrophil β2-integrin LFA-1 as a potential mechanistic biomarker in ANCA-associated vasculitis via microarray and validation analyses. Arthritis Res Ther 2021;23:136. [PMID: 33957974 DOI: 10.1186/s13075-021-02510-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
181 Harris C, Cummings JRF. JAK1 inhibition and inflammatory bowel disease. Rheumatology (Oxford) 2021;60:ii45-51. [PMID: 33950226 DOI: 10.1093/rheumatology/keaa896] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
182 Mahmoud R, van Lieshout C, Frederix GWJ, Jharap B, Oldenburg B. Continuation of Anti-TNF in Patients With Ulcerative Colitis in Remission Is Not Cost-effective Compared With Treatment Withdrawal: A Markov Model. J Crohns Colitis 2021;15:709-18. [PMID: 33125060 DOI: 10.1093/ecco-jcc/jjaa219] [Reference Citation Analysis]
183 Wiendl M, Becker E, Müller TM, Voskens CJ, Neurath MF, Zundler S. Targeting Immune Cell Trafficking - Insights From Research Models and Implications for Future IBD Therapy. Front Immunol 2021;12:656452. [PMID: 34017333 DOI: 10.3389/fimmu.2021.656452] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
184 Khan N, Pernes T, Weiss A, Trivedi C, Patel M, Xie D, Yang YX. Incidence of Infections and Malignancy Among Elderly Male Patients with IBD Exposed to Vedolizumab, Prednisone, and 5-ASA Medications: A Nationwide Retrospective Cohort Study. Adv Ther 2021;38:2586-98. [PMID: 33844132 DOI: 10.1007/s12325-021-01713-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
185 Danne C, Rolhion N, Sokol H. Recipient factors in faecal microbiota transplantation: one stool does not fit all. Nat Rev Gastroenterol Hepatol 2021;18:503-13. [PMID: 33907321 DOI: 10.1038/s41575-021-00441-5] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 31.0] [Reference Citation Analysis]
186 Nakase H, Uchino M, Shinzaki S, Matsuura M, Matsuoka K, Kobayashi T, Saruta M, Hirai F, Hata K, Hiraoka S, Esaki M, Sugimoto K, Fuji T, Watanabe K, Nakamura S, Inoue N, Itoh T, Naganuma M, Hisamatsu T, Watanabe M, Miwa H, Enomoto N, Shimosegawa T, Koike K. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. J Gastroenterol 2021;56:489-526. [PMID: 33885977 DOI: 10.1007/s00535-021-01784-1] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 45.0] [Reference Citation Analysis]
187 Singh A, Mahajan R, Kedia S, Dutta AK, Anand A, Bernstein CN, Desai D, Pai CG, Makharia G, Tevethia HV, Mak JW, Kaur K, Peddi K, Ranjan MK, Arkkila P, Kochhar R, Banerjee R, Sinha SK, Ng SC, Hanauer S, Verma S, Dutta U, Midha V, Mehta V, Ahuja V, Sood A. Use of thiopurines in inflammatory bowel disease: an update. Intest Res 2022;20:11-30. [PMID: 33845546 DOI: 10.5217/ir.2020.00155] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 12.0] [Reference Citation Analysis]
188 Scott FI, Luo M, Shah Y, Lasch K, Vajravelu RK, Mamtani R, Fennimore B, Gerich ME, Lewis JD. Identification of the Most Cost-effective Position of Vedolizumab Among the Available Biologic Drugs for the Treatment of Ulcerative Colitis. J Crohns Colitis 2020;14:575-87. [PMID: 31901085 DOI: 10.1093/ecco-jcc/jjz212] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
189 Al-Bawardy B, Shivashankar R, Proctor DD. Novel and Emerging Therapies for Inflammatory Bowel Disease. Front Pharmacol 2021;12:651415. [PMID: 33935763 DOI: 10.3389/fphar.2021.651415] [Cited by in Crossref: 6] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
190 Schmidt C, Grunert PC, Stallmach A. An Update for Pharmacologists on New Treatment Options for Inflammatory Bowel Disease: The Clinicians' Perspective. Front Pharmacol 2021;12:655054. [PMID: 33912062 DOI: 10.3389/fphar.2021.655054] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
191 George J, Singh S, Dulai PS, Ma C, Nguyen T, Feagan BG, Sandborn WJ, Jairath V. Corticosteroid-Free Remission vs Overall Remission in Clinical Trials of Moderate-Severe Ulcerative Colitis and Crohn's Disease. Inflamm Bowel Dis 2020;26:515-23. [PMID: 31504528 DOI: 10.1093/ibd/izz193] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
192 Iizuka M, Etou T, Shimodaira Y, Hatakeyama T, Sagara S. Cytapheresis re-induces high-rate steroid-free remission in patients with steroid-dependent and steroid-refractory ulcerative colitis. World J Gastroenterol 2021; 27(12): 1194-1212 [PMID: 33828394 DOI: 10.3748/wjg.v27.i12.1194] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
193 Sommer K, Wiendl M, Müller TM, Heidbreder K, Voskens C, Neurath MF, Zundler S. Intestinal Mucosal Wound Healing and Barrier Integrity in IBD-Crosstalk and Trafficking of Cellular Players. Front Med (Lausanne) 2021;8:643973. [PMID: 33834033 DOI: 10.3389/fmed.2021.643973] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
194 Rosiou K, Selinger CP. Acute severe ulcerative colitis: management advice for internal medicine and emergency physicians. Intern Emerg Med 2021;16:1433-42. [PMID: 33754227 DOI: 10.1007/s11739-021-02704-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
195 Holvoet T, Lobaton T, Hindryckx P. Optimal Management of Acute Severe Ulcerative Colitis (ASUC): Challenges and Solutions. Clin Exp Gastroenterol 2021;14:71-81. [PMID: 33727846 DOI: 10.2147/CEG.S197719] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
196 Caio G, Lungaro L, Caputo F, Muccinelli M, Marcello MC, Zoli E, Volta U, De Giorgio R, Zoli G. Recurrent myocarditis in a patient with active ulcerative colitis: a case report and review of the literature. BMJ Open Gastroenterol 2021;8:e000587. [PMID: 33722804 DOI: 10.1136/bmjgast-2020-000587] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
197 Restellini S, Afif W. Update on TDM (Therapeutic Drug Monitoring) with Ustekinumab, Vedolizumab and Tofacitinib in Inflammatory Bowel Disease. J Clin Med 2021;10:1242. [PMID: 33802816 DOI: 10.3390/jcm10061242] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
198 Hoshi N, Inoue J, Sasaki D, Sasaki K. The Kobe University Human Intestinal Microbiota Model for gut intervention studies. Appl Microbiol Biotechnol 2021;105:2625-32. [PMID: 33718974 DOI: 10.1007/s00253-021-11217-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
199 Domènech E, Grífols JR, Akbar A, Dignass AU. Use of granulocyte/monocytapheresis in ulcerative colitis: A practical review from a European perspective. World J Gastroenterol 2021; 27(10): 908-918 [PMID: 33776362 DOI: 10.3748/wjg.v27.i10.908] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
200 Bamias G, Kokkotis G, Gizis M, Kapizioni C, Karmiris K, Koureta E, Kyriakos N, Leonidakis G, Makris K, Markopoulos P, Michalopoulos G, Michopoulos S, Papaconstantinou I, Polymeros D, Siakavellas SI, Triantafyllou K, Tsironi E, Tsoukali E, Tzouvala M, Viazis N, Xourafas V, Zacharopoulou E, Zampeli E, Zografos K, Papatheodoridis G, Mantzaris G. Predictors of Response to Vedolizumab in Patients with Ulcerative Colitis: Results from the Greek VEDO-IBD Cohort. Dig Dis Sci 2021. [PMID: 33751325 DOI: 10.1007/s10620-021-06907-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
201 Jin QW, Wang XD. Progress in research of vedolizumab in treatment of inflammatory bowel disease. Shijie Huaren Xiaohua Zazhi 2021; 29(5): 248-255 [DOI: 10.11569/wcjd.v29.i5.248] [Reference Citation Analysis]
202 Sparrow MP, Papamichael K, Ward MG, Riviere P, Laharie D, Paul S, Roblin X. Therapeutic Drug Monitoring of Biologics During Induction to Prevent Primary Non-Response. J Crohns Colitis 2020;14:542-56. [PMID: 31549158 DOI: 10.1093/ecco-jcc/jjz162] [Cited by in Crossref: 16] [Cited by in F6Publishing: 23] [Article Influence: 16.0] [Reference Citation Analysis]
203 Mader O, Juillerat P, Biedermann L, Michetti P, Hruz P, Pittet V, Rogler G, Zahnd-Straumann N, Seibold F. Factors influencing the outcome of vedolizumab treatment: Real-life data with objective outcome measurements. United European Gastroenterol J 2021;9:398-406. [PMID: 33203339 DOI: 10.1177/2050640620965106] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
204 Choi S, Choi BS, Choe BH, Kang B. Successful treatment with vedolizumab in an adolescent with Crohn disease who had developed active pulmonary tuberculosis while receiving infliximab. Yeungnam Univ J Med 2021;38:251-7. [PMID: 33601494 DOI: 10.12701/yujm.2020.00878] [Reference Citation Analysis]
205 Jairath V, Chan K, Lasch K, Keeping S, Agboton C, Blake A, Patel H. Integrating efficacy and safety of vedolizumab compared with other advanced therapies to assess net clinical benefit of ulcerative colitis treatments: a network meta-analysis. Expert Rev Gastroenterol Hepatol 2021;15:711-22. [PMID: 33599181 DOI: 10.1080/17474124.2021.1880319] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
206 Privitera G, Pugliese D, Rapaccini GL, Gasbarrini A, Armuzzi A, Guidi L. Predictors and Early Markers of Response to Biological Therapies in Inflammatory Bowel Diseases. J Clin Med 2021;10:853. [PMID: 33669579 DOI: 10.3390/jcm10040853] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
207 Riedel JH, Turner JE, Panzer U. T helper cell trafficking in autoimmune kidney diseases. Cell Tissue Res 2021. [PMID: 33598825 DOI: 10.1007/s00441-020-03403-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
208 Di Paolo A, Luci G. Personalized Medicine of Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacogenetics, Therapeutic Drug Monitoring, and Beyond. Front Pharmacol 2020;11:610806. [PMID: 33628180 DOI: 10.3389/fphar.2020.610806] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
209 Sun W, Fennimore B, Beaulieu DB, Arsenescu R, Stein AC, Chen J, Lin T, McKnight S, Kadali H, Rosario M, Lirio RA. Vedolizumab Concentrations in Breast Milk: Results from a Prospective, Postmarketing, Milk-Only Lactation Study in Nursing Mothers with Inflammatory Bowel Disease. Clin Pharmacokinet 2021;60:811-8. [PMID: 33544318 DOI: 10.1007/s40262-021-00985-4] [Reference Citation Analysis]
210 Luzentales-Simpson M, Pang YCF, Zhang A, Sousa JA, Sly LM. Vedolizumab: Potential Mechanisms of Action for Reducing Pathological Inflammation in Inflammatory Bowel Diseases. Front Cell Dev Biol 2021;9:612830. [PMID: 33614645 DOI: 10.3389/fcell.2021.612830] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
211 Debnath P, Rathi PM. Vedolizumab in Inflammatory Bowel Disease: West versus East. Inflamm Intest Dis 2021;6:1-17. [PMID: 33850834 DOI: 10.1159/000512805] [Reference Citation Analysis]
212 Pauwels RWM, van der Woude CJ, Erler NS, de Vries AC. Fecal calprotectin is an early predictor of endoscopic response and histologic remission after the start of vedolizumab in inflammatory bowel disease. Therap Adv Gastroenterol 2020;13:1756284820979765. [PMID: 33488771 DOI: 10.1177/1756284820979765] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
213 Marafini I, Troncone E, Rocchetti I, Monteleone G. Respiratory Tract Infections in Inflammatory Bowel Disease Patients Taking Vedolizumab: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Front Pharmacol 2020;11:585732. [PMID: 33551798 DOI: 10.3389/fphar.2020.585732] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
214 Mühl L, Becker E, Müller TM, Atreya R, Atreya I, Neurath MF, Zundler S. Clinical experiences and predictors of success of treatment with vedolizumab in IBD patients: a cohort study. BMC Gastroenterol 2021;21:33. [PMID: 33482730 DOI: 10.1186/s12876-021-01604-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
215 Shen Z, Zheng K, Zou J, Gu P, Xing J, Zhang L, Zhu L, Shen H. Chinese herbal extract granules combined with 5-aminosalicylic acid for patients with moderately active ulcerative colitis: study protocol for a multicenter randomized double-blind placebo-controlled trial. Trials 2021;22:55. [PMID: 33441157 DOI: 10.1186/s13063-020-05012-8] [Reference Citation Analysis]
216 Zou F, Wang X, Glitza Oliva IC, McQuade JL, Wang J, Zhang HC, Thompson JA, Thomas AS, Wang Y. Fecal calprotectin concentration to assess endoscopic and histologic remission in patients with cancer with immune-mediated diarrhea and colitis. J Immunother Cancer 2021;9:e002058. [PMID: 33436487 DOI: 10.1136/jitc-2020-002058] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
217 Sarvestani SK, Signs S, Hu B, Yeu Y, Feng H, Ni Y, Hill DR, Fisher RC, Ferrandon S, DeHaan RK, Stiene J, Cruise M, Hwang TH, Shen X, Spence JR, Huang EH. Induced organoids derived from patients with ulcerative colitis recapitulate colitic reactivity. Nat Commun 2021;12:262. [PMID: 33431859 DOI: 10.1038/s41467-020-20351-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
218 Bakthavatsalam D, Craft JW Jr, Kazansky A, Nguyen N, Bae G, Caivano AR, Gundlach CW 4th, Aslam A, Ali S, Gupta S, Lin SY, Parthiban HD, Vanderslice P, Stephan CC, Woodside DG. Identification of Inhibitors of Integrin Cytoplasmic Domain Interactions With Syk. Front Immunol 2020;11:575085. [PMID: 33488575 DOI: 10.3389/fimmu.2020.575085] [Reference Citation Analysis]
219 Groudan K, Gupta K, Singhania R. Vedolizumab (Entyvio®) for the Treatment of Pyoderma Gangrenosum in a Crohn's Disease Patient. Cureus 2021;13:e12582. [PMID: 33457145 DOI: 10.7759/cureus.12582] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
220 Hanzel J, Ma C, Casteele NV, Khanna R, Jairath V, Feagan BG. Vedolizumab and Extraintestinal Manifestations in Inflammatory Bowel Disease. Drugs 2021;81:333-47. [PMID: 33400241 DOI: 10.1007/s40265-020-01460-3] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
221 Sleiman J, El Ouali S, Qazi T, Cohen B, Steele SR, Baker ME, Rieder F. Prevention and Treatment of Stricturing Crohn's Disease - Perspectives and Challenges. Expert Rev Gastroenterol Hepatol 2021;15:401-11. [PMID: 33225766 DOI: 10.1080/17474124.2021.1854732] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
222 Shivaji UN, Bazarova A, Critchlow T, Smith SCL, Nardone OM, Love M, Davis J, Ghosh S, Iacucci M. Clinical outcomes, predictors of prognosis and health economics consequences in IBD patients after discontinuation of the first biological therapy. Therap Adv Gastroenterol 2020;13:1756284820981216. [PMID: 34104206 DOI: 10.1177/1756284820981216] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
223 Sun W, Lirio RA, Schneider J, Aubrecht J, Kadali H, Baratta M, Gulati P, Suri A, Lin T, Vasudevan R, Rosario M. Assessment of Vedolizumab Disease-Drug-Drug Interaction Potential in Patients With Inflammatory Bowel Diseases. Clin Pharmacol Drug Dev 2021;10:734-47. [PMID: 33331142 DOI: 10.1002/cpdd.891] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
224 Oulghazi S, Wegner SK, Spohn G, Müller N, Harenkamp S, Stenzinger A, Papayannopoulou T, Bonig H. Adaptive Immunity and Pathogenesis of Diabetes: Insights Provided by the α4-Integrin Deficient NOD Mouse. Cells 2020;9:E2597. [PMID: 33291571 DOI: 10.3390/cells9122597] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
225 Nakase H. Optimizing the Use of Current Treatments and Emerging Therapeutic Approaches to Achieve Therapeutic Success in Patients with Inflammatory Bowel Disease. Gut Liver 2020;14:7-19. [PMID: 30919602 DOI: 10.5009/gnl18203] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
226 Dohos D, Hanák L, Szakács Z, Kiss S, Párniczky A, Erőss B, Pázmány P, Hegyi P, Sarlós P. Systematic review with meta-analysis: the effects of immunomodulator or biological withdrawal from mono- or combination therapy in inflammatory bowel disease. Aliment Pharmacol Ther 2021;53:220-33. [PMID: 33249621 DOI: 10.1111/apt.16182] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
227 Jefremow A, Neurath MF. SARS-CoV-2 Virus Manifestations in the Gastrointestinal Tract: Therapeutic Implications. Visc Med 2021;37:63-9. [PMID: 33693046 DOI: 10.1159/000513180] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
228 Alkhatry M, Al-Rifai A, Annese V, Georgopoulos F, Jazzar AN, Khassouan AM, Koutoubi Z, Nathwani R, Taha MS, Limdi JK. First United Arab Emirates consensus on diagnosis and management of inflammatory bowel diseases: A 2020 Delphi consensus. World J Gastroenterol 2020; 26(43): 6710-6769 [PMID: 33268959 DOI: 10.3748/wjg.v26.i43.6710] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
229 Ferenczi S, Solymosi N, Horváth I, Szeőcs N, Grózer Z, Kuti D, Juhász B, Winkler Z, Pankotai T, Sükösd F, Stágel A, Paholcsek M, Dóra D, Nagy N, Kovács KJ, Zanoni I, Szallasi Z. Efficient treatment of a preclinical inflammatory bowel disease model with engineered bacteria. Mol Ther Methods Clin Dev 2021;20:218-26. [PMID: 33426148 DOI: 10.1016/j.omtm.2020.11.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
230 Kucharzik T, Koletzko S, Kannengiesser K, Dignass A. Ulcerative Colitis-Diagnostic and Therapeutic Algorithms.Dtsch Arztebl Int. 2020;117:564-574. [PMID: 33148393 DOI: 10.3238/arztebl.2020.0564] [Cited by in Crossref: 4] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
231 Danese S, Subramaniam K, Van Zyl J, Adsul S, Lindner D, Roth J, Vermeire S. Vedolizumab treatment persistence and safety in a 2-year data analysis of an extended access programme. Aliment Pharmacol Ther 2021;53:265-72. [PMID: 33210333 DOI: 10.1111/apt.16160] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
232 Wyant T, Yang L, Rosario M. Comparison of the ELISA and ECL Assay for Vedolizumab Anti-drug Antibodies: Assessing the Impact on Pharmacokinetics and Safety Outcomes of the Phase 3 GEMINI Trials. AAPS J 2020;23:3. [PMID: 33200296 DOI: 10.1208/s12248-020-00518-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
233 Hernandez L, Kuwabara H, Shah A, Yamabe K, Burnett H, Fahrbach K, Koufopoulou M, Iwakiri R. Cost-Effectiveness Analysis of Vedolizumab Compared with Other Biologics in Anti-TNF-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan. Pharmacoeconomics 2020;38:69-84. [PMID: 31552601 DOI: 10.1007/s40273-019-00841-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
234 Domenis R, Marino M, Cifù A, Scardino G, Curcio F, Fabris M. Circulating exosomes express α4β7 integrin and compete with CD4+ T cells for the binding to Vedolizumab. PLoS One 2020;15:e0242342. [PMID: 33180848 DOI: 10.1371/journal.pone.0242342] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
235 Park EJ, Myint PK, Ito A, Appiah MG, Darkwah S, Kawamoto E, Shimaoka M. Integrin-Ligand Interactions in Inflammation, Cancer, and Metabolic Disease: Insights Into the Multifaceted Roles of an Emerging Ligand Irisin. Front Cell Dev Biol 2020;8:588066. [PMID: 33195249 DOI: 10.3389/fcell.2020.588066] [Cited by in Crossref: 8] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
236 Karuppuchamy T, Tyler CJ, Lundborg LR, Pérez-Jeldres T, Kimball AK, Clambey ET, Jedlicka P, Rivera-Nieves J. Sphingosine-1-Phosphate Lyase Inhibition Alters the S1P Gradient and Ameliorates Crohn's-Like Ileitis by Suppressing Thymocyte Maturation. Inflamm Bowel Dis 2020;26:216-28. [PMID: 31807751 DOI: 10.1093/ibd/izz174] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
237 Yarur AJ, Deepak P, Vande Casteele N, Battat R, Jain A, Okada L, Osterman M, Regueiro M. Association Between Vedolizumab Levels, Anti-vedolizumab Antibodies, and Endoscopic Healing Index in a Large Population of Patients with Inflammatory Bowel Diseases. Dig Dis Sci 2021;66:3563-9. [PMID: 33089483 DOI: 10.1007/s10620-020-06669-6] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
238 McCarthy NE, Stagg AJ, Price CL, Mann ER, Gellatly NL, Al-Hassi HO, Knight SC, Panoskaltsis N. Patients with gastrointestinal irritability after TGN1412-induced cytokine storm displayed selective expansion of gut-homing αβ and γδT cells. Cancer Immunol Immunother 2021;70:1143-53. [PMID: 33048222 DOI: 10.1007/s00262-020-02723-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
239 Ikeuchi A, Kakiuchi T, Ibi A, Matsuo M. A pediatric case of moderate active ulcerative colitis successfully treated with vedolizumab in Japan. Clin J Gastroenterol 2021;14:146-51. [PMID: 33040281 DOI: 10.1007/s12328-020-01260-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
240 McGuinty M, Angel JB, Cooper CL, Cowan J, MacPherson PA, Kumar A, Murthy S, Sy R, Dennehy M, Tremblay N, Byrareddy SN, Cameron DW. Vedolizumab treatment across antiretroviral treatment interruption in chronic HIV infection: the HAVARTI protocol for a pilot dose-ranging clinical trial to assess safety, tolerance, immunological and virological activity. BMJ Open 2020;10:e041359. [PMID: 33033101 DOI: 10.1136/bmjopen-2020-041359] [Reference Citation Analysis]
241 Moriichi K, Fujiya M, Okumura T. The endoscopic diagnosis of mucosal healing and deep remission in inflammatory bowel disease. Dig Endosc 2021;33:1008-23. [PMID: 33020947 DOI: 10.1111/den.13863] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
242 Gamliel A, Werner L, Pinsker M, Salamon N, Weiss B, Shouval DS. Circulating α4β7+ Memory T Cells in Pediatric IBD Patients Express a Polyclonal T Cell Receptor Repertoire. Clin Exp Gastroenterol 2020;13:439-47. [PMID: 33061522 DOI: 10.2147/CEG.S271565] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
243 De Vries LCS, Ghiboub M, van Hamersveld PHP, Welting O, Verseijden C, Bell MJ, Rioja I, Prinjha RK, Koelink PJ, Strobl B, Müller M, D'Haens GR, Wildenberg ME, De Jonge WJ. Tyrosine Kinase 2 Signalling Drives Pathogenic T cells in Colitis. J Crohns Colitis 2021;15:617-30. [PMID: 33005945 DOI: 10.1093/ecco-jcc/jjaa199] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
244 Gao RY, Shearn CT, Orlicky DJ, Battista KD, Alexeev EE, Cartwright IM, Lanis JM, Kostelecky RE, Ju C, Colgan SP, Fennimore BP. Bile acids modulate colonic MAdCAM-1 expression in a murine model of combined cholestasis and colitis. Mucosal Immunol 2021;14:479-90. [PMID: 33004979 DOI: 10.1038/s41385-020-00347-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
245 Vaughn BP, Yarur AJ, Graziano E, Campbell JP, Bhattacharya A, Lee JY, Gheysens K, Papamichael K, Osterman MT, Cheifetz AS, Cross RK. Vedolizumab Serum Trough Concentrations and Response to Dose Escalation in Inflammatory Bowel Disease. J Clin Med 2020;9:E3142. [PMID: 32998473 DOI: 10.3390/jcm9103142] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
246 Törüner M, Akpınar H, Akyüz F, Dağlı Ü, Över Hamzaoğlu H, Tezel A, Ünsal B, Yıldırım S, Çelik AF. 2019 Expert opinion on biological treatment use in inflammatory bowel disease management. Turk J Gastroenterol 2019;30:S913-46. [PMID: 32207688 DOI: 10.5152/tjg.2019.061119] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
247 Osterman MT, VanDussen KL, Gordon IO, Davis EM, Li K, Simpson K, Ciorba M, Glover SC, Abraham B, Guo X, Yee EU, Allard FD, Perrigoue JG, Claggett B, Shen B, Stappenbeck TS, Liu JJ. Epithelial Cell Biomarkers Are Predictive of Response to Biologic Agents in Crohn's Disease. Inflamm Bowel Dis 2021;27:677-85. [PMID: 32964238 DOI: 10.1093/ibd/izaa251] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
248 Verma A, Sharda S, Rathi B, Somvanshi P, Pandey BD. Elucidating potential molecular signatures through host-microbe interactions for reactive arthritis and inflammatory bowel disease using combinatorial approach. Sci Rep 2020;10:15131. [PMID: 32934294 DOI: 10.1038/s41598-020-71674-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
249 Asscher VER, Biemans VBC, Pierik MJ, Dijkstra G, Löwenberg M, van der Marel S, de Boer NKH, Bodelier AGL, Jansen JM, West RL, Haans JJL, van Dop WA, Weersma RK, Hoentjen F, Maljaars PWJ; Dutch Initiative on Crohn and Colitis (ICC) . Comorbidity, not patient age, is associated with impaired safety outcomes in vedolizumab- and ustekinumab-treated patients with inflammatory bowel disease-a prospective multicentre cohort study. Aliment Pharmacol Ther 2020;52:1366-76. [PMID: 32901983 DOI: 10.1111/apt.16073] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
250 Dou Y, Li C, Li L, Guo J, Zhang J. Bioresponsive drug delivery systems for the treatment of inflammatory diseases. J Control Release 2020;327:641-66. [PMID: 32911014 DOI: 10.1016/j.jconrel.2020.09.008] [Cited by in Crossref: 19] [Cited by in F6Publishing: 47] [Article Influence: 9.5] [Reference Citation Analysis]
251 Ooi CJ, Hilmi IN, Kim HJ, Jalihal U, Wu DC, Demuth D, Lindner D, Adsul S. Efficacy and safety of vedolizumab in ulcerative colitis in patients from Asian countries in the GEMINI 1 study. Intest Res 2021;19:71-82. [PMID: 32877600 DOI: 10.5217/ir.2019.09159] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
252 Argollo M, Kotze PG, Kakkadasam P, D'Haens G. Optimizing biologic therapy in IBD: how essential is therapeutic drug monitoring? Nat Rev Gastroenterol Hepatol 2020;17:702-10. [PMID: 32879465 DOI: 10.1038/s41575-020-0352-2] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 12.0] [Reference Citation Analysis]
253 Gunst JD, Schleimann MH, Pahus MH, Østergaard L, Tolstrup M, Søgaard OS. HIV-1 acquisition in a man with ulcerative colitis on anti-α4β7 mAb vedolizumab treatment. AIDS 2020;34:1689-92. [PMID: 32769767 DOI: 10.1097/QAD.0000000000002619] [Reference Citation Analysis]
254 Shashi P, Gopalakrishnan D, Parikh MP, Shen B, Kochhar G. Efficacy and safety of vedolizumab in elderly patients with inflammatory bowel disease: a matched case-control study. Gastroenterol Rep (Oxf) 2020;8:306-11. [PMID: 32843978 DOI: 10.1093/gastro/goz041] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
255 Petryszyn P, Ekk-Cierniakowski P, Zurakowski G. Infliximab, adalimumab, golimumab, vedolizumab and tofacitinib in moderate to severe ulcerative colitis: comparative cost-effectiveness study in Poland. Therap Adv Gastroenterol 2020;13:1756284820941179. [PMID: 32922513 DOI: 10.1177/1756284820941179] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
256 Radeke HH, Stein J, Van Assche G, Rogler G, Lakatos PL, Muellershausen F, Moulin P, Jarvis P, Colin L, Gergely P, Kruis W. A Multicentre, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of the S1P Receptor Agonist KRP203 in Patients with Moderately Active Refractory Ulcerative Colitis. Inflamm Intest Dis 2020;5:180-90. [PMID: 33313070 DOI: 10.1159/000509393] [Cited by in Crossref: 5] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
257 Sasson SC, Zaunders JJ, Nahar K, Munier CML, Fairfax BP, Olsson-Brown A, Jolly C, Read SA, Ahlenstiel G, Palendira U, Scolyer RA, Carlino MS, Payne MJ, Cheung VTF, Gupta T, Klenerman P, Long GV, Brain O, Menzies AM, Kelleher AD. Mucosal-associated invariant T (MAIT) cells are activated in the gastrointestinal tissue of patients with combination ipilimumab and nivolumab therapy-related colitis in a pathology distinct from ulcerative colitis. Clin Exp Immunol 2020;202:335-52. [PMID: 32734627 DOI: 10.1111/cei.13502] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
258 Olbjørn C, Rove JB, Jahnsen J. Combination of Biological Agents in Moderate to Severe Pediatric Inflammatory Bowel Disease: A Case Series and Review of the Literature. Paediatr Drugs 2020;22:409-16. [PMID: 32378002 DOI: 10.1007/s40272-020-00396-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
259 Pulusu SSR, Srinivasan A, Krishnaprasad K, Cheng D, Begun J, Keung C, Van Langenberg D, Thin L, Mogilevski T, De Cruz P, Radford-Smith G, Flanagan E, Bell S, Kashkooli S, Sparrow M, Ghaly S, Bampton P, Sawyer E, Connor S, Rizvi QUA, Andrews JM, Mahy G, Chivers P, Travis S, Lawrance IC. Vedolizumab for ulcerative colitis: Real world outcomes from a multicenter observational cohort of Australia and Oxford. World J Gastroenterol 2020; 26(30): 4428-4441 [PMID: 32874055 DOI: 10.3748/wjg.v26.i30.4428] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 6] [Article Influence: 5.5] [Reference Citation Analysis]
260 Weissman S, Sinh P, Mehta TI, Thaker RK, Derman A, Heiberger C, Qureshi N, Amrutiya V, Atoot A, Dave M, Tabibian JH. Atherosclerotic cardiovascular disease in inflammatory bowel disease: The role of chronic inflammation. World J Gastrointest Pathophysiol 2020; 11(5): 104-113 [PMID: 32832194 DOI: 10.4291/wjgp.v11.i5.104] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
261 Naganuma M. Solving the questions regarding 5-aminosalitylate formulation in the treatment of ulcerative colitis. J Gastroenterol 2020;55:1013-22. [PMID: 32778960 DOI: 10.1007/s00535-020-01713-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
262 Macaluso FS, Fries W, Renna S, Viola A, Muscianisi M, Cappello M, Guida L, Siringo S, Camilleri S, Garufi S, Privitera AC, Belluardo N, Giangreco E, Bertolami C, Vassallo R, Rizzuto G, Orlando R, Ventimiglia M, Orlando A; Sicilian Network for Inflammatory Bowel Disease (SN-IBD). Effectiveness and safety of vedolizumab in biologically naïve patients: A real-world multi-centre study. United European Gastroenterol J 2020;8:1045-55. [PMID: 32772830 DOI: 10.1177/2050640620948802] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
263 Nakamura M, Yamamura T, Maeda K, Sawada T, Mizutani Y, Ishikawa E, Ohashi A, Kajikawa G, Furukawa K, Ohno E, Honda T, Kawashima H, Ishigami M, Fujishiro M. Refractory Ulcerative Colitis Improved by Scheduled Combination Therapy of Vedolizumab and Granulocyte and Monocyte Adsorptive Apheresis. Intern Med 2020;59:3009-14. [PMID: 32727993 DOI: 10.2169/internalmedicine.5302-20] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
264 Chapuy L, Bsat M, Rubio M, Sarkizova S, Therrien A, Bouin M, Orlicka K, Weber A, Soucy G, Villani AC, Sarfati M. IL-12 and Mucosal CD14+ Monocyte-Like Cells Induce IL-8 in Colonic Memory CD4+ T Cells of Patients With Ulcerative Colitis but not Crohn's Disease. J Crohns Colitis 2020;14:79-95. [PMID: 31206576 DOI: 10.1093/ecco-jcc/jjz115] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
265 Perry C, Fischer K, Elmoursi A, Kern C, Currier A, Kudaravalli P, Akanbi O, Tripathi N, Yarra P, Su L, Flomenhoft D, Stromberg A, Barrett TA. Vedolizumab Dose Escalation Improves Therapeutic Response in a Subset of Patients with Ulcerative Colitis. Dig Dis Sci 2021;66:2051-8. [PMID: 32710192 DOI: 10.1007/s10620-020-06486-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
266 Le N, Mazahery C, Nguyen K, Levine AD. Regulation of Intestinal Epithelial Barrier and Immune Function by Activated T Cells. Cell Mol Gastroenterol Hepatol 2021;11:55-76. [PMID: 32659380 DOI: 10.1016/j.jcmgh.2020.07.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
267 Okamoto H, Dirks NL, Rosario M, Hori T, Hibi T. Population pharmacokinetics of vedolizumab in Asian and non-Asian patients with ulcerative colitis and Crohn's disease. Intest Res 2021;19:95-105. [PMID: 32635680 DOI: 10.5217/ir.2019.09167] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
268 Di Jiang C, Raine T. IBD considerations in spondyloarthritis. Ther Adv Musculoskelet Dis 2020;12:1759720X20939410. [PMID: 32695235 DOI: 10.1177/1759720X20939410] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
269 Helwig U, Mross M, Schubert S, Hartmann H, Brandes A, Stein D, Kempf C, Knop J, Campbell-Hill S, Ehehalt R. Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn's disease patients: a German retrospective chart review. BMC Gastroenterol. 2020;20:211. [PMID: 32640990 DOI: 10.1186/s12876-020-01332-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
270 Scarozza P, De Cristofaro E, Scucchi L, Rocchetti I, Marafini I, Neri B, Salvatori S, Biancone L, Calabrese E, Monteleone G. Effect of Vedolizumab on Anemia of Chronic Disease in Patients with Inflammatory Bowel Diseases. J Clin Med 2020;9:E2126. [PMID: 32640680 DOI: 10.3390/jcm9072126] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
271 Dubois E, Moens A, Geelen R, Sabino J, Ferrante M, Vermeire S. Long-term outcomes of patients with ulcerative proctitis: Analysis from a large referral centre cohort. United European Gastroenterol J 2020;8:933-41. [PMID: 32631177 DOI: 10.1177/2050640620941345] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
272 Papa A, Tursi A, Danese S, Rapaccini G, Gasbarrini A, Papa V. Venous Thromboembolism in Patients with Inflammatory Bowel Disease: The Role of Pharmacological Therapy and Surgery. J Clin Med 2020;9:E2115. [PMID: 32635542 DOI: 10.3390/jcm9072115] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
273 Sandborn WJ, Vermeire S, Tyrrell H, Hassanali A, Lacey S, Tole S, Tatro AR; Etrolizumab Global Steering Committee. Etrolizumab for the Treatment of Ulcerative Colitis and Crohn's Disease: An Overview of the Phase 3 Clinical Program. Adv Ther 2020;37:3417-31. [PMID: 32445184 DOI: 10.1007/s12325-020-01366-2] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 15.0] [Reference Citation Analysis]
274 Neurath MF. COVID-19 and immunomodulation in IBD. Gut 2020;69:1335-42. [PMID: 32303609 DOI: 10.1136/gutjnl-2020-321269] [Cited by in Crossref: 153] [Cited by in F6Publishing: 150] [Article Influence: 76.5] [Reference Citation Analysis]
275 Berg DR, Colombel JF, Ungaro R. The Role of Early Biologic Therapy in Inflammatory Bowel Disease. Inflamm Bowel Dis 2019;25:1896-905. [PMID: 30934053 DOI: 10.1093/ibd/izz059] [Cited by in Crossref: 52] [Cited by in F6Publishing: 48] [Article Influence: 26.0] [Reference Citation Analysis]
276 Abreu MT. DDS Perspective: My Take on Therapeutic Drug Monitoring in IBD. Dig Dis Sci 2019;64:3377-81. [PMID: 31628571 DOI: 10.1007/s10620-019-05796-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
277 Lightner AL. Inflammation of the Ileal Anal Pouch: Do Biologics Really Change the Trajectory? Inflamm Bowel Dis 2020;26:1087-8. [PMID: 31587041 DOI: 10.1093/ibd/izz229] [Reference Citation Analysis]
278 Judge C, McGettigan N, Ryan T, Hazel K, Singh P, Parihar V, Stack R, O'Connor A, Dunne C, Cullen G, Egan L, Harewood G, MacCarthy F, McKiernan S, Mulcahy H, Murray F, Patchett S, Sheridan J, Cheriyan D, Farrell R, Keohane J, Kelly O, McNamara D, Ryan B, O'Morain C, Sengupta S, O'Toole A, Buckley M, McCarthy J, Doherty G, Kevans D, Slattery E. Irish data on the safety and efficacy of vedolizumab in the treatment of inflammatory bowel disease. Scand J Gastroenterol 2020;55:786-94. [PMID: 32544012 DOI: 10.1080/00365521.2020.1779340] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
279 Loftus EV Jr, Sands BE, Colombel JF, Dotan I, Khalid JM, Tudor D, Geransar P. Sustained Corticosteroid-Free Clinical Remission During Vedolizumab Maintenance Therapy in Patients with Ulcerative Colitis on Stable Concomitant Corticosteroids During Induction Therapy: A Post Hoc Analysis of GEMINI 1. Clin Exp Gastroenterol 2020;13:211-20. [PMID: 32606883 DOI: 10.2147/CEG.S248597] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
280 Steijaert MJ, Schaap G, Riet JV. Two-sided science: Communicating scientific uncertainty increases trust in scientists and donation intention by decreasing attribution of communicator bias. Communications 2021;46:297-316. [DOI: 10.1515/commun-2019-0123] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
281 Koliani-Pace JL, Singh S, Luo M, Hirten R, Aniwan S, Kochhar G, Chang S, Lukin D, Gao Y, Bohm M, Swaminath A, Gupta N, Shmidt E, Meserve J, Winters A, Chablaney S, Faleck DM, Yang J, Huang Z, Boland BS, Shashi P, Weiss A, Hudesman D, Varma S, Fischer M, Sultan K, Shen B, Kane S, Loftus EV, Sands BE, Colombel JF, Sandborn WJ, Lasch K, Siegel CA, Dulai PS. Changes in Vedolizumab Utilization Across US Academic Centers and Community Practice Are Associated With Improved Effectiveness and Disease Outcomes. Inflamm Bowel Dis 2019;25:1854-61. [PMID: 31050734 DOI: 10.1093/ibd/izz071] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
282 Breidert M, Eftekhari P, Louis F, Rotoiu C, Rath T, Neurath MF, Atreya R. Functional Molecular Network Analysis Enables Prediction of Response to Vedolizumab Therapy in Anti-TNF Refractory IBD Patients. Crohns Colitis 360 2020;2:otaa037. [PMID: 32776006 DOI: 10.1093/crocol/otaa037] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
283 Troncone E, Marafini I, Del Vecchio Blanco G, Di Grazia A, Monteleone G. Novel Therapeutic Options for People with Ulcerative Colitis: An Update on Recent Developments with Janus Kinase (JAK) Inhibitors. Clin Exp Gastroenterol 2020;13:131-9. [PMID: 32440190 DOI: 10.2147/CEG.S208020] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
284 Pauwels RWM, de Vries AC, van der Woude CJ. Fecal calprotectin is a reliable marker of endoscopic response to vedolizumab therapy: A simple algorithm for clinical practice. J Gastroenterol Hepatol 2020;35:1893-901. [PMID: 32291796 DOI: 10.1111/jgh.15063] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
285 Breton J, Kastl A, Hoffmann N, Rogers R, Grossman AB, Mamula P, Kelsen JR, Baldassano RN, Albenberg L. Efficacy of Combination Antibiotic Therapy for Refractory Pediatric Inflammatory Bowel Disease. Inflamm Bowel Dis 2019;25:1586-93. [PMID: 30715364 DOI: 10.1093/ibd/izz006] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
286 Yarlas A, Maher S, Bayliss M, Lovley A, Cappelleri JC, Bushmakin AG, DiBonaventura MD. The Inflammatory Bowel Disease Questionnaire in Randomized Controlled Trials of Treatment for Ulcerative Colitis: Systematic Review and Meta-Analysis. J Patient Cent Res Rev 2020;7:189-205. [PMID: 32377552 DOI: 10.17294/2330-0698.1722] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
287 Zezos P, Kabakchiev B, Weizman AV, Nguyen GC, Narula N, Croitoru K, Steinhart AH, Silverberg MS. Ulcerative Colitis Patients Continue to Improve Over the First Six Months of Vedolizumab Treatment: 12-Month Clinical and Mucosal Healing Effectiveness. J Can Assoc Gastroenterol 2020;3:74-82. [PMID: 32328546 DOI: 10.1093/jcag/gwy065] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
288 Na SY, Moon W. Perspectives on Current and Novel Treatments for Inflammatory Bowel Disease. Gut Liver. 2019;13:604-616. [PMID: 31195433 DOI: 10.5009/gnl19019] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 21.0] [Reference Citation Analysis]
289 Farrell D, Artom M, Czuber-Dochan W, Jelsness-Jørgensen LP, Norton C, Savage E. Interventions for fatigue in inflammatory bowel disease. Cochrane Database Syst Rev 2020;4:CD012005. [PMID: 32297974 DOI: 10.1002/14651858.CD012005.pub2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
290 Allner C, Melde M, Becker E, Fuchs F, Mühl L, Klenske E, Müller L, Morgenstern N, Fietkau K, Hirschmann S, Atreya R, Atreya I, Neurath MF, Zundler S. Baseline levels of dynamic CD4+ T cell adhesion to MAdCAM-1 correlate with clinical response to vedolizumab treatment in ulcerative colitis: a cohort study. BMC Gastroenterol 2020;20:103. [PMID: 32293299 DOI: 10.1186/s12876-020-01253-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
291 Lin E, Katz S. Acute Pancreatitis in a Patient With Ulcerative Colitis on Vedolizumab. Inflamm Bowel Dis 2020;26:e44. [PMID: 32100867 DOI: 10.1093/ibd/izaa042] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
292 Sandborn WJ, Bhandari BR, Randall C, Younes ZH, Romanczyk T, Xin Y, Wendt E, Chai H, McKevitt M, Zhao S, Sundy JS, Keshav S, Danese S. Andecaliximab [Anti-matrix Metalloproteinase-9] Induction Therapy for Ulcerative Colitis: A Randomised, Double-Blind, Placebo-Controlled, Phase 2/3 Study in Patients With Moderate to Severe Disease. J Crohns Colitis 2018;12:1021-9. [PMID: 29767728 DOI: 10.1093/ecco-jcc/jjy049] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
293 Roosenboom B, Lochem EGV, Meijer J, Smids C, Nierkens S, Brand EC, Erp LWV, Kemperman LGJM, Groenen MJM, Horje CSHT, Wahab PJ. Development of Mucosal PNAd+ and MAdCAM-1+ Venules during Disease Course in Ulcerative Colitis. Cells 2020;9:E891. [PMID: 32268498 DOI: 10.3390/cells9040891] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
294 Blackwell J, Selinger C, Raine T, Parkes G, Smith MA, Pollok R. Steroid use and misuse: a key performance indicator in the management of IBD. Frontline Gastroenterol 2021;12:207-13. [PMID: 33907617 DOI: 10.1136/flgastro-2019-101288] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
295 Meserve J, Dulai P. Predicting Response to Vedolizumab in Inflammatory Bowel Disease. Front Med (Lausanne) 2020;7:76. [PMID: 32300596 DOI: 10.3389/fmed.2020.00076] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
296 Takatsu N, Hisabe T, Higashi D, Ueki T, Matsui T. Vedolizumab in the Treatment of Ulcerative Colitis: An Evidence-Based Review of Safety, Efficacy, and Place of Therapy. Core Evid 2020;15:7-20. [PMID: 32280316 DOI: 10.2147/CE.S179053] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
297 Vesterhus M, Karlsen TH. Emerging therapies in primary sclerosing cholangitis: pathophysiological basis and clinical opportunities. J Gastroenterol 2020;55:588-614. [PMID: 32222826 DOI: 10.1007/s00535-020-01681-z] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 12.0] [Reference Citation Analysis]
298 Feagan BG, Schreiber S, Wolf DC, Axler JL, Kaviya A, James A, Curtis RI, Geransar P, Stallmach A, Ehehalt R, Bokemeyer B, Khalid JM, O'Byrne S. Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis. Inflamm Bowel Dis 2019;25:1028-35. [PMID: 30365009 DOI: 10.1093/ibd/izy323] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
299 Zhang S, Liang W, Luo L, Sun S, Wang F. The role of T cell trafficking in CTLA-4 blockade-induced gut immunopathology. BMC Biol 2020;18:29. [PMID: 32183814 DOI: 10.1186/s12915-020-00765-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
300 Zundler S, Tauschek V, Neurath MF. Immune Cell Circuits in Mucosal Wound Healing: Clinical Implications. Visc Med 2020;36:129-36. [PMID: 32355670 DOI: 10.1159/000506846] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
301 Kamal N, Marciano B, Curtin B, Strongin A, DeRavin SS, Bousvaros A, Koh C, Malech HL, Holland SM, Zerbe C, Heller T. The response to vedolizumab in chronic granulomatous disease-related inflammatory bowel disease. Gastroenterol Rep (Oxf) 2020;8:404-6. [PMID: 33708388 DOI: 10.1093/gastro/goaa005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
302 Chudy-Onwugaje KO, Christian KE, Farraye FA, Cross RK. A State-of-the-Art Review of New and Emerging Therapies for the Treatment of IBD. Inflamm Bowel Dis 2019;25:820-30. [PMID: 30445504 DOI: 10.1093/ibd/izy327] [Cited by in Crossref: 51] [Cited by in F6Publishing: 51] [Article Influence: 25.5] [Reference Citation Analysis]
303 Click B, Regueiro M. A Practical Guide to the Safety and Monitoring of New IBD Therapies. Inflamm Bowel Dis. 2019;25:831-842. [PMID: 30312391 DOI: 10.1093/ibd/izy313] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 10.5] [Reference Citation Analysis]
304 Crooks B, Barnes T, Limdi JK. Vedolizumab in the treatment of inflammatory bowel disease: evolving paradigms. Drugs Context. 2020;9:2019-10. [PMID: 32180822 DOI: 10.7573/dic.2019-10-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
305 Berends SE, Strik AS, Löwenberg M, D'Haens GR, Mathôt RAA. Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Ulcerative Colitis. Clin Pharmacokinet 2019;58:15-37. [PMID: 29752633 DOI: 10.1007/s40262-018-0676-z] [Cited by in Crossref: 30] [Cited by in F6Publishing: 42] [Article Influence: 15.0] [Reference Citation Analysis]
306 Bertani L, Baglietto L, Antonioli L, Fornai M, Tapete G, Albano E, Ceccarelli L, Mumolo MG, Pellegrini C, Lucenteforte E, de Bortoli N, Bellini M, Marchi S, Blandizzi C, Costa F. Assessment of serum cytokines predicts clinical and endoscopic outcomes to vedolizumab in ulcerative colitis patients. Br J Clin Pharmacol 2020;86:1296-305. [PMID: 32027388 DOI: 10.1111/bcp.14235] [Cited by in Crossref: 11] [Cited by in F6Publishing: 18] [Article Influence: 5.5] [Reference Citation Analysis]
307 Reinisch W, Bressler B, Curtis R, Parikh A, Yang H, Rosario M, Røseth A, Danese S, Feagan B, Sands BE, Ginsburg P, Dassopoulos T, Lewis J, Xu J, Wyant T. Fecal Calprotectin Responses Following Induction Therapy With Vedolizumab in Moderate to Severe Ulcerative Colitis: A Post Hoc Analysis of GEMINI 1. Inflamm Bowel Dis 2019;25:803-10. [PMID: 30295811 DOI: 10.1093/ibd/izy304] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 8.5] [Reference Citation Analysis]
308 Dulai PS, Singh S, Casteele NV, Meserve J, Winters A, Chablaney S, Aniwan S, Shashi P, Kochhar G, Weiss A, Koliani-Pace JL, Gao Y, Boland BS, Chang JT, Faleck D, Hirten R, Ungaro R, Lukin D, Sultan K, Hudesman D, Chang S, Bohm M, Varma S, Fischer M, Shmidt E, Swaminath A, Gupta N, Rosario M, Jairath V, Guizzetti L, Feagan BG, Siegel CA, Shen B, Kane S, Loftus EV Jr, Sandborn WJ, Sands BE, Colombel JF, Lasch K, Cao C. Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol 2020;18:2952-2961.e8. [PMID: 32062041 DOI: 10.1016/j.cgh.2020.02.010] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 14.0] [Reference Citation Analysis]
309 Sands BE, Cheifetz AS, Nduaka CI, Quirk D, Wang W, Maller E, Friedman GS, Su C, Higgins PDR. The Impact of Raising the Bar for Clinical Trials in Ulcerative Colitis. J Crohns Colitis 2019;13:1217-26. [PMID: 30879034 DOI: 10.1093/ecco-jcc/jjz038] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
310 Tanida S, Ozeki K, Mizoshita T, Kitagawa M, Ozeki T, Tanaka M, Nishie H, Shimura T, Kubota E, Kataoka H. Combination Therapy With Tofacitinib Plus Intensive Granulocyte and Monocyte Adsorptive Apheresis as Induction Therapy for Refractory Ulcerative Colitis. J Clin Med Res 2020;12:36-40. [PMID: 32010420 DOI: 10.14740/jocmr4037] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
311 Hazel K, O'Connor A. Emerging treatments for inflammatory bowel disease. Ther Adv Chronic Dis 2020;11:2040622319899297. [PMID: 32076497 DOI: 10.1177/2040622319899297] [Cited by in Crossref: 28] [Cited by in F6Publishing: 50] [Article Influence: 14.0] [Reference Citation Analysis]
312 Ordovas-Montanes J, Beyaz S, Rakoff-Nahoum S, Shalek AK. Distribution and storage of inflammatory memory in barrier tissues. Nat Rev Immunol 2020;20:308-20. [PMID: 32015472 DOI: 10.1038/s41577-019-0263-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
313 Schleier L, Wiendl M, Heidbreder K, Binder MT, Atreya R, Rath T, Becker E, Schulz-Kuhnt A, Stahl A, Schulze LL, Ullrich K, Merz SF, Bornemann L, Gunzer M, Watson AJM, Neufert C, Atreya I, Neurath MF, Zundler S. Non-classical monocyte homing to the gut via α4β7 integrin mediates macrophage-dependent intestinal wound healing. Gut 2020;69:252-63. [PMID: 31092589 DOI: 10.1136/gutjnl-2018-316772] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 23.0] [Reference Citation Analysis]
314 Scarozza P, Marafini I, Laudisi F, Troncone E, Schmitt H, Lenti MV, Costa S, Rocchetti I, De Cristofaro E, Salvatori S, Frezzati L, Di Sabatino A, Atreya R, Neurath MF, Calabrese E, Monteleone G. Extent of Mucosal Inflammation in Ulcerative Colitis Influences the Clinical Remission Induced by Vedolizumab. J Clin Med 2020;9:E385. [PMID: 32024071 DOI: 10.3390/jcm9020385] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
315 Ungaro RC, Yarur A, Jossen J, Phan BL, Chefitz E, Sehgal P, Kamal K, Bruss A, Beniwal-Patel P, Fox C, Patel A, Bahur B, Jain A, Stein D, Naik S, Dubinsky MC. Higher Trough Vedolizumab Concentrations During Maintenance Therapy are Associated With Corticosteroid-Free Remission in Inflammatory Bowel Disease. J Crohns Colitis 2019;13:963-9. [PMID: 31087100 DOI: 10.1093/ecco-jcc/jjz041] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 13.0] [Reference Citation Analysis]
316 Chang S, Hudesman D. First-Line Biologics or Small Molecules in Inflammatory Bowel Disease: a Practical Guide for the Clinician. Curr Gastroenterol Rep 2020;22:7. [PMID: 32002688 DOI: 10.1007/s11894-020-0745-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
317 Mancuso RV, Casper J, Schmidt AG, Krähenbühl S, Weitz-Schmidt G. Anti-αLβ2 antibodies reveal novel endocytotic cross-modulatory functionality. Br J Pharmacol 2020;177:2696-711. [PMID: 31985813 DOI: 10.1111/bph.14996] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
318 Singh S, Murad MH, Fumery M, Dulai PS, Sandborn WJ. First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis. Clin Gastroenterol Hepatol 2020;18:2179-2191.e6. [PMID: 31945470 DOI: 10.1016/j.cgh.2020.01.008] [Cited by in Crossref: 100] [Cited by in F6Publishing: 81] [Article Influence: 50.0] [Reference Citation Analysis]
319 Singh S, Allegretti JR, Siddique SM, Terdiman JP. AGA Technical Review on the Management of Moderate to Severe Ulcerative Colitis.Gastroenterology. 2020;158:1465-1496.e17. [PMID: 31945351 DOI: 10.1053/j.gastro.2020.01.007] [Cited by in Crossref: 23] [Cited by in F6Publishing: 31] [Article Influence: 11.5] [Reference Citation Analysis]
320 Ibraheim H, Samaan MA, Srinivasan A, Brain O, Digby-Bell J, Irving PM, Norman I, Jawad I, Biedermann J, Ibarra A, Kok KB, Parkes G, Rimmer J, Compot E, Parkes M, Segal J, Oppong P, Hart A, Hayee B, Powell N. Effectiveness and safety of vedolizumab in inflammatory bowel disease patients aged 60 and over: an observational multicenter UK experience. Ann Gastroenterol 2020;33:170-7. [PMID: 32127738 DOI: 10.20524/aog.2020.0447] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
321 Pérez-Jeldres T, Tyler CJ, Boyer JD, Karuppuchamy T, Bamias G, Dulai PS, Boland BS, Sandborn WJ, Patel DR, Rivera-Nieves J. Cell Trafficking Interference in Inflammatory Bowel Disease: Therapeutic Interventions Based on Basic Pathogenesis Concepts. Inflamm Bowel Dis 2019;25:270-82. [PMID: 30165490 DOI: 10.1093/ibd/izy269] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 15.0] [Reference Citation Analysis]
322 Battat R, Dulai PS, Vande Casteele N, Evans E, Hester KD, Webster E, Jain A, Proudfoot JA, Mairalles A, Neill J, Singh S, Chang JT, Rivera-Nieves J, Sandborn WJ, Boland BS. Biomarkers Are Associated With Clinical and Endoscopic Outcomes With Vedolizumab Treatment in Ulcerative Colitis. Inflamm Bowel Dis 2019;25:410-20. [PMID: 30295781 DOI: 10.1093/ibd/izy307] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
323 Chiba M, Tsuji T, Nakane K, Tsuda S, Ishii H, Ohno H, Obara Y, Komatsu M, Tozawa H. High Remission Rate with Infliximab and Plant-Based Diet as First-Line (IPF) Therapy for Severe Ulcerative Colitis: Single-Group Trial. Perm J 2020;24:1-10. [PMID: 33482946 DOI: 10.7812/TPP/19.166] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
324 Kayal M, Shah S. Ulcerative Colitis: Current and Emerging Treatment Strategies. J Clin Med 2019;9:E94. [PMID: 31905945 DOI: 10.3390/jcm9010094] [Cited by in Crossref: 12] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
325 Shibuya T, Nomura K, Okahara K, Haga K, Nomura O, Murakami T, Uchida S, Kodani T, Ishikawa D, Sakamoto N, Ogihara T, Osada T, Nagahara A. Budesonide Foam for Ulcerative Colitis Patients Experiencing Inadequate Response to Biological Therapy. Med Sci Monit 2019;25:9855-63. [PMID: 31865359 DOI: 10.12659/MSM.918562] [Reference Citation Analysis]
326 Biemans VBC, van der Woude CJ, Dijkstra G, van der Meulen-de Jong AE, Oldenburg B, de Boer NK, Löwenberg M, Srivastava N, Bodelier AGL, West RL, Jansen JM, de Vries AC, Haans JJL, de Jong DJ, Pierik MJ, Hoentjen F. Vedolizumab for Inflammatory Bowel Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, A Nationwide Prospective Observational Cohort Study: ICC Registry - Vedolizumab. Clin Pharmacol Ther 2020;107:1189-99. [PMID: 31677154 DOI: 10.1002/cpt.1712] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
327 Verdon C, Bessissow T, Lakatos PL. Management of Acute Severe Colitis in the Era of Biologicals and Small Molecules. J Clin Med 2019;8:E2169. [PMID: 31817972 DOI: 10.3390/jcm8122169] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
328 Naganuma M, Yokoyama Y, Motoya S, Watanabe K, Sawada K, Hirai F, Yamamoto T, Hanai H, Omori T, Kanai T, Hibi T; CAPTAIN study Group. Efficacy of apheresis as maintenance therapy for patients with ulcerative colitis in an open-label prospective multicenter randomised controlled trial. J Gastroenterol. 2020;55:390-400. [PMID: 31811562 DOI: 10.1007/s00535-019-01651-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
329 Ivashkin VT, Shelygin YA, Belousova EA, Abdulganieva DI, Alekseeva OA, Achkasov SI, Valuiskikh EY, Vardanyan AV, Veselov AV, Veselov VV, Golovenko OV, Gubonina IV, Zhigalova TN, Kashnikov VN, Knyazev OV, Makarchuk PA, Moskaliev AI, Nanaeva BA, Nizov AA, Nikitina NV, Nikolaeva NN, Pavlenko VV, Poluektova EA, Svetlova IO, Tarasova LV, Tkachev AV, Frolov SA, Khlynova OV, Chashkova EY, Shapina MV, Sheptulin AA, Shifrin OS, Shchukina OB. PROJECT: CLINICAL GUIDELINES FOR THE DIAGNOSTICS AND TREATMENT OF ULCERATIVE COLITIS. Koloproktologiâ 2019;18:7-36. [DOI: 10.33878/2073-7556-2019-18-4-7-36] [Cited by in Crossref: 16] [Cited by in F6Publishing: 3] [Article Influence: 5.3] [Reference Citation Analysis]
330 Cross RK, Chiorean M, Vekeman F, Xiao Y, Wu E, Chao J, Wang AW. Assessment of the real-world safety profile of vedolizumab using the United States Food and Drug Administration adverse event reporting system. PLoS One 2019;14:e0225572. [PMID: 31800627 DOI: 10.1371/journal.pone.0225572] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
331 D'Haens GRAM, Lindsay JO, Panaccione R, Schreiber S. Ulcerative Colitis: Shifting Sands. Drugs R D 2019;19:227-34. [PMID: 30827006 DOI: 10.1007/s40268-019-0263-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
332 Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, Hayee B, Lomer MCE, Parkes GC, Selinger C, Barrett KJ, Davies RJ, Bennett C, Gittens S, Dunlop MG, Faiz O, Fraser A, Garrick V, Johnston PD, Parkes M, Sanderson J, Terry H, Gaya DR, Iqbal TH, Taylor SA, Smith M, Brookes M, Hansen R, Hawthorne AB; IBD guidelines eDelphi consensus group. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut 2019;68:s1-s106. [PMID: 31562236 DOI: 10.1136/gutjnl-2019-318484] [Cited by in Crossref: 617] [Cited by in F6Publishing: 555] [Article Influence: 205.7] [Reference Citation Analysis]
333 Dulai PS, Singh S, Jairath V, Ma C, Narula N, Vande Casteele N, Peyrin-Biroulet L, Vermeire S, D'Haens G, Feagan BG, Sandborn WJ. Prevalence of endoscopic improvement and remission according to patient-reported outcomes in ulcerative colitis. Aliment Pharmacol Ther 2020;51:435-45. [PMID: 31755121 DOI: 10.1111/apt.15577] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
334 Fujiya M, Ueno N, Kashima S, Tanaka K, Sakatani A, Ando K, Moriichi K, Konishi H, Kamiyama N, Tasaki Y, Omura T, Matsubara K, Taruishi M, Okumura T. Long-Chain Polyphosphate Is a Potential Agent for Inducing Mucosal Healing of the Colon in Ulcerative Colitis. Clin Pharmacol Ther 2020;107:452-61. [PMID: 31513280 DOI: 10.1002/cpt.1628] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
335 Card T, Ungaro R, Bhayat F, Blake A, Hantsbarger G, Travis S. Vedolizumab use is not associated with increased malignancy incidence: GEMINI LTS study results and post-marketing data. Aliment Pharmacol Ther 2020;51:149-57. [PMID: 31747086 DOI: 10.1111/apt.15538] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
336 Thornhill JP, Lynch KD, Skelton JK, Dorner M, Khan M, Martin GE, Hoare J, Peake S, Frater J, Fidler S. Vedolizumab use and the associations between α4β7 expression and HIV reservoir in the gut during treated primary HIV infection. AIDS 2019;33:2268-71. [PMID: 31688047 DOI: 10.1097/QAD.0000000000002344] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
337 Actis GC, Pellicano R, Fagoonee S, Ribaldone DG. History of Inflammatory Bowel Diseases. J Clin Med. 2019;8:1970. [PMID: 31739460 DOI: 10.3390/jcm8111970] [Cited by in Crossref: 31] [Cited by in F6Publishing: 47] [Article Influence: 10.3] [Reference Citation Analysis]
338 Sun H, Kuk W, Rivera-Nieves J, Lopez-Ramirez MA, Eckmann L, Ginsberg MH. β7 Integrin Inhibition Can Increase Intestinal Inflammation by Impairing Homing of CD25hiFoxP3+ Regulatory T Cells. Cell Mol Gastroenterol Hepatol 2020;9:369-85. [PMID: 31707128 DOI: 10.1016/j.jcmgh.2019.10.012] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
339 Choi AJ, Atteberry P, Lukin DJ. Vaccination in the Elderly and IBD. Curr Treat Options Gastroenterol 2019;17:492-505. [PMID: 31686385 DOI: 10.1007/s11938-019-00257-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
340 Einwächter H. Current Concepts of Pharmacotherapy in Crohn's Disease. Visc Med 2019;35:344-7. [PMID: 31934581 DOI: 10.1159/000504101] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
341 Guo J, Li D, Tao H, Li G, Liu R, Dou Y, Jin T, Li L, Huang J, Hu H, Zhang J. Cyclodextrin-Derived Intrinsically Bioactive Nanoparticles for Treatment of Acute and Chronic Inflammatory Diseases. Adv Mater 2019;31:e1904607. [PMID: 31583783 DOI: 10.1002/adma.201904607] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 16.0] [Reference Citation Analysis]
342 Thiagarajan S, Neurath MF, Hildner K. Resolution of acute intestinal graft-versus-host disease. Semin Immunopathol 2019;41:655-64. [PMID: 31673757 DOI: 10.1007/s00281-019-00769-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
343 Jerger L, Hyams JS. Special considerations for biologic medications in pediatric ulcerative colitis. Expert Opin Biol Ther 2020;20:429-35. [PMID: 31652087 DOI: 10.1080/14712598.2020.1685492] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
344 Nowacki TM, Lenz P, Bettenworth D, Brückner M, Bokemeyer A, Tepasse PR, Helfen A, Wildgruber M, Eisenblätter M. Target-Specific Fluorescence-Mediated Tomography for Non-Invasive and Dynamic Assessment of Early Neutrophil Infiltration in Murine Experimental Colitis. Cells 2019;8:E1328. [PMID: 31661876 DOI: 10.3390/cells8111328] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
345 Pugliese D, Privitera G, Pizzolante F, Gasbarrini A, Guidi L, Armuzzi A. Therapeutic drug monitoring with vedolizumab in inflammatory bowel disease. Minerva Gastroenterol Dietol 2019;65:280-90. [PMID: 31646853 DOI: 10.23736/S1121-421X.19.02625-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
346 Randhawa M, Gaughran G, Archer C, Pavli P, Morey A, Ali S, Yip D. Vedolizumab in combined immune checkpoint therapy-induced infliximab-refractory colitis in a patient with metastatic melanoma: A case report. World J Clin Oncol 2019; 10(10): 350-357 [PMID: 31799150 DOI: 10.5306/wjco.v10.i10.350] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
347 Barnes EL, Jiang Y, Kappelman MD, Long MD, Sandler RS, Kinlaw AC, Herfarth HH. Decreasing Colectomy Rate for Ulcerative Colitis in the United States Between 2007 and 2016: A Time Trend Analysis. Inflamm Bowel Dis 2020;26:1225-31. [PMID: 31634390 DOI: 10.1093/ibd/izz247] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
348 Derijks LJJ, Wong DR, Hommes DW, van Bodegraven AA. Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Inflammatory Bowel Disease. Clin Pharmacokinet 2018;57:1075-106. [PMID: 29512050 DOI: 10.1007/s40262-018-0639-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
349 Picardo S, Seow CH. A Pharmacological Approach to Managing Inflammatory Bowel Disease During Conception, Pregnancy and Breastfeeding: Biologic and Oral Small Molecule Therapy. Drugs 2019;79:1053-63. [PMID: 31183768 DOI: 10.1007/s40265-019-01141-w] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
350 Uzzan M, Tokuyama M, Rosenstein AK, Tomescu C, SahBandar IN, Ko HM, Leyre L, Chokola A, Kaplan-Lewis E, Rodriguez G, Seki A, Corley MJ, Aberg J, La Porte A, Park EY, Ueno H, Oikonomou I, Doron I, Iliev ID, Chen BK, Lui J, Schacker TW, Furtado GC, Lira SA, Colombel JF, Horowitz A, Lim JK, Chomont N, Rahman AH, Montaner LJ, Ndhlovu LC, Mehandru S. Anti-α4β7 therapy targets lymphoid aggregates in the gastrointestinal tract of HIV-1-infected individuals. Sci Transl Med 2018;10:eaau4711. [PMID: 30282696 DOI: 10.1126/scitranslmed.aau4711] [Cited by in Crossref: 31] [Cited by in F6Publishing: 44] [Article Influence: 10.3] [Reference Citation Analysis]
351 Dobsch P, Michels B, Müller-Schilling M, Kandulski A. [Therapeutic regimens using monoclonal antibodies in gastroenterology]. Internist (Berl) 2019;60:1043-58. [PMID: 31501913 DOI: 10.1007/s00108-019-00682-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
352 Shah J, Dutta U, Das A, Sharma V, Mandavdhare H, Sharma P, Kalsi D, Popli P, Kochhar R. Relationship between Mayo endoscopic score and histological scores in ulcerative colitis: A prospective study. JGH Open 2020;4:382-6. [PMID: 32514441 DOI: 10.1002/jgh3.12260] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
353 Ma C, Battat R, Dulai PS, Parker CE, Sandborn WJ, Feagan BG, Jairath V. Innovations in Oral Therapies for Inflammatory Bowel Disease. Drugs 2019;79:1321-35. [PMID: 31317509 DOI: 10.1007/s40265-019-01169-y] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 8.3] [Reference Citation Analysis]
354 Randhawa M, Gaughran G, Archer C, Pavli P, Morey A, Ali S, Yip D. Vedolizumab in combined immune checkpoint therapy-induced infliximab-refractory colitis in a patient with metastatic melanoma: A case report. WJCO 2019;10:349-56. [DOI: 10.5306/wjco.v10.i10.349] [Reference Citation Analysis]
355 Sivro A, Schuetz A, Sheward D, Joag V, Yegorov S, Liebenberg LJ, Yende-Zuma N, Stalker A, Mwatelah RS, Selhorst P, Garrett N, Samsunder N, Balgobin A, Nawaz F, Cicala C, Arthos J, Fauci AS, Anzala AO, Kimani J, Bagaya BS, Kiwanuka N, Williamson C, Kaul R, Passmore JS, Phanuphak N, Ananworanich J, Ansari A, Abdool Karim Q, Abdool Karim SS, McKinnon LR; CAPRISA004 and RV254 study groups. Integrin α4β7 expression on peripheral blood CD4+ T cells predicts HIV acquisition and disease progression outcomes. Sci Transl Med 2018;10:eaam6354. [PMID: 29367348 DOI: 10.1126/scitranslmed.aam6354] [Cited by in Crossref: 57] [Cited by in F6Publishing: 62] [Article Influence: 19.0] [Reference Citation Analysis]
356 Naganuma M, Sugimoto S, Fukuda T, Mitsuyama K, Kobayashi T, Yoshimura N, Ohi H, Tanaka S, Andoh A, Ohmiya N, Saigusa K, Yamamoto T, Morohoshi Y, Ichikawa H, Matsuoka K, Hisamatsu T, Watanabe K, Mizuno S, Abe T, Suzuki Y, Kanai T; INDIGO Study Group. Indigo naturalis is effective even in treatment-refractory patients with ulcerative colitis: a post hoc analysis from the INDIGO study. J Gastroenterol 2020;55:169-80. [PMID: 31529220 DOI: 10.1007/s00535-019-01625-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
357 Nishida T, Iijima H, Adachi S. Immune checkpoint inhibitor-induced diarrhea/colitis: Endoscopic and pathologic findings. World J Gastrointest Pathophysiol 2019; 10(2): 17-28 [PMID: 31559106 DOI: 10.4291/wjgp.v10.i2.17] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
358 Singh S, Dulai PS, Vande Casteele N, Battat R, Fumery M, Boland BS, Sandborn WJ. Systematic review with meta-analysis: association between vedolizumab trough concentration and clinical outcomes in patients with inflammatory bowel diseases. Aliment Pharmacol Ther 2019;50:848-57. [PMID: 31483522 DOI: 10.1111/apt.15484] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 6.7] [Reference Citation Analysis]
359 Wang C, Baer HM, Gaya DR, Nibbs RJB, Milling S. Can molecular stratification improve the treatment of inflammatory bowel disease? Pharmacol Res 2019;148:104442. [PMID: 31491469 DOI: 10.1016/j.phrs.2019.104442] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
360 Guidi L, Pugliese D, Panici Tonucci T, Bertani L, Costa F, Privitera G, Tolusso B, Di Mario C, Albano E, Tapete G, Gremese E, Papa A, Gasbarrini A, Rapaccini GL, Armuzzi A. Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease. United European Gastroenterol J 2019;7:1189-97. [PMID: 31700632 DOI: 10.1177/2050640619873784] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 7.7] [Reference Citation Analysis]
361 Zundler S, Becker E, Schulze LL, Neurath MF. Immune cell trafficking and retention in inflammatory bowel disease: mechanistic insights and therapeutic advances. Gut 2019;68:1688-700. [PMID: 31127023 DOI: 10.1136/gutjnl-2018-317977] [Cited by in Crossref: 55] [Cited by in F6Publishing: 54] [Article Influence: 18.3] [Reference Citation Analysis]
362 Kochar B, Jiang Y, Winn A, Barnes EL, Martin CF, Long MD, Kappelman MD. The Early Experience With Vedolizumab in the United States. Crohns Colitis 360 2019;1:otz027. [PMID: 31667469 DOI: 10.1093/crocol/otz027] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
363 Cakir OO. Effectiveness of vedolizumab treatment in two different anti-tumor necrosis factor alpha refractory pouchitis: A case report. World J Clin Cases 2019; 7(16): 2316-2321 [PMID: 31531325 DOI: 10.12998/wjcc.v7.i16.2316] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
364 Shen B, Blake A, Lasch K, Smyth M, Bhayat F. Vedolizumab use in patients with inflammatory bowel diseases undergoing surgery: clinical trials and post-marketing experience. Gastroenterol Rep (Oxf) 2019;7:322-30. [PMID: 31687151 DOI: 10.1093/gastro/goz034] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
365 Yoo JH, Donowitz M. Intestinal enteroids/organoids: A novel platform for drug discovery in inflammatory bowel diseases. World J Gastroenterol 2019; 25(30): 4125-4147 [PMID: 31435168 DOI: 10.3748/wjg.v25.i30.4125] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 21] [Article Influence: 8.7] [Reference Citation Analysis]
366 Cushing KC, Mino-Kenudson M, Garber J, Lochhead P, Khalili H. Vedolizumab as a Novel Treatment for Refractory Collagenous Colitis: A Case Report. Am J Gastroenterol 2018;113:632-3. [PMID: 29610507 DOI: 10.1038/ajg.2018.7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
367 Colombel JF. Herpes Zoster in Patients Receiving JAK Inhibitors For Ulcerative Colitis: Mechanism, Epidemiology, Management, and Prevention. Inflamm Bowel Dis 2018;24:2173-82. [PMID: 29788127 DOI: 10.1093/ibd/izy150] [Cited by in Crossref: 62] [Cited by in F6Publishing: 62] [Article Influence: 20.7] [Reference Citation Analysis]
368 Lohan C, Diamantopoulos A, LeReun C, Wright E, Bohm N, Sawyer LM. Tofacitinib for the treatment of moderately to severely active ulcerative colitis: a systematic review, network meta-analysis and economic evaluation. BMJ Open Gastroenterol 2019;6:e000302. [PMID: 31413856 DOI: 10.1136/bmjgast-2019-000302] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
369 Samaan M, Campbell S, Cunningham G, Tamilarasan AG, Irving PM, McCartney S. Biologic therapies for Crohn's disease: optimising the old and maximising the new. F1000Res 2019;8:F1000 Faculty Rev-1210. [PMID: 31448080 DOI: 10.12688/f1000research.18902.1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
370 Holmer A, Singh S. Overall and comparative safety of biologic and immunosuppressive therapy in inflammatory bowel diseases. Expert Rev Clin Immunol 2019;15:969-79. [PMID: 31322018 DOI: 10.1080/1744666X.2019.1646127] [Cited by in Crossref: 17] [Cited by in F6Publishing: 28] [Article Influence: 5.7] [Reference Citation Analysis]
371 Zhang M, Merlin D. Nanoparticle-Based Oral Drug Delivery Systems Targeting the Colon for Treatment of Ulcerative Colitis. Inflamm Bowel Dis 2018;24:1401-15. [PMID: 29788186 DOI: 10.1093/ibd/izy123] [Cited by in Crossref: 57] [Cited by in F6Publishing: 55] [Article Influence: 19.0] [Reference Citation Analysis]
372 Samaan MA, Birdi S, Morales MS, Honap S, Tamilarasan AG, Cunningham G, Koumoutsos I, Ray S, Mawdsley J, Anderson SHC, Sanderson J, Irving PM. Effectiveness of vedolizumab dose intensification to achieve inflammatory bowel disease control in cases of suboptimal response. Frontline Gastroenterol 2020;11:188-93. [PMID: 32419909 DOI: 10.1136/flgastro-2019-101259] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
373 Baiula M, Spampinato S, Gentilucci L, Tolomelli A. Novel Ligands Targeting α4β1 Integrin: Therapeutic Applications and Perspectives. Front Chem 2019;7:489. [PMID: 31338363 DOI: 10.3389/fchem.2019.00489] [Cited by in Crossref: 16] [Cited by in F6Publishing: 25] [Article Influence: 5.3] [Reference Citation Analysis]
374 Schreiner P, Neurath MF, Ng SC, El-Omar EM, Sharara AI, Kobayashi T, Hisamatsu T, Hibi T, Rogler G. Mechanism-Based Treatment Strategies for IBD: Cytokines, Cell Adhesion Molecules, JAK Inhibitors, Gut Flora, and More. Inflamm Intest Dis 2019;4:79-96. [PMID: 31559260 DOI: 10.1159/000500721] [Cited by in Crossref: 23] [Cited by in F6Publishing: 35] [Article Influence: 7.7] [Reference Citation Analysis]
375 Plevris N, Jenkinson PW, Chuah CS, Lyons M, Merchant LM, Pattenden RJ, Arnott ID, Jones GR, Lees CW. Association of trough vedolizumab levels with clinical, biological and endoscopic outcomes during maintenance therapy in inflammatory bowel disease. Frontline Gastroenterol 2020;11:117-23. [PMID: 32133110 DOI: 10.1136/flgastro-2019-101197] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
376 Annese V. An update on treatment of ulcerative colitis. Expert Opinion on Orphan Drugs 2019;7:295-304. [DOI: 10.1080/21678707.2019.1638249] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
377 Fu YY, Egorova A, Sobieski C, Kuttiyara J, Calafiore M, Takashima S, Clevers H, Hanash AM. T Cell Recruitment to the Intestinal Stem Cell Compartment Drives Immune-Mediated Intestinal Damage after Allogeneic Transplantation. Immunity 2019;51:90-103.e3. [PMID: 31278057 DOI: 10.1016/j.immuni.2019.06.003] [Cited by in Crossref: 23] [Cited by in F6Publishing: 33] [Article Influence: 7.7] [Reference Citation Analysis]
378 Jairath V, Peyrin-Biroulet L, Zou G, Mosli M, Vande Casteele N, Pai RK, Valasek MA, Marchal-Bressenot A, Stitt LW, Shackelton LM, Khanna R, D'Haens GR, Sandborn WJ, Olson A, Feagan BG, Pai RK. Responsiveness of histological disease activity indices in ulcerative colitis: a post hoc analysis using data from the TOUCHSTONE randomised controlled trial. Gut 2019;68:1162-8. [PMID: 30076171 DOI: 10.1136/gutjnl-2018-316702] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 10.7] [Reference Citation Analysis]
379 Czarnewski P, Parigi SM, Sorini C, Diaz OE, Das S, Gagliani N, Villablanca EJ. Conserved transcriptomic profile between mouse and human colitis allows unsupervised patient stratification. Nat Commun 2019;10:2892. [PMID: 31253778 DOI: 10.1038/s41467-019-10769-x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 30] [Article Influence: 8.3] [Reference Citation Analysis]
380 Mahagna H, Ben-Horin S. Biologics' switching: new insights toward establishing practice norms. United European Gastroenterol J 2019;7:733-4. [PMID: 31316776 DOI: 10.1177/2050640619851683] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
381 Spadaccini M, Aghemo A, Caprioli F, Lleo A, Invernizzi F, Danese S, Donato MF. Safety of vedolizumab in liver transplant recipients: A systematic review. United European Gastroenterol J 2019;7:875-80. [PMID: 31428411 DOI: 10.1177/2050640619858050] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
382 Dotan I, Allez M, Danese S, Keir M, Tole S, McBride J. The role of integrins in the pathogenesis of inflammatory bowel disease: Approved and investigational anti-integrin therapies. Med Res Rev 2020;40:245-62. [PMID: 31215680 DOI: 10.1002/med.21601] [Cited by in Crossref: 17] [Cited by in F6Publishing: 26] [Article Influence: 5.7] [Reference Citation Analysis]
383 Rubin SJS, Bai L, Haileselassie Y, Garay G, Yun C, Becker L, Streett SE, Sinha SR, Habtezion A. Mass cytometry reveals systemic and local immune signatures that distinguish inflammatory bowel diseases. Nat Commun. 2019;10:2686. [PMID: 31217423 DOI: 10.1038/s41467-019-10387-7] [Cited by in Crossref: 28] [Cited by in F6Publishing: 38] [Article Influence: 9.3] [Reference Citation Analysis]
384 Pagnini C, Pizarro TT, Cominelli F. Novel Pharmacological Therapy in Inflammatory Bowel Diseases: Beyond Anti-Tumor Necrosis Factor. Front Pharmacol. 2019;10:671. [PMID: 31316377 DOI: 10.3389/fphar.2019.00671] [Cited by in Crossref: 32] [Cited by in F6Publishing: 39] [Article Influence: 10.7] [Reference Citation Analysis]
385 Gao C, Liu L, Zhou Y, Bian Z, Wang S, Wang Y. Novel drug delivery systems of Chinese medicine for the treatment of inflammatory bowel disease. Chin Med 2019;14:23. [PMID: 31236131 DOI: 10.1186/s13020-019-0245-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 22] [Article Influence: 4.7] [Reference Citation Analysis]
386 Card T, Xu J, Liang H, Bhayat F. What Is the Risk of Progressive Multifocal Leukoencephalopathy in Patients With Ulcerative Colitis or Crohn's Disease Treated With Vedolizumab? Inflamm Bowel Dis 2018;24:953-9. [PMID: 29668955 DOI: 10.1093/ibd/izx097] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
387 Ooi CJ, Hilmi I, Banerjee R, Chuah SW, Ng SC, Wei SC, Makharia GK, Pisespongsa P, Chen MH, Ran ZH, Ye BD, Park DI, Ling KL, Ong D, Ahuja V, Goh KL, Sollano J, Lim WC, Leung WK, Ali RAR, Wu DC, Ong E, Mustaffa N, Limsrivilai J, Hisamatsu T, Yang SK, Ouyang Q, Geary R, De Silva JH, Rerknimitr R, Simadibrata M, Abdullah M, Leong RW; Asia Pacific Association of Gastroenterology (APAGE) Working Group on Inflammatory Bowel Disease and Asian Organization for Crohn’s and Colitis. Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia. Intest Res 2019;17:285-310. [PMID: 31146509 DOI: 10.5217/ir.2019.00026] [Cited by in Crossref: 30] [Cited by in F6Publishing: 38] [Article Influence: 10.0] [Reference Citation Analysis]
388 Sandborn WJ, Colombel JF, Panaccione R, Dulai PS, Rosario M, Cao C, Barocas M, Lasch K. Deep Remission With Vedolizumab in Patients With Moderately to Severely Active Ulcerative Colitis: A GEMINI 1 post hoc Analysis. J Crohns Colitis 2019;13:172-81. [PMID: 30285104 DOI: 10.1093/ecco-jcc/jjy149] [Cited by in Crossref: 12] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
389 Sabino J, Verstockt B, Vermeire S, Ferrante M. New biologics and small molecules in inflammatory bowel disease: an update. Therap Adv Gastroenterol 2019;12:1756284819853208. [PMID: 31205488 DOI: 10.1177/1756284819853208] [Cited by in Crossref: 37] [Cited by in F6Publishing: 50] [Article Influence: 12.3] [Reference Citation Analysis]
390 Aardoom MA, Veereman G, de Ridder L. A Review on the Use of Anti-TNF in Children and Adolescents with Inflammatory Bowel Disease. Int J Mol Sci 2019;20:E2529. [PMID: 31126015 DOI: 10.3390/ijms20102529] [Cited by in Crossref: 17] [Cited by in F6Publishing: 31] [Article Influence: 5.7] [Reference Citation Analysis]
391 Christensen B, Colman RJ, Micic D, Gibson PR, Goeppinger SR, Yarur A, Weber CR, Cohen RD, Rubin DT. Vedolizumab as Induction and Maintenance for Inflammatory Bowel Disease: 12-month Effectiveness and Safety. Inflamm Bowel Dis 2018;24:849-60. [PMID: 29562271 DOI: 10.1093/ibd/izx067] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 9.0] [Reference Citation Analysis]
392 Lynch KD, Chapman RW, Keshav S, Montano-Loza AJ, Mason AL, Kremer AE, Vetter M, de Krijger M, Ponsioen CY, Trivedi P, Hirschfield G, Schramm C, Liu CH, Bowlus CL, Estes DJ, Pratt D, Hedin C, Bergquist A, de Vries AC, van der Woude CJ, Yu L, Assis DN, Boyer J, Ytting H, Hallibasic E, Trauner M, Marschall HU, Daretti LM, Marzioni M, Yimam KK, Perin N, Floreani A, Beretta-Piccoli BT, Rogers JK, Levy C; International Primary Sclerosing Cholangitis Study Group (IPSCSG). Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol 2020;18:179-187.e6. [PMID: 31100458 DOI: 10.1016/j.cgh.2019.05.013] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 9.7] [Reference Citation Analysis]
393 Fragoulis GE, Liava C, Daoussis D, Akriviadis E, Garyfallos A, Dimitroulas T. Inflammatory bowel diseases and spondyloarthropathies: From pathogenesis to treatment. World J Gastroenterol 2019; 25(18): 2162-2176 [PMID: 31143068 DOI: 10.3748/wjg.v25.i18.2162] [Cited by in CrossRef: 67] [Cited by in F6Publishing: 51] [Article Influence: 22.3] [Reference Citation Analysis]
394 Feagan BG, Sandborn WJ, Colombel JF, Byrne SO, Khalid JM, Kempf C, Geransar P, Bhayat F, Rubin DT. Incidence of Arthritis/Arthralgia in Inflammatory Bowel Disease with Long-term Vedolizumab Treatment: Post Hoc Analyses of the GEMINI Trials. J Crohns Colitis. 2019;13:50-57. [PMID: 30203005 DOI: 10.1093/ecco-jcc/jjy125] [Cited by in Crossref: 36] [Cited by in F6Publishing: 40] [Article Influence: 12.0] [Reference Citation Analysis]
395 Pouillon L, Vermeire S, Bossuyt P. Vedolizumab trough level monitoring in inflammatory bowel disease: a state-of-the-art overview. BMC Med 2019;17:89. [PMID: 31064370 DOI: 10.1186/s12916-019-1323-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 27] [Article Influence: 5.3] [Reference Citation Analysis]
396 Battat R, Dulai PS, Jairath V, Vande Casteele N. A product review of vedolizumab in inflammatory bowel disease. Hum Vaccin Immunother 2019;15:2482-90. [PMID: 30897022 DOI: 10.1080/21645515.2019.1591139] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
397 Trigo-Vicente C, Gimeno-Ballester V, López-Del Val A. Cost-effectiveness analysis of infliximab, adalimumab, golimumab, vedolizumab and tofacitinib for moderate to severe ulcerative colitis in Spain. Eur J Hosp Pharm 2020;27:355-60. [PMID: 33097619 DOI: 10.1136/ejhpharm-2018-001833] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
398 Tran V, Shammas RM, Sauk JS, Padua D. Evaluating tofacitinib citrate in the treatment of moderate-to-severe active ulcerative colitis: design, development and positioning of therapy. Clin Exp Gastroenterol 2019;12:179-91. [PMID: 31118734 DOI: 10.2147/CEG.S150908] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
399 Shah J, Thakur ML, Dutta U. Mucosal healing in inflammatory bowel disease: Expanding horizon. Indian J Gastroenterol 2019;38:98-109. [PMID: 31037509 DOI: 10.1007/s12664-019-00950-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
400 Kim WM, Kaser A, Blumberg RS. A role for oncostatin M in inflammatory bowel disease. Nat Med 2017;23:535-6. [PMID: 28475567 DOI: 10.1038/nm.4338] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
401 Romano B, Lleo A, Sala E, D’amico G, Marino DI, Ciccocioppo R, Vetrano S. Mesenchymal Stem Cells to Treat Digestive System Disorders: Progress Made and Future Directions. Curr Transpl Rep 2019;6:134-45. [DOI: 10.1007/s40472-019-00238-1] [Reference Citation Analysis]
402 Grandinetti T, Biedermann L, Bussmann C, Straumann A, Hruz P. Eosinophilic Gastroenteritis: Clinical Manifestation, Natural Course, and Evaluation of Treatment with Corticosteroids and Vedolizumab. Dig Dis Sci. 2019;. [PMID: 30982212 DOI: 10.1007/s10620-019-05617-3] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 8.7] [Reference Citation Analysis]
403 Abu-Sbeih H, Ali FS, Wang X, Mallepally N, Chen E, Altan M, Bresalier R, Charabaty A, Dadu R, Jazaeri A, Lashner B, Wang Y. Early introduction of selective immunosuppressive therapy associated with favourable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis. J Immunother Cancer. 2019;7:93. [PMID: 30940209 DOI: 10.1186/s40425-019-0577-1] [Cited by in Crossref: 59] [Cited by in F6Publishing: 74] [Article Influence: 19.7] [Reference Citation Analysis]
404 Belarif L, Danger R, Kermarrec L, Nerrière-Daguin V, Pengam S, Durand T, Mary C, Kerdreux E, Gauttier V, Kucik A, Thepenier V, Martin JC, Chang C, Rahman A, Guen NS, Braudeau C, Abidi A, David G, Malard F, Takoudju C, Martinet B, Gérard N, Neveu I, Neunlist M, Coron E, MacDonald TT, Desreumaux P, Mai HL, Le Bas-Bernardet S, Mosnier JF, Merad M, Josien R, Brouard S, Soulillou JP, Blancho G, Bourreille A, Naveilhan P, Vanhove B, Poirier N. IL-7 receptor influences anti-TNF responsiveness and T cell gut homing in inflammatory bowel disease. J Clin Invest 2019;129:1910-25. [PMID: 30939120 DOI: 10.1172/JCI121668] [Cited by in Crossref: 33] [Cited by in F6Publishing: 39] [Article Influence: 11.0] [Reference Citation Analysis]
405 Liefferinckx C, Verstockt B, Gils A, Tops S, Van Moerkercke W, Vermeire S, Franchimont D. Impact of first-line infliximab on the pharmacokinetics of second-line vedolizumab in inflammatory bowel diseases. United European Gastroenterol J 2019;7:750-8. [PMID: 31316779 DOI: 10.1177/2050640619841538] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
406 Fenster M, Ungaro RC, Hirten R, Gallinger Z, Cohen L, Atreja A, Mehandru S, Colombel JF, Cohen BL. Home vs Hospital Infusion of Biologic Agents for Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol 2020;18:257-8. [PMID: 30910602 DOI: 10.1016/j.cgh.2019.03.030] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
407 Hanžel J, Sever N, Ferkolj I, Štabuc B, Smrekar N, Kurent T, Koželj M, Novak G, Compernolle G, Tops S, Gils A, Drobne D. Early vedolizumab trough levels predict combined endoscopic and clinical remission in inflammatory bowel disease. United European Gastroenterol J 2019;7:741-9. [PMID: 31316778 DOI: 10.1177/2050640619840211] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
408 Ling L, Wu T, To KKW, Cheung KW, Lui KOL, Niu M, Lam KS, Wang CC, Li J, Wang H, Yuen KY, Chen Z. Vedolizumab-mediated integrin α4β7 blockade does not control HIV-1SF162 rebound after combination antiretroviral therapy interruption in humanized mice. AIDS 2019;33:F1-F12. [PMID: 30829743 DOI: 10.1097/QAD.0000000000002149] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
409 Castro-Dopico T, Dennison TW, Ferdinand JR, Mathews RJ, Fleming A, Clift D, Stewart BJ, Jing C, Strongili K, Labzin LI, Monk EJM, Saeb-Parsy K, Bryant CE, Clare S, Parkes M, Clatworthy MR. Anti-commensal IgG Drives Intestinal Inflammation and Type 17 Immunity in Ulcerative Colitis. Immunity 2019;50:1099-1114.e10. [PMID: 30876876 DOI: 10.1016/j.immuni.2019.02.006] [Cited by in Crossref: 58] [Cited by in F6Publishing: 73] [Article Influence: 19.3] [Reference Citation Analysis]
410 Yarur AJ, Bruss A, Naik S, Beniwal-Patel P, Fox C, Jain A, Berens B, Patel A, Ungaro R, Bahur B, Dubinsky M, Stein DJ. Vedolizumab Concentrations Are Associated with Long-Term Endoscopic Remission in Patients with Inflammatory Bowel Diseases. Dig Dis Sci 2019;64:1651-9. [PMID: 30835029 DOI: 10.1007/s10620-019-05570-1] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
411 Cummings F, Gaya DR, Levison S, Subramanian S, Owen G, Rathmell A, Glen F, Demuth D, Meadowcroft S, Irving PM. A retrospective observational study of early experiences of vedolizumab treatment for inflammatory bowel disease in the UK: The REVIVE study. Medicine (Baltimore) 2019;98:e14681. [PMID: 30817598 DOI: 10.1097/MD.0000000000014681] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
412 Motoya S, Watanabe K, Ogata H, Kanai T, Matsui T, Suzuki Y, Shikamura M, Sugiura K, Oda K, Hori T, Araki T, Watanabe M, Hibi T. Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study. PLoS One 2019;14:e0212989. [PMID: 30807613 DOI: 10.1371/journal.pone.0212989] [Cited by in Crossref: 19] [Cited by in F6Publishing: 30] [Article Influence: 6.3] [Reference Citation Analysis]
413 Ichikawa R, Lamb CA, Eastham-Anderson J, Scherl A, Raffals L, Faubion WA, Bennett MR, Long AK, Mansfield JC, Kirby JA, Keir ME. AlphaE Integrin Expression Is Increased in the Ileum Relative to the Colon and Unaffected by Inflammation. J Crohns Colitis 2018;12:1191-9. [PMID: 29912405 DOI: 10.1093/ecco-jcc/jjy084] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
414 Ma H, Tao W, Zhu S. T lymphocytes in the intestinal mucosa: defense and tolerance. Cell Mol Immunol 2019;16:216-24. [PMID: 30787416 DOI: 10.1038/s41423-019-0208-2] [Cited by in Crossref: 25] [Cited by in F6Publishing: 44] [Article Influence: 8.3] [Reference Citation Analysis]
415 Adar T, Faleck D, Sasidharan S, Cushing K, Borren NZ, Nalagatla N, Ungaro R, Sy W, Owen SC, Patel A, Cohen BL, Ananthakrishnan AN. Comparative safety and effectiveness of tumor necrosis factor α antagonists and vedolizumab in elderly IBD patients: a multicentre study. Aliment Pharmacol Ther 2019;49:873-9. [PMID: 30773667 DOI: 10.1111/apt.15177] [Cited by in Crossref: 47] [Cited by in F6Publishing: 41] [Article Influence: 15.7] [Reference Citation Analysis]
416 Thomas MG, Bayliss C, Bond S, Dowling F, Galea J, Jairath V, Lamb C, Probert C, Timperley-Preece E, Watson A, Whitehead L, Williams JG, Parkes M, Kaser A, Raine T. Trial summary and protocol for a phase II randomised placebo-controlled double-blinded trial of Interleukin 1 blockade in Acute Severe Colitis: the IASO trial. BMJ Open 2019;9:e023765. [PMID: 30772849 DOI: 10.1136/bmjopen-2018-023765] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
417 Hibi T, Motoya S, Ashida T, Sai S, Sameshima Y, Nakamura S, Maemoto A, Nii M, Sullivan BA, Gasser RA Jr, Suzuki Y. Efficacy and safety of abrilumab, an α4β7 integrin inhibitor, in Japanese patients with moderate-to-severe ulcerative colitis: a phase II study. Intest Res 2019;17:375-86. [PMID: 30739435 DOI: 10.5217/ir.2018.00141] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
418 Weisshof R, Aharoni Golan M, Sossenheimer PH, El Jurdi K, Ollech JE, Pekow J, Cohen RD, Sakuraba A, Dalal S, Rubin DT. Real-World Experience with Tofacitinib in IBD at a Tertiary Center. Dig Dis Sci. 2019;64:1945-1951. [PMID: 30734234 DOI: 10.1007/s10620-019-05492-y] [Cited by in Crossref: 52] [Cited by in F6Publishing: 43] [Article Influence: 17.3] [Reference Citation Analysis]
419 Lichnog C, Klabunde S, Becker E, Fuh F, Tripal P, Atreya R, Klenske E, Erickson R, Chiu H, Reed C, Chung S, Neufert C, Atreya I, McBride J, Neurath MF, Zundler S. Cellular Mechanisms of Etrolizumab Treatment in Inflammatory Bowel Disease. Front Pharmacol 2019;10:39. [PMID: 30774593 DOI: 10.3389/fphar.2019.00039] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
420 Singh A, Khan F, Lopez R, Shen B, Philpott J. Vedolizumab for chronic antibiotic-refractory pouchitis. Gastroenterol Rep (Oxf) 2019;7:121-6. [PMID: 30976425 DOI: 10.1093/gastro/goz001] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
421 Fukuda T, Naganuma M, Kanai T. Current new challenges in the management of ulcerative colitis. Intest Res 2019;17:36-44. [PMID: 30678445 DOI: 10.5217/ir.2018.00126] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 5.7] [Reference Citation Analysis]
422 Ma C, Battat R, Jairath V, Vande Casteele N. Advances in Therapeutic Drug Monitoring for Small-Molecule and Biologic Therapies in Inflammatory Bowel Disease. Curr Treat Options Gastroenterol 2019;17:127-45. [PMID: 30680599 DOI: 10.1007/s11938-019-00222-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
423 Osterman MT, Rosario M, Lasch K, Barocas M, Wilbur JD, Dirks NL, Gastonguay MR. Vedolizumab exposure levels and clinical outcomes in ulcerative colitis: determining the potential for dose optimisation. Aliment Pharmacol Ther 2019;49:408-18. [PMID: 30663076 DOI: 10.1111/apt.15113] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 14.0] [Reference Citation Analysis]
424 Tamilarasan AG, Cunningham G, Irving PM, Samaan MA. Recent advances in monoclonal antibody therapy in IBD: practical issues. Frontline Gastroenterol 2019;10:409-16. [PMID: 31656567 DOI: 10.1136/flgastro-2018-101054] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
425 Click B, Regueiro M. Managing Risks with Biologics. Curr Gastroenterol Rep 2019;21:1. [PMID: 30635807 DOI: 10.1007/s11894-019-0669-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
426 Khanna R, Vande Casteele N. Use of Precision Medicine in Clinical Trials in Inflammatory Bowel Disease. Inflamm Bowel Dis 2019;25:213-6. [PMID: 30256949 DOI: 10.1093/ibd/izy295] [Reference Citation Analysis]
427 Wilcock A, Bahri R, Bulfone-Paus S, Arkwright PD. Mast cell disorders: From infancy to maturity. Allergy 2019;74:53-63. [PMID: 30390314 DOI: 10.1111/all.13657] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 10.7] [Reference Citation Analysis]
428 Zeissig S, Rosati E, Dowds CM, Aden K, Bethge J, Schulte B, Pan WH, Mishra N, Zuhayra M, Marx M, Paulsen M, Strigli A, Conrad C, Schuldt D, Sinha A, Ebsen H, Kornell SC, Nikolaus S, Arlt A, Kabelitz D, Ellrichmann M, Lützen U, Rosenstiel PC, Franke A, Schreiber S. Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease. Gut 2019;68:25-39. [PMID: 29730603 DOI: 10.1136/gutjnl-2018-316023] [Cited by in Crossref: 102] [Cited by in F6Publishing: 103] [Article Influence: 34.0] [Reference Citation Analysis]
429 Feagan BG, Bhayat F, Khalid M, Blake A, Travis SPL. Respiratory Tract Infections in Patients With Inflammatory Bowel Disease: Safety Analyses From Vedolizumab Clinical Trials. J Crohns Colitis 2018;12:905-19. [PMID: 29788248 DOI: 10.1093/ecco-jcc/jjy047] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
430 Jansen JP, Khalid JM, Smyth MD, Patel H. The number needed to treat and relevant between-trial comparisons of competing interventions. Clinicoecon Outcomes Res 2018;10:865-71. [PMID: 30588048 DOI: 10.2147/CEOR.S180491] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
431 Merkley SD, Chock CJ, Yang XO, Harris J, Castillo EF. Modulating T Cell Responses via Autophagy: The Intrinsic Influence Controlling the Function of Both Antigen-Presenting Cells and T Cells. Front Immunol. 2018;9:2914. [PMID: 30619278 DOI: 10.3389/fimmu.2018.02914] [Cited by in Crossref: 20] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
432 Abu-Sbeih H, Ali FS, Alsaadi D, Jennings J, Luo W, Gong Z, Richards DM, Charabaty A, Wang Y. Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study. J Immunother Cancer. 2018;6:142. [PMID: 30518410 DOI: 10.1186/s40425-018-0461-4] [Cited by in Crossref: 64] [Cited by in F6Publishing: 88] [Article Influence: 16.0] [Reference Citation Analysis]
433 Selinger CP, Carbery I, Al-Asiry J. The role of biologics in the treatment of patients with inflammatory bowel disease. Br J Hosp Med (Lond) 2018;79:686-93. [PMID: 30526103 DOI: 10.12968/hmed.2018.79.12.686] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
434 Li SJ, Perez-Chada LM, Merola JF. TNF Inhibitor-Induced Psoriasis: Proposed Algorithm for Treatment and Management. J Psoriasis Psoriatic Arthritis 2019;4:70-80. [PMID: 31093599 DOI: 10.1177/2475530318810851] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 4.3] [Reference Citation Analysis]
435 Parikh A, Stephens K, Major E, Fox I, Milch C, Sankoh S, Lev MH, Provenzale JM, Shick J, Patti M, McAuliffe M, Berger JR, Clifford DB. A Programme for Risk Assessment and Minimisation of Progressive Multifocal Leukoencephalopathy Developed for Vedolizumab Clinical Trials. Drug Saf 2018;41:807-16. [PMID: 29737503 DOI: 10.1007/s40264-018-0669-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
436 Weisshof R, El Jurdi K, Zmeter N, Rubin DT. Emerging Therapies for Inflammatory Bowel Disease. Adv Ther 2018;35:1746-62. [PMID: 30374806 DOI: 10.1007/s12325-018-0795-9] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 11.8] [Reference Citation Analysis]
437 Kuehn F, Hodin RA. Impact of Modern Drug Therapy on Surgery: Ulcerative Colitis. Visc Med 2018;34:426-31. [PMID: 30675487 DOI: 10.1159/000493492] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
438 Singh S, George J, Boland BS, Vande Casteele N, Sandborn WJ. Primary Non-Response to Tumor Necrosis Factor Antagonists is Associated with Inferior Response to Second-line Biologics in Patients with Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis. J Crohns Colitis 2018;12:635-43. [PMID: 29370397 DOI: 10.1093/ecco-jcc/jjy004] [Cited by in Crossref: 47] [Cited by in F6Publishing: 67] [Article Influence: 11.8] [Reference Citation Analysis]
439 Okabayashi S, Kobayashi T, Hibi T. Drug Lag for Inflammatory Bowel Disease Treatments in the East and West. Inflamm Intest Dis 2018;3:25-31. [PMID: 30505839 DOI: 10.1159/000491878] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
440 Gerner RR, Klepsch V, Macheiner S, Arnhard K, Adolph TE, Grander C, Wieser V, Pfister A, Moser P, Hermann-Kleiter N, Baier G, Oberacher H, Tilg H, Moschen AR. NAD metabolism fuels human and mouse intestinal inflammation. Gut 2018;67:1813-23. [PMID: 28877980 DOI: 10.1136/gutjnl-2017-314241] [Cited by in Crossref: 59] [Cited by in F6Publishing: 62] [Article Influence: 14.8] [Reference Citation Analysis]
441 Sham HP, Bazett M, Bosiljcic M, Yang H, Luk B, Law HT, Morampudi V, Yu HB, Pankovich J, Sutcliffe S, Bressler B, Marshall JK, Fedorak RN, Chen J, Jones M, Gunn H, Kalyan S, Vallance BA. Immune Stimulation Using a Gut Microbe-Based Immunotherapy Reduces Disease Pathology and Improves Barrier Function in Ulcerative Colitis. Front Immunol 2018;9:2211. [PMID: 30319652 DOI: 10.3389/fimmu.2018.02211] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
442 Wright AP, Fontana RJ, Stidham RW. Vedolizumab is safe and effective in moderate-to-severe inflammatory bowel disease following liver transplantation. Liver Transpl 2017;23:968-71. [PMID: 28296011 DOI: 10.1002/lt.24757] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
443 Becker E, Schramm S, Binder MT, Allner C, Wiendl M, Neufert C, Atreya I, Neurath M, Zundler S. Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease. J Vis Exp 2018. [PMID: 30295649 DOI: 10.3791/58210] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
444 Khanna R, Zou G, Feagan BG. Evolution of the Randomized Controlled Trial in Inflammatory Bowel Disease: Current Challenges and Future Solutions. Inflamm Bowel Dis 2018;24:2155-64. [PMID: 29788218 DOI: 10.1093/ibd/izy117] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
445 Schneider AM, Weghuber D, Hetzer B, Entenmann A, Müller T, Zimmermann G, Schütz S, Huber WD, Pichler J. Vedolizumab use after failure of TNF-α antagonists in children and adolescents with inflammatory bowel disease. BMC Gastroenterol 2018;18:140. [PMID: 30219028 DOI: 10.1186/s12876-018-0868-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 4.5] [Reference Citation Analysis]
446 Kobayashi K, Suzuki Y, Watanabe K, Oda K, Mukae M, Yamada A, Yamagami H, Nishimura A, Okamoto H. A Phase 1, Multiple-Dose Study of Vedolizumab in Japanese Patients With Ulcerative Colitis. J Clin Pharmacol 2019;59:271-9. [PMID: 30192378 DOI: 10.1002/jcph.1307] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
447 D'Haens G, Vermeire S, Vogelsang H, Allez M, Desreumaux P, Van Gossum A, Sandborn WJ, Baumgart DC, Ransohoff RM, Comer GM, Ahmad A, Cataldi F, Cheng J, Clare R, Gorelick KJ, Kaminski A, Pradhan V, Rivers S, Sikpi MO, Zhang Y, Hassan-Zahraee M, Reinisch W, Stuve O. Effect of PF-00547659 on Central Nervous System Immune Surveillance and Circulating β7+ T Cells in Crohn's Disease: Report of the TOSCA Study. J Crohns Colitis 2018;12:188-96. [PMID: 28961770 DOI: 10.1093/ecco-jcc/jjx128] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
448 Reinglas J, Gonczi L, Kurt Z, Bessissow T, Lakatos PL. Positioning of old and new biologicals and small molecules in the treatment of inflammatory bowel diseases. World J Gastroenterol 2018; 24(32): 3567-3582 [PMID: 30166855 DOI: 10.3748/wjg.v24.i32.3567] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 25] [Article Influence: 7.3] [Reference Citation Analysis]
449 Fiorucci S, Biagioli M, Distrutti E. Immunephenotype Predicts Response to Vedolizumab: Integrating Clinical and Biochemical Biomarkers in the Treatment of Inflammatory Bowel Diseases. Dig Dis Sci 2018;63:2168-71. [PMID: 29611077 DOI: 10.1007/s10620-018-5039-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
450 Hansson-Hedblom A, Almond C, Borgström F, Sly I, Enkusson D, Troelsgaard Buchholt A, Karlsson L. Cost-effectiveness of ustekinumab in moderate to severe Crohn's disease in Sweden. Cost Eff Resour Alloc 2018;16:28. [PMID: 30123097 DOI: 10.1186/s12962-018-0114-y] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
451 Kho ZY, Lal SK. The Human Gut Microbiome - A Potential Controller of Wellness and Disease. Front Microbiol 2018;9:1835. [PMID: 30154767 DOI: 10.3389/fmicb.2018.01835] [Cited by in Crossref: 285] [Cited by in F6Publishing: 334] [Article Influence: 71.3] [Reference Citation Analysis]
452 Wehkamp J, Stange EF. Recent advances and emerging therapies in the non-surgical management of ulcerative colitis. F1000Res 2018;7:F1000 Faculty Rev-1207. [PMID: 30135722 DOI: 10.12688/f1000research.15159.1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
453 Rath T, Billmeier U, Ferrazzi F, Vieth M, Ekici A, Neurath MF, Atreya R. Effects of Anti-Integrin Treatment With Vedolizumab on Immune Pathways and Cytokines in Inflammatory Bowel Diseases. Front Immunol 2018;9:1700. [PMID: 30131801 DOI: 10.3389/fimmu.2018.01700] [Cited by in Crossref: 17] [Cited by in F6Publishing: 22] [Article Influence: 4.3] [Reference Citation Analysis]
454 Drobne D, Kurent T, Golob S, Svegl P, Rajar P, Terzic S, Kozelj M, Novak G, Smrekar N, Plut S, Sever N, Strnisa L, Hanzel J, Brecelj J, Urlep D, Osredkar J, Homan M, Orel R, Stabuc B, Ferkolj I, Smid A. Success and safety of high infliximab trough levels in inflammatory bowel disease. Scand J Gastroenterol 2018;53:940-6. [PMID: 29987967 DOI: 10.1080/00365521.2018.1486882] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 6.0] [Reference Citation Analysis]
455 Cohn HM, Dave M, Loftus EV. Understanding the Cautions and Contraindications of Immunomodulator and Biologic Therapies for Use in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017;23:1301-1315. [PMID: 28708806 DOI: 10.1097/mib.0000000000001199] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
456 Khan F, Gao XH, Singh A, Philpott JR, Shen B. Vedolizumab in the treatment of Crohn's disease of the pouch. Gastroenterol Rep (Oxf). 2018;6:184-188. [PMID: 30151202 DOI: 10.1093/gastro/goy014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
457 Singh S, Proudfoot JA, Dulai PS, Jairath V, Fumery M, Xu R, Feagan BG, Sandborn WJ. No Benefit of Concomitant 5-Aminosalicylates in Patients With Ulcerative Colitis Escalated to Biologic Therapy: Pooled Analysis of Individual Participant Data From Clinical Trials. Am J Gastroenterol 2018;113:1197-205. [PMID: 29925913 DOI: 10.1038/s41395-018-0144-2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 6.5] [Reference Citation Analysis]
458 Kotze PG, Ma C, Mckenna N, Almutairdi A, Kaplan GG, Raffals LE, Loftus EV Jr, Panaccione R, Lightner AL. Vedolizumab and early postoperative complications in nonintestinal surgery: a case-matched analysis. Therap Adv Gastroenterol 2018;11:1756284818783614. [PMID: 29977340 DOI: 10.1177/1756284818783614] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
459 Scribano ML. Vedolizumab for inflammatory bowel disease: From randomized controlled trials to real-life evidence. World J Gastroenterol 2018; 24(23): 2457-2467 [PMID: 29930467 DOI: 10.3748/wjg.v24.i23.2457] [Cited by in CrossRef: 50] [Cited by in F6Publishing: 40] [Article Influence: 12.5] [Reference Citation Analysis]
460 Shim HH, Chan PW, Chuah SW, Schwender BJ, Kong SC, Ling KL. A review of vedolizumab and ustekinumab for the treatment of inflammatory bowel diseases. JGH Open 2018;2:223-34. [PMID: 30483594 DOI: 10.1002/jgh3.12065] [Cited by in Crossref: 9] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
461 Paramsothy S, Rosenstein AK, Mehandru S, Colombel JF. The current state of the art for biological therapies and new small molecules in inflammatory bowel disease. Mucosal Immunol 2018;11:1558-70. [PMID: 29907872 DOI: 10.1038/s41385-018-0050-3] [Cited by in Crossref: 39] [Cited by in F6Publishing: 45] [Article Influence: 9.8] [Reference Citation Analysis]
462 Støy S, Sandahl TD, Hansen AL, Deleuran B, Vorup-Jensen T, Vilstrup H, Kragstrup TW. Decreased monocyte shedding of the migration inhibitor soluble CD18 in alcoholic hepatitis. Clin Transl Gastroenterol 2018;9:160. [PMID: 29904132 DOI: 10.1038/s41424-018-0022-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
463 Dubé PE, Liu CY, Girish N, Washington MK, Polk DB. Pharmacological activation of epidermal growth factor receptor signaling inhibits colitis-associated cancer in mice. Sci Rep 2018;8:9119. [PMID: 29904166 DOI: 10.1038/s41598-018-27353-w] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
464 Park KT, Sceats L, Dehghan M, Trickey AW, Wren A, Wong JJ, Bensen R, Limketkai BN, Keyashian K, Kin C. Risk of post-operative surgical site infections after vedolizumab vs anti-tumour necrosis factor therapy: a propensity score matching analysis in inflammatory bowel disease. Aliment Pharmacol Ther 2018;48:340-6. [PMID: 29876995 DOI: 10.1111/apt.14842] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
465 Schreiber S, Dignass A, Peyrin-Biroulet L, Hather G, Demuth D, Mosli M, Curtis R, Khalid JM, Loftus EV Jr. Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease. J Gastroenterol. 2018;53:1048-1064. [PMID: 29869016 DOI: 10.1007/s00535-018-1480-0] [Cited by in Crossref: 75] [Cited by in F6Publishing: 69] [Article Influence: 18.8] [Reference Citation Analysis]
466 Soendergaard C, Seidelin JB, Steenholdt C, Nielsen OH. Putative biomarkers of vedolizumab resistance and underlying inflammatory pathways involved in IBD. BMJ Open Gastroenterol 2018;5:e000208. [PMID: 29915667 DOI: 10.1136/bmjgast-2018-000208] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
467 Rosario M, Dirks NL, Milch C, Parikh A, Bargfrede M, Wyant T, Fedyk E, Fox I. A Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Vedolizumab. Clin Pharmacokinet 2017;56:1287-301. [PMID: 28523450 DOI: 10.1007/s40262-017-0546-0] [Cited by in Crossref: 74] [Cited by in F6Publishing: 79] [Article Influence: 18.5] [Reference Citation Analysis]
468 Lord JD, Long SA, Shows DM, Thorpe J, Schwedhelm K, Chen J, Kita M, Buckner JH. Circulating integrin alpha4/beta7+ lymphocytes targeted by vedolizumab have a pro-inflammatory phenotype. Clin Immunol. 2018;193:24-32. [PMID: 29842945 DOI: 10.1016/j.clim.2018.05.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
469 Catalan-Serra I, Brenna Ø. Immunotherapy in inflammatory bowel disease: Novel and emerging treatments. Hum Vaccin Immunother 2018;14:2597-611. [PMID: 29624476 DOI: 10.1080/21645515.2018.1461297] [Cited by in Crossref: 10] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
470 Celiberto LS, Graef FA, Healey GR, Bosman ES, Jacobson K, Sly LM, Vallance BA. Inflammatory bowel disease and immunonutrition: novel therapeutic approaches through modulation of diet and the gut microbiome. Immunology 2018;155:36-52. [PMID: 29693729 DOI: 10.1111/imm.12939] [Cited by in Crossref: 43] [Cited by in F6Publishing: 57] [Article Influence: 10.8] [Reference Citation Analysis]
471 Paschos P, Katsoula A, Giouleme O, Sarigianni M, Liakos A, Athanasiadou E, Bekiari E, Tsapas A. Tofacitinib for induction of remission in ulcerative colitis: systematic review and meta-analysis. Ann Gastroenterol 2018;31:572-82. [PMID: 30174394 DOI: 10.20524/aog.2018.0276] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
472 Ward MG, Sparrow MP, Roblin X. Therapeutic drug monitoring of vedolizumab in inflammatory bowel disease: current data and future directions.Therap Adv Gastroenterol. 2018;11:1756284818772786. [PMID: 29774052 DOI: 10.1177/1756284818772786] [Cited by in Crossref: 21] [Cited by in F6Publishing: 31] [Article Influence: 5.3] [Reference Citation Analysis]
473 Christensen B, Gibson PR, Micic D, Colman RJ, Goeppinger SR, Kassim O, Yarur A, Weber CR, Cohen RD, Rubin DT. Safety and Efficacy of Combination Treatment With Calcineurin Inhibitors and Vedolizumab in Patients With Refractory Inflammatory Bowel Disease. Clin Gastroenterol Hepatol 2019;17:486-93. [PMID: 29751166 DOI: 10.1016/j.cgh.2018.04.060] [Cited by in Crossref: 53] [Cited by in F6Publishing: 43] [Article Influence: 13.3] [Reference Citation Analysis]
474 Park SC, Jeen YT. Anti-integrin therapy for inflammatory bowel disease. World J Gastroenterol 2018; 24(17): 1868-1880 [PMID: 29740202 DOI: 10.3748/wjg.v24.i17.1868] [Cited by in CrossRef: 59] [Cited by in F6Publishing: 50] [Article Influence: 14.8] [Reference Citation Analysis]
475 Motoya S, Watanabe M, Kim HJ, Kim YH, Han DS, Yuasa H, Tabira J, Isogawa N, Arai S, Kawaguchi I. Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studies. Intest Res. 2018;16:233-245. [PMID: 29743836 DOI: 10.5217/ir.2018.16.2.233] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
476 Fousekis FS, Theopistos VI, Katsanos KH, Tsianos EV, Christodoulou DK. Hepatobiliary Manifestations and Complications in Inflammatory Bowel Disease: A Review. Gastroenterology Res. 2018;11:83-94. [PMID: 29707074 DOI: 10.14740/gr990w] [Cited by in Crossref: 14] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
477 Vanga R, Long MD. Contemporary Management of Ulcerative Colitis. Curr Gastroenterol Rep. 2018;20:12. [PMID: 29589185 DOI: 10.1007/s11894-018-0622-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
478 Ananthakrishnan AN, Donaldson T, Lasch K, Yajnik V. Management of Inflammatory Bowel Disease in the Elderly Patient: Challenges and Opportunities. Inflamm Bowel Dis. 2017;23:882-893. [PMID: 28375885 DOI: 10.1097/mib.0000000000001099] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 10.8] [Reference Citation Analysis]
479 Sun H, Lagarrigue F, Gingras AR, Fan Z, Ley K, Ginsberg MH. Transmission of integrin β7 transmembrane domain topology enables gut lymphoid tissue development. J Cell Biol 2018;217:1453-65. [PMID: 29535192 DOI: 10.1083/jcb.201707055] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
480 Lamb CA, Mansfield JC, Tew GW, Gibbons D, Long AK, Irving P, Diehl L, Eastham-Anderson J, Price MB, O'Boyle G, Jones DEJ, O'Byrne S, Hayday A, Keir ME, Egen JG, Kirby JA. αEβ7 Integrin Identifies Subsets of Pro-Inflammatory Colonic CD4+ T Lymphocytes in Ulcerative Colitis. J Crohns Colitis 2017;11:610-20. [PMID: 28453768 DOI: 10.1093/ecco-jcc/jjw189] [Cited by in Crossref: 9] [Cited by in F6Publishing: 30] [Article Influence: 2.3] [Reference Citation Analysis]
481 Fleisher M, Marsal J, Lee SD, Frado LE, Parian A, Korelitz BI, Feagan BG. Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease. Dig Dis Sci 2018;63:825-33. [PMID: 29484571 DOI: 10.1007/s10620-018-4971-1] [Cited by in Crossref: 49] [Cited by in F6Publishing: 37] [Article Influence: 12.3] [Reference Citation Analysis]
482 Rubin DT, Dubinsky MC, Martino S, Hewett KA, Panés J. Communication Between Physicians and Patients with Ulcerative Colitis: Reflections and Insights from a Qualitative Study of In-Office Patient-Physician Visits. Inflamm Bowel Dis 2017;23:494-501. [PMID: 28296817 DOI: 10.1097/MIB.0000000000001048] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
483 Allamneni C, Venkata K, Yun H, Xie F, DeLoach L, Malik TA. Comparative Effectiveness of Vedolizumab vs. Infliximab Induction Therapy in Ulcerative Colitis: Experience of a Real-World Cohort at a Tertiary Inflammatory Bowel Disease Center. Gastroenterology Res 2018;11:41-5. [PMID: 29511405 DOI: 10.14740/gr934w] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
484 Hamel B, Wu M, Hamel EO, Bass DM, Park KT. Outcome of tacrolimus and vedolizumab after corticosteroid and anti-TNF failure in paediatric severe colitis. BMJ Open Gastroenterol 2018;5:e000195. [PMID: 29527316 DOI: 10.1136/bmjgast-2017-000195] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
485 Martins D, Ministro P, Silva A. Refractory Chronic Pouchitis and Autoimmune Hemolytic Anemia Successfully Treated with Vedolizumab. GE Port J Gastroenterol. 2018;25:340-341. [PMID: 30480056 DOI: 10.1159/000486803] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
486 Perciani CT, Jaoko W, Farah B, Ostrowski MA, Anzala O, MacDonald KS; KAVI-ICR Team. αEβ7, α4β7 and α4β1 integrin contributions to T cell distribution in blood, cervix and rectal tissues: Potential implications for HIV transmission. PLoS One 2018;13:e0192482. [PMID: 29420608 DOI: 10.1371/journal.pone.0192482] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
487 Christensen B, Micic D, Gibson PR, Yarur A, Bellaguarda E, Corsello P, Gaetano JN, Kinnucan J, Rao VL, Reddy S, Singh S, Pekow J, Rubin DT. Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease. Aliment Pharmacol Ther 2018;47:753-62. [PMID: 29377235 DOI: 10.1111/apt.14525] [Cited by in Crossref: 48] [Cited by in F6Publishing: 40] [Article Influence: 12.0] [Reference Citation Analysis]
488 Boden EK, Shows DM, Chiorean MV, Lord JD. Identification of Candidate Biomarkers Associated with Response to Vedolizumab in Inflammatory Bowel Disease. Dig Dis Sci. 2018;63:2419-2429. [PMID: 29372476 DOI: 10.1007/s10620-018-4924-8] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 8.5] [Reference Citation Analysis]
489 Waljee AK, Liu B, Sauder K, Zhu J, Govani SM, Stidham RW, Higgins PDR. Predicting corticosteroid-free endoscopic remission with vedolizumab in ulcerative colitis. Aliment Pharmacol Ther. 2018;47:763-772. [PMID: 29359519 DOI: 10.1111/apt.14510] [Cited by in Crossref: 52] [Cited by in F6Publishing: 45] [Article Influence: 13.0] [Reference Citation Analysis]
490 Lee SH, Kwon JE, Cho ML. Immunological pathogenesis of inflammatory bowel disease. Intest Res. 2018;16:26-42. [PMID: 29422795 DOI: 10.5217/ir.2018.16.1.26] [Cited by in Crossref: 128] [Cited by in F6Publishing: 184] [Article Influence: 32.0] [Reference Citation Analysis]
491 Picardo S, So K, Venugopal K, Chin M. Vedolizumab-induced acute pancreatitis: the first reported clinical case. BMJ Case Rep 2018;2018:bcr-2017-222554. [PMID: 29305366 DOI: 10.1136/bcr-2017-222554] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
492 Arijs I, De Hertogh G, Lemmens B, Van Lommel L, de Bruyn M, Vanhove W, Cleynen I, Machiels K, Ferrante M, Schuit F, Van Assche G, Rutgeerts P, Vermeire S. Effect of vedolizumab (anti-α4β7-integrin) therapy on histological healing and mucosal gene expression in patients with UC. Gut 2018;67:43-52. [PMID: 27802155 DOI: 10.1136/gutjnl-2016-312293] [Cited by in Crossref: 98] [Cited by in F6Publishing: 80] [Article Influence: 24.5] [Reference Citation Analysis]
493 Ho TH, Serie DJ, Parasramka M, Cheville JC, Bot BM, Tan W, Wang L, Joseph RW, Hilton T, Leibovich BC, Parker AS, Eckel-Passow JE. Differential gene expression profiling of matched primary renal cell carcinoma and metastases reveals upregulation of extracellular matrix genes. Ann Oncol 2017;28:604-10. [PMID: 27993815 DOI: 10.1093/annonc/mdw652] [Cited by in Crossref: 36] [Cited by in F6Publishing: 51] [Article Influence: 7.2] [Reference Citation Analysis]
494 Santangelo PJ, Cicala C, Byrareddy SN, Ortiz KT, Little D, Lindsay KE, Gumber S, Hong JJ, Jelicic K, Rogers KA, Zurla C, Villinger F, Ansari AA, Fauci AS, Arthos J. Early treatment of SIV+ macaques with an α4β7 mAb alters virus distribution and preserves CD4+ T cells in later stages of infection. Mucosal Immunol 2018;11:932-46. [PMID: 29346349 DOI: 10.1038/mi.2017.112] [Cited by in Crossref: 27] [Cited by in F6Publishing: 32] [Article Influence: 5.4] [Reference Citation Analysis]
495 Cheung AC, Lazaridis KN, LaRusso NF, Gores GJ. Emerging pharmacologic therapies for primary sclerosing cholangitis. Curr Opin Gastroenterol 2017;33:149-57. [PMID: 28257308 DOI: 10.1097/MOG.0000000000000352] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
496 Saifuddin A, Harris A. Tacrolimus therapy in moderate to subacute ulcerative proctocolitis: a large single-centre cohort study. Frontline Gastroenterol. 2018;9:148-153. [PMID: 29588844 DOI: 10.1136/flgastro-2017-100888] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
497 Lee HS, Park SK, Park DI. Novel treatments for inflammatory bowel disease. Korean J Intern Med 2018;33:20-7. [PMID: 29223139 DOI: 10.3904/kjim.2017.393] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
498 Calenda G, Keawvichit R, Arrode-Brusés G, Pattanapanyasat K, Frank I, Byrareddy SN, Arthos J, Cicala C, Grasperge B, Blanchard JL, Gettie A, Reimann KA, Ansari AA, Martinelli E. Integrin α4β7 Blockade Preferentially Impacts CCR6+ Lymphocyte Subsets in Blood and Mucosal Tissues of Naive Rhesus Macaques. J Immunol 2018;200:810-20. [PMID: 29196458 DOI: 10.4049/jimmunol.1701150] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
499 Wei X, Gibiansky L, Wang Y, Fuh F, Erickson R, O'Byrne S, Tang MT. Pharmacokinetic and Pharmacodynamic Modeling of Serum Etrolizumab and Circulating β7 Receptor Occupancy in Patients With Ulcerative Colitis. J Clin Pharmacol 2018;58:386-98. [PMID: 29178491 DOI: 10.1002/jcph.1031] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
500 Zundler S, Schillinger D, Fischer A, Atreya R, López-Posadas R, Watson A, Neufert C, Atreya I, Neurath MF. Blockade of αEβ7 integrin suppresses accumulation of CD8+ and Th9 lymphocytes from patients with IBD in the inflamed gut in vivo. Gut 2017;66:1936-48. [PMID: 27543429 DOI: 10.1136/gutjnl-2016-312439] [Cited by in Crossref: 65] [Cited by in F6Publishing: 65] [Article Influence: 13.0] [Reference Citation Analysis]
501 Gaspar R, Liberal R, Macedo G. Mucosal Healing in Ulcerative Colitis Patients Treated With Vedolizumab: Patient-, Dose-, or Duration-Dependent? J Crohns Colitis 2017;11:1403-4. [PMID: 28531313 DOI: 10.1093/ecco-jcc/jjx074] [Reference Citation Analysis]
502 Kump P, Wurm P, Gröchenig HP, Wenzl H, Petritsch W, Halwachs B, Wagner M, Stadlbauer V, Eherer A, Hoffmann KM, Deutschmann A, Reicht G, Reiter L, Slawitsch P, Gorkiewicz G, Högenauer C. The taxonomic composition of the donor intestinal microbiota is a major factor influencing the efficacy of faecal microbiota transplantation in therapy refractory ulcerative colitis. Aliment Pharmacol Ther 2018;47:67-77. [PMID: 29052237 DOI: 10.1111/apt.14387] [Cited by in Crossref: 96] [Cited by in F6Publishing: 79] [Article Influence: 19.2] [Reference Citation Analysis]
503 Wilson MR, Azzabi Zouraq I, Chevrou-Severac H, Selby R, Kerrigan MC. Cost-effectiveness of vedolizumab compared with conventional therapy for ulcerative colitis patients in the UK. Clinicoecon Outcomes Res 2017;9:641-52. [PMID: 29081667 DOI: 10.2147/CEOR.S135609] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
504 Shaikh SA, Fitzgerald L, Tischer S. Safety and Efficacy of Biologic Agents for the Management of Inflammatory Bowel Disease After Liver Transplantation. Pharmacotherapy 2017;37:1578-85. [PMID: 28960437 DOI: 10.1002/phar.2036] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
505 Holleran G, Lopetuso L, Petito V, Graziani C, Ianiro G, McNamara D, Gasbarrini A, Scaldaferri F. The Innate and Adaptive Immune System as Targets for Biologic Therapies in Inflammatory Bowel Disease. Int J Mol Sci. 2017;18. [PMID: 28934123 DOI: 10.3390/ijms18102020] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 6.8] [Reference Citation Analysis]
506 Toyonaga T, Kobayashi T, Nakano M, Saito E, Umeda S, Okabayashi S, Ozaki R, Hibi T. Usefulness of fecal calprotectin for the early prediction of short-term outcomes of remission-induction treatments in ulcerative colitis in comparison with two-item patient-reported outcome. PLoS One 2017;12:e0185131. [PMID: 28934315 DOI: 10.1371/journal.pone.0185131] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
507 Vasudevan A, Gibson PR, Langenberg DRV. Time to clinical response and remission for therapeutics in inflammatory bowel diseases: What should the clinician expect, what should patients be told? World J Gastroenterol 2017; 23(35): 6385-6402 [PMID: 29085188 DOI: 10.3748/wjg.v23.i35.6385] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 26] [Article Influence: 7.2] [Reference Citation Analysis]
508 Dudley-Brown S. Optimizing Inflammatory Bowel Disease Management: An Overview for the Gastroenterology Nurse. Gastroenterol Nurs 2017;40 Suppl 1S:S1-S14. [PMID: 27922458 DOI: 10.1097/SGA.0000000000000277] [Reference Citation Analysis]
509 Sheasgreen C, Nguyen GC. The Evolving Evidence for Therapeutic Drug Monitoring of Monoclonal Antibodies in Inflammatory Bowel Disease. Curr Gastroenterol Rep 2017;19:19. [PMID: 28397129 DOI: 10.1007/s11894-017-0559-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
510 Jairath V, Zou GY, Parker CE, MacDonald JK, AlAmeel T, Al Beshir M, Almadi MA, Al-Taweel T, Atkinson NS, Biswas S, Chapman T, Dulai PS, Glaire MA, Hoekman DR, Koutsoumpas A, Minas E, Mosli MH, Samaan M, Khanna R, Travis S, D'Haens G, Sandborn WJ, Feagan BG. Placebo response and remission rates in randomised trials of induction and maintenance therapy for ulcerative colitis. Cochrane Database Syst Rev 2017;9:CD011572. [PMID: 28886205 DOI: 10.1002/14651858.CD011572.pub2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
511 Vetter M, Neurath MF. Emerging oral targeted therapies in inflammatory bowel diseases: opportunities and challenges. Therap Adv Gastroenterol 2017;10:773-90. [PMID: 29051788 DOI: 10.1177/1756283X17727388] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
512 Schäffler H, Huth A, Lamprecht G, Anders O. Vedolizumab Treatment for Ulcerative Colitis in an Elderly Multimorbid Patient with Hemophilia A. Case Rep Gastroenterol 2017;11:774-9. [PMID: 29606934 DOI: 10.1159/000485372] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
513 Castaneda G, Liu B, Torres S, Bhuket T, Wong RJ. Race/Ethnicity-Specific Disparities in the Severity of Disease at Presentation in Adults with Ulcerative Colitis: A Cross-Sectional Study. Dig Dis Sci 2017;62:2876-81. [PMID: 28856475 DOI: 10.1007/s10620-017-4733-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
514 Zwicker S, Lira-Junior R, Höög C, Almer S, Boström EA. Systemic Chemokine Levels with "Gut-Specific" Vedolizumab in Patients with Inflammatory Bowel Disease-A Pilot Study. Int J Mol Sci 2017;18:E1827. [PMID: 28829369 DOI: 10.3390/ijms18081827] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
515 . Inflammatory Bowel Disease Clinical. Journal of Gastroenterology and Hepatology 2017;32:121-54. [DOI: 10.1111/jgh.13895] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
516 Costello SP, Soo W, Bryant RV, Jairath V, Hart AL, Andrews JM. Editorial: faecal microbiota transplantation for ulcerative colitis-not quite there yet? Authors' reply. Aliment Pharmacol Ther 2017;46:631-2. [PMID: 28805321 DOI: 10.1111/apt.14246] [Reference Citation Analysis]
517 De Vries LCS, Ludbrook VJ, Hicks KJ, D'Haens GR. GSK2586184, a JAK1 selective inhibitor, in two patients with ulcerative colitis. BMJ Case Rep 2017;2017:bcr-2017-221078. [PMID: 28790099 DOI: 10.1136/bcr-2017-221078] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
518 Zundler S, Becker E, Weidinger C, Siegmund B. Anti-Adhesion Therapies in Inflammatory Bowel Disease-Molecular and Clinical Aspects. Front Immunol. 2017;8:891. [PMID: 28804488 DOI: 10.3389/fimmu.2017.00891] [Cited by in Crossref: 35] [Cited by in F6Publishing: 39] [Article Influence: 7.0] [Reference Citation Analysis]
519 De Vos M, Dhooghe B, Vermeire S, Louis E, Mana F, Elewaut A, Bossuyt P, Baert F, Reenaers C, Van Gossum M, Macken E, Ferrante M, Hindryckx P, Dewit O, Holvoet T, Franchimont D; Belgian Inflammatory Bowel Disease Research and Development (BIRD). Efficacy of vedolizumab for induction of clinical response and remission in patients with moderate to severe inflammatory bowel disease who failed at least two TNF antagonists. United European Gastroenterol J 2018;6:439-45. [PMID: 29774158 DOI: 10.1177/2050640617722310] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
520 Sofia MA, Rubin DT. The Impact of Therapeutic Antibodies on the Management of Digestive Diseases: History, Current Practice, and Future Directions. Dig Dis Sci 2017;62:833-42. [PMID: 28197743 DOI: 10.1007/s10620-017-4479-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
521 Mir F, Yousef MH, Partyka EK, Tahan V. Successful treatment of chronic refractory pouchitis with vedolizumab. Int J Colorectal Dis. 2017;32:1517-1518. [PMID: 28698974 DOI: 10.1007/s00384-017-2854-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
522 Fuchs F, Schillinger D, Atreya R, Hirschmann S, Fischer S, Neufert C, Atreya I, Neurath MF, Zundler S. Clinical Response to Vedolizumab in Ulcerative Colitis Patients Is Associated with Changes in Integrin Expression Profiles. Front Immunol 2017;8:764. [PMID: 28717358 DOI: 10.3389/fimmu.2017.00764] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 5.8] [Reference Citation Analysis]
523 Tsuchiya A, Kojima Y, Ikarashi S, Seino S, Watanabe Y, Kawata Y, Terai S. Clinical trials using mesenchymal stem cells in liver diseases and inflammatory bowel diseases. Inflamm Regen. 2017;37:16. [PMID: 29259715 DOI: 10.1186/s41232-017-0045-6] [Cited by in Crossref: 49] [Cited by in F6Publishing: 53] [Article Influence: 9.8] [Reference Citation Analysis]
524 Zitomersky NL, Demers M, Martinod K, Gallant M, Cifuni SM, Biswas A, Snapper S, Wagner DD. ADAMTS13 Deficiency Worsens Colitis and Exogenous ADAMTS13 Administration Decreases Colitis Severity in Mice. TH Open 2017;1:e11-23. [PMID: 29376146 DOI: 10.1055/s-0037-1603927] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
525 Currò D, Pugliese D, Armuzzi A. Frontiers in Drug Research and Development for Inflammatory Bowel Disease. Front Pharmacol 2017;8:400. [PMID: 28690543 DOI: 10.3389/fphar.2017.00400] [Cited by in Crossref: 15] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
526 Stawowczyk E, Kawalec P. Cost-effectiveness of biological treatment of ulcerative colitis - a systematic review. Prz Gastroenterol 2017;12:90-7. [PMID: 28702096 DOI: 10.5114/pg.2017.68166] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
527 Ma C, Panaccione R, Fedorak RN, Parker CE, Khanna R, Levesque BG, Sandborn WJ, Feagan BG, Jairath V. Development of a core outcome set for clinical trials in inflammatory bowel disease: study protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey. BMJ Open 2017;7:e016146. [PMID: 28601837 DOI: 10.1136/bmjopen-2017-016146] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 4.6] [Reference Citation Analysis]
528 Oliveira SB, Monteiro IM. Diagnosis and management of inflammatory bowel disease in children. BMJ. 2017;357:j2083. [PMID: 28566467 DOI: 10.1136/bmj.j2083] [Cited by in Crossref: 39] [Cited by in F6Publishing: 48] [Article Influence: 7.8] [Reference Citation Analysis]
529 Ihara S, Hirata Y, Koike K. TGF-β in inflammatory bowel disease: a key regulator of immune cells, epithelium, and the intestinal microbiota. J Gastroenterol 2017;52:777-87. [PMID: 28534191 DOI: 10.1007/s00535-017-1350-1] [Cited by in Crossref: 117] [Cited by in F6Publishing: 111] [Article Influence: 23.4] [Reference Citation Analysis]
530 Flamant M, Paul S, Roblin X. Golimumab for the treatment of ulcerative colitis. Expert Opin Biol Ther 2017;17:879-86. [PMID: 28472597 DOI: 10.1080/14712598.2017.1327576] [Cited by in Crossref: 13] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
531 Hindryckx P, Novak G, Vande Casteele N, Khanna R, Laukens D, Jairath V, Feagan BG. Incidence, Prevention and Management of Anti-Drug Antibodies Against Therapeutic Antibodies in Inflammatory Bowel Disease: A Practical Overview. Drugs 2017;77:363-77. [PMID: 28233275 DOI: 10.1007/s40265-017-0693-5] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 5.4] [Reference Citation Analysis]
532 Kerur B, Litman HJ, Stern JB, Weber S, Lightdale JR, Rufo PA, Bousvaros A. Correlation of endoscopic disease severity with pediatric ulcerative colitis activity index score in children and young adults with ulcerative colitis. World J Gastroenterol 2017; 23(18): 3322-3329 [PMID: 28566893 DOI: 10.3748/wjg.v23.i18.3322] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.2] [Reference Citation Analysis]
533 Westerveld D, Grajo J, Beattie L, Glover S. Vedolizumab: a novel medical intervention in the treatment of primary sclerosing cholangitis. BMJ Case Rep 2017;2017:bcr-2017-220351. [PMID: 28501828 DOI: 10.1136/bcr-2017-220351] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
534 Tran-Minh ML, Sousa P, Maillet M, Allez M, Gornet JM. Hepatic complications induced by immunosuppressants and biologics in inflammatory bowel disease. World J Hepatol 2017; 9(13): 613-626 [PMID: 28539989 DOI: 10.4254/wjh.v9.i13.613] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
535 Sultan KS, Berkowitz JC, Khan S. Combination therapy for inflammatory bowel disease. World J Gastrointest Pharmacol Ther 2017; 8(2): 103-113 [PMID: 28533919 DOI: 10.4292/wjgpt.v8.i2.103] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.6] [Reference Citation Analysis]
536 Colombel JF, Sands BE, Rutgeerts P, Sandborn W, Danese S, D'Haens G, Panaccione R, Loftus EV Jr, Sankoh S, Fox I, Parikh A, Milch C, Abhyankar B, Feagan BG. The safety of vedolizumab for ulcerative colitis and Crohn's disease. Gut 2017;66:839-51. [PMID: 26893500 DOI: 10.1136/gutjnl-2015-311079] [Cited by in Crossref: 465] [Cited by in F6Publishing: 407] [Article Influence: 93.0] [Reference Citation Analysis]
537 Brückner M, Heidemann J, Nowacki TM, Cordes F, Stypmann J, Lenz P, Gohar F, Lügering A, Bettenworth D. Detection and characterization of murine colitis and carcinogenesis by molecularly targeted contrast-enhanced ultrasound. World J Gastroenterol 2017; 23(16): 2899-2911 [PMID: 28522908 DOI: 10.3748/wjg.v23.i16.2899] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
538 Boal Carvalho P, Cotter J. Mucosal Healing in Ulcerative Colitis: A Comprehensive Review. Drugs. 2017;77:159-173. [PMID: 28078646 DOI: 10.1007/s40265-016-0676-y] [Cited by in Crossref: 39] [Cited by in F6Publishing: 56] [Article Influence: 7.8] [Reference Citation Analysis]
539 Gidwaney NG, Pawa S, Das KM. Pathogenesis and clinical spectrum of primary sclerosing cholangitis. World J Gastroenterol 2017; 23(14): 2459-2469 [PMID: 28465630 DOI: 10.3748/wjg.v23.i14.2459] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
540 Allegretti JR, Barnes EL, Stevens B, Storm M, Ananthakrishnan A, Yajnik V, Korzenik J. Predictors of Clinical Response and Remission at 1 Year Among a Multicenter Cohort of Patients with Inflammatory Bowel Disease Treated with Vedolizumab. Dig Dis Sci. 2017;62:1590-1596. [PMID: 28357697 DOI: 10.1007/s10620-017-4549-3] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 9.2] [Reference Citation Analysis]
541 Cholapranee A, Hazlewood GS, Kaplan GG, Peyrin-Biroulet L, Ananthakrishnan AN. Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials. Aliment Pharmacol Ther. 2017;45:1291-1302. [PMID: 28326566 DOI: 10.1111/apt.14030] [Cited by in Crossref: 172] [Cited by in F6Publishing: 158] [Article Influence: 34.4] [Reference Citation Analysis]
542 Varyani F, Fleming JO, Maizels RM. Helminths in the gastrointestinal tract as modulators of immunity and pathology. Am J Physiol Gastrointest Liver Physiol 2017;312:G537-49. [PMID: 28302598 DOI: 10.1152/ajpgi.00024.2017] [Cited by in Crossref: 46] [Cited by in F6Publishing: 35] [Article Influence: 9.2] [Reference Citation Analysis]
543 Wilson MR, Bergman A, Chevrou-Severac H, Selby R, Smyth M, Kerrigan MC. Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom. Eur J Health Econ 2018;19:229-40. [PMID: 28271250 DOI: 10.1007/s10198-017-0879-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
544 Cominelli F, Arseneau KO, Rodriguez-Palacios A, Pizarro TT. Uncovering Pathogenic Mechanisms of Inflammatory Bowel Disease Using Mouse Models of Crohn's Disease-Like Ileitis: What is the Right Model? Cell Mol Gastroenterol Hepatol. 2017;4:19-32. [PMID: 28560286 DOI: 10.1016/j.jcmgh.2017.02.010] [Cited by in Crossref: 28] [Cited by in F6Publishing: 34] [Article Influence: 5.6] [Reference Citation Analysis]
545 Dart RJ, Samaan MA, Powell N, Irving PM. Vedolizumab: toward a personalized therapy paradigm for people with ulcerative colitis. Clin Exp Gastroenterol 2017;10:57-66. [PMID: 28424557 DOI: 10.2147/CEG.S110547] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
546 Kim DH, Cheon JH. Pathogenesis of Inflammatory Bowel Disease and Recent Advances in Biologic Therapies. Immune Netw 2017;17:25-40. [PMID: 28261018 DOI: 10.4110/in.2017.17.1.25] [Cited by in Crossref: 129] [Cited by in F6Publishing: 153] [Article Influence: 25.8] [Reference Citation Analysis]
547 Atreya R, Neurath MF. Current and Future Targets for Mucosal Healing in Inflammatory Bowel Disease. Visc Med. 2017;33:82-88. [PMID: 28612022 DOI: 10.1159/000458006] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 4.6] [Reference Citation Analysis]
548 Bergqvist V, Hertervig E, Gedeon P, Kopljar M, Griph H, Kinhult S, Carneiro A, Marsal J. Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis. Cancer Immunol Immunother. 2017;66:581-592. [PMID: 28204866 DOI: 10.1007/s00262-017-1962-6] [Cited by in Crossref: 117] [Cited by in F6Publishing: 131] [Article Influence: 23.4] [Reference Citation Analysis]
549 Bethge J, Meffert S, Ellrichmann M, Conrad C, Nikolaus S, Schreiber S. Combination therapy with vedolizumab and etanercept in a patient with pouchitis and spondylarthritis. BMJ Open Gastroenterol 2017;4:e000127. [PMID: 28243458 DOI: 10.1136/bmjgast-2016-000127] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 7.0] [Reference Citation Analysis]
550 Barlow JJ, Hawthorne AB. Crohn's disease for the general physician: management. Br J Hosp Med (Lond) 2017;78:77-81. [PMID: 28165796 DOI: 10.12968/hmed.2017.78.2.77] [Reference Citation Analysis]
551 Olivera P, Danese S, Peyrin-Biroulet L. Next generation of small molecules in inflammatory bowel disease. Gut 2017;66:199-209. [PMID: 27856614 DOI: 10.1136/gutjnl-2016-312912] [Cited by in Crossref: 77] [Cited by in F6Publishing: 70] [Article Influence: 15.4] [Reference Citation Analysis]
552 Neurath MF. Current and emerging therapeutic targets for IBD. Nat Rev Gastroenterol Hepatol. 2017;14:269-278. [PMID: 28144028 DOI: 10.1038/nrgastro.2016.208] [Cited by in Crossref: 287] [Cited by in F6Publishing: 267] [Article Influence: 57.4] [Reference Citation Analysis]
553 Hanauer SB. Issue Highlights. Clinical Gastroenterology and Hepatology 2017;15:161-3. [DOI: 10.1016/j.cgh.2016.12.001] [Reference Citation Analysis]
554 Yajnik V, Khan N, Dubinsky M, Axler J, James A, Abhyankar B, Lasch K. Efficacy and Safety of Vedolizumab in Ulcerative Colitis and Crohn's Disease Patients Stratified by Age. Adv Ther 2017;34:542-59. [PMID: 28070861 DOI: 10.1007/s12325-016-0467-6] [Cited by in Crossref: 54] [Cited by in F6Publishing: 47] [Article Influence: 10.8] [Reference Citation Analysis]
555 Choi CH, Moon W, Kim YS, Kim ES, Lee BI, Jung Y, Yoon YS, Lee H, Park DI, Han DS; IBD Study Group of the Korean Association for the Study of Intestinal Diseases. Second Korean guidelines for the management of ulcerative colitis. Intest Res. 2017;15:7-37. [PMID: 28239313 DOI: 10.5217/ir.2017.15.1.7] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 7.4] [Reference Citation Analysis]
556 Horjus Talabur Horje CS, Smids C, Meijer JW, Groenen MJ, Rijnders MK, van Lochem EG, Wahab PJ. High endothelial venules associated with T cell subsets in the inflamed gut of newly diagnosed inflammatory bowel disease patients. Clin Exp Immunol 2017;188:163-73. [PMID: 28033681 DOI: 10.1111/cei.12918] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
557 Dulai PS, Sandborn WJ. Next-Generation Therapeutics for Inflammatory Bowel Disease. Curr Gastroenterol Rep 2016;18:51. [PMID: 27461274 DOI: 10.1007/s11894-016-0522-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
558 Aggarwal A, Sabol T, Vaziri H. Update on the Use of Biologic Therapy in Ulcerative Colitis. Curr Treat Options Gastroenterol 2017;15:155-67. [PMID: 28120279 DOI: 10.1007/s11938-017-0120-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
559 Chung C, Gorelick FS. Targeting αv Integrins in Pancreatic Fibrosis: Progress in Resolving the Scar. Cell Mol Gastroenterol Hepatol 2016;2:405-6. [PMID: 28090563 DOI: 10.1016/j.jcmgh.2016.05.002] [Reference Citation Analysis]
560 Wehkamp J, Götz M, Herrlinger K, Steurer W, Stange EF. Inflammatory Bowel Disease. Dtsch Arztebl Int 2016;113:72-82. [PMID: 26900160 DOI: 10.3238/arztebl.2016.0072] [Cited by in Crossref: 20] [Cited by in F6Publishing: 37] [Article Influence: 4.0] [Reference Citation Analysis]
561 de Lange KM, Moutsianas L, Lee JC, Lamb CA, Luo Y, Kennedy NA, Jostins L, Rice DL, Gutierrez-Achury J, Ji SG, Heap G, Nimmo ER, Edwards C, Henderson P, Mowat C, Sanderson J, Satsangi J, Simmons A, Wilson DC, Tremelling M, Hart A, Mathew CG, Newman WG, Parkes M, Lees CW, Uhlig H, Hawkey C, Prescott NJ, Ahmad T, Mansfield JC, Anderson CA, Barrett JC. Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease. Nat Genet 2017;49:256-61. [PMID: 28067908 DOI: 10.1038/ng.3760] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
562 de Lange KM, Moutsianas L, Lee JC, Lamb CA, Luo Y, Kennedy NA, Jostins L, Rice DL, Gutierrez-Achury J, Ji SG, Heap G, Nimmo ER, Edwards C, Henderson P, Mowat C, Sanderson J, Satsangi J, Simmons A, Wilson DC, Tremelling M, Hart A, Mathew CG, Newman WG, Parkes M, Lees CW, Uhlig H, Hawkey C, Prescott NJ, Ahmad T, Mansfield JC, Anderson CA, Barrett JC. Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease. Nat Genet. 2017;49:256-261. [PMID: 28067908 DOI: 10.1038/ng.3760] [Cited by in Crossref: 517] [Cited by in F6Publishing: 460] [Article Influence: 103.4] [Reference Citation Analysis]
563 Rosario M, Wyant T, Leach T, Sankoh S, Scholz C, Parikh A, Fox I, Feagan BG. Vedolizumab Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability Following Administration of a Single, Ascending, Intravenous Dose to Healthy Volunteers. Clin Drug Investig 2016;36:913-23. [PMID: 27422740 DOI: 10.1007/s40261-016-0437-4] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 7.0] [Reference Citation Analysis]
564 Mosli MH, Feagan BG, Zou G, Sandborn WJ, D'Haens G, Khanna R, Shackelton LM, Walker CW, Nelson S, Vandervoort MK, Frisbie V, Samaan MA, Jairath V, Driman DK, Geboes K, Valasek MA, Pai RK, Lauwers GY, Riddell R, Stitt LW, Levesque BG. Development and validation of a histological index for UC. Gut 2017;66:50-8. [PMID: 26475633 DOI: 10.1136/gutjnl-2015-310393] [Cited by in Crossref: 169] [Cited by in F6Publishing: 163] [Article Influence: 33.8] [Reference Citation Analysis]
565 Dulai PS, Singh S, Casteele NV, Boland BS, Sandborn WJ. How Will Evolving Future Therapies and Strategies Change How We Position the Use of Biologics in Moderate to Severely Active Inflammatory Bowel Disease. Inflamm Bowel Dis 2016;22:998-1009. [PMID: 26835982 DOI: 10.1097/MIB.0000000000000661] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
566 Kaur M, Panikkath D, Yan X, Liu Z, Berel D, Li D, Vasiliauskas EA, Ippoliti A, Dubinsky M, Shih DQ, Melmed GY, Haritunians T, Fleshner P, Targan SR, McGovern DP. Perianal Crohn's Disease is Associated with Distal Colonic Disease, Stricturing Disease Behavior, IBD-Associated Serologies and Genetic Variation in the JAK-STAT Pathway. Inflamm Bowel Dis 2016;22:862-9. [PMID: 26937622 DOI: 10.1097/MIB.0000000000000705] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
567 Sands BE, Joshi S, Haddad J, Freudenberg JM, Oommen DE, Hoffmann E, McCallum SW, Jacobson E. Assessing Colonic Exposure, Safety, and Clinical Activity of SRT2104, a Novel Oral SIRT1 Activator, in Patients with Mild to Moderate Ulcerative Colitis. Inflamm Bowel Dis 2016;22:607-14. [PMID: 26595549 DOI: 10.1097/MIB.0000000000000597] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
568 Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet. 2017;389:1756-1770. [PMID: 27914657 DOI: 10.1016/s0140-6736(16)32126-2] [Cited by in Crossref: 830] [Cited by in F6Publishing: 1116] [Article Influence: 138.3] [Reference Citation Analysis]
569 Feagan BG, Patel H, Colombel JF, Rubin DT, James A, Mody R, Lasch K. Effects of vedolizumab on health-related quality of life in patients with ulcerative colitis: results from the randomised GEMINI 1 trial. Aliment Pharmacol Ther 2017;45:264-75. [PMID: 27859410 DOI: 10.1111/apt.13852] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 4.7] [Reference Citation Analysis]
570 Prieux-Klotz C, Nahon S, Amiot A, Sinayoko L, Galéano-Cassaz C, Chaussade S, Coriat R, Lahmek P, Abitbol V. Rate and Predictors of Mucosal Healing in Ulcerative Colitis Treated with Thiopurines: Results of a Multicentric Cohort Study. Dig Dis Sci 2017;62:473-80. [PMID: 27853898 DOI: 10.1007/s10620-016-4374-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
571 Chan HC, Ng SC. Emerging biologics in inflammatory bowel disease. J Gastroenterol. 2017;52:141-150. [PMID: 27832357 DOI: 10.1007/s00535-016-1283-0] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 7.7] [Reference Citation Analysis]
572 DeFilippis EM, Longman R, Harbus M, Dannenberg K, Scherl EJ. Crohn's Disease: Evolution, Epigenetics, and the Emerging Role of Microbiome-Targeted Therapies. Curr Gastroenterol Rep 2016;18:13. [PMID: 26908281 DOI: 10.1007/s11894-016-0487-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
573 Stevens BW, Borren NZ, Velonias G, Conway G, Cleland T, Andrews E, Khalili H, Garber JG, Xavier RJ, Yajnik V, Ananthakrishnan AN. Vedolizumab Therapy Is Associated with an Improvement in Sleep Quality and Mood in Inflammatory Bowel Diseases. Dig Dis Sci 2017;62:197-206. [PMID: 27796768 DOI: 10.1007/s10620-016-4356-2] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 5.8] [Reference Citation Analysis]
574 Vickers AD, Ainsworth C, Mody R, Bergman A, Ling CS, Medjedovic J, Smyth M. Systematic Review with Network Meta-Analysis: Comparative Efficacy of Biologics in the Treatment of Moderately to Severely Active Ulcerative Colitis. PLoS One. 2016;11:e0165435. [PMID: 27776175 DOI: 10.1371/journal.pone.0165435] [Cited by in Crossref: 58] [Cited by in F6Publishing: 58] [Article Influence: 9.7] [Reference Citation Analysis]
575 Viazis N, Giakoumis M, Bamias G, Goukos D, Koukouratos T, Katopodi K, Karatzas P, Triantos C, Tsolias C, Theocharis G, Daikos GL, Ladas SD, Karamanolis DG, Mantzaris GJ. Predictors of tissue healing in ulcerative colitis patients treated with anti-TNF. Dig Liver Dis 2017;49:29-33. [PMID: 27866814 DOI: 10.1016/j.dld.2016.10.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
576 Fischer A, Zundler S, Atreya R, Rath T, Voskens C, Hirschmann S, López-Posadas R, Watson A, Becker C, Schuler G, Neufert C, Atreya I, Neurath MF. Differential effects of α4β7 and GPR15 on homing of effector and regulatory T cells from patients with UC to the inflamed gut in vivo. Gut 2016;65:1642-64. [PMID: 26209553 DOI: 10.1136/gutjnl-2015-310022] [Cited by in Crossref: 92] [Cited by in F6Publishing: 93] [Article Influence: 15.3] [Reference Citation Analysis]
577 McLean LP, Cross RK. Integrin antagonists as potential therapeutic options for the treatment of Crohn's disease. Expert Opin Investig Drugs 2016;25:263-73. [PMID: 26822204 DOI: 10.1517/13543784.2016.1148137] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
578 Delmas A, Oikonomopoulos A, Lacey PN, Fallahi M, Hommes DW, Sundrud MS. Informatics-Based Discovery of Disease-Associated Immune Profiles. PLoS One 2016;11:e0163305. [PMID: 27669154 DOI: 10.1371/journal.pone.0163305] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
579 Harper JW, Zisman TL. Interaction of obesity and inflammatory bowel disease. World J Gastroenterol 2016; 22(35): 7868-7881 [PMID: 27672284 DOI: 10.3748/wjg.v22.i35.7868] [Cited by in CrossRef: 88] [Cited by in F6Publishing: 75] [Article Influence: 14.7] [Reference Citation Analysis]
580 Lenz P, Brückner M, Ketelhut S, Heidemann J, Kemper B, Bettenworth D. Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing. J Vis Exp 2016. [PMID: 27685659 DOI: 10.3791/54460] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
581 Shelton E, Allegretti JR, Stevens B, Lucci M, Khalili H, Nguyen DD, Sauk J, Giallourakis C, Garber J, Hamilton MJ, Tomczak M, Makrauer F, Burakoff RB, Levine J, de Silva P, Friedman S, Ananthakrishnan A, Korzenik JR, Yajnik V. Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients: A Multicenter Cohort. Inflamm Bowel Dis. 2015;21:2879-2885. [PMID: 26288002 DOI: 10.1097/mib.0000000000000561] [Cited by in Crossref: 126] [Cited by in F6Publishing: 113] [Article Influence: 21.0] [Reference Citation Analysis]
582 Stansfield C. Considerations in the management of ulcerative colitis. Gastrointestinal Nursing 2016;14:42-50. [DOI: 10.12968/gasn.2016.14.7.42] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
583 Vuitton L, Marteau P, Sandborn WJ, Levesque BG, Feagan B, Vermeire S, Danese S, D'Haens G, Lowenberg M, Khanna R, Fiorino G, Travis S, Mary JY, Peyrin-Biroulet L. IOIBD technical review on endoscopic indices for Crohn's disease clinical trials. Gut 2016;65:1447-55. [PMID: 26353983 DOI: 10.1136/gutjnl-2015-309903] [Cited by in Crossref: 106] [Cited by in F6Publishing: 106] [Article Influence: 17.7] [Reference Citation Analysis]
584 Samaan MA, Pavlidis P, Johnston E, Warner B, Digby-Bell J, Koumoutsos I, Fong S, Goldberg R, Patel K, Gulati S. Vedolizumab: early experience and medium-term outcomes from two UK tertiary IBD centres. Frontline Gastroenterol. 2017;8:196-202. [PMID: 28839909 DOI: 10.1136/flgastro-2016-100720] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 4.7] [Reference Citation Analysis]
585 Dave M, Mehta K, Luther J, Baruah A, Dietz AB, Faubion WA. Mesenchymal Stem Cell Therapy for Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Inflamm Bowel Dis. 2015;21:2696-2707. [PMID: 26230863 DOI: 10.1097/mib.0000000000000543] [Cited by in Crossref: 64] [Cited by in F6Publishing: 57] [Article Influence: 10.7] [Reference Citation Analysis]
586 John ES, Katz K, Saxena M, Chokhavatia S, Katz S. Management of Inflammatory Bowel Disease in the Elderly. Curr Treat Options Gastroenterol. 2016;14:285-304. [PMID: 27387455 DOI: 10.1007/s11938-016-0099-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
587 Zhou F, Wu J. Progress in medical treatment of ulcerative colitis. Shijie Huaren Xiaohua Zazhi 2016; 24(20): 3149-3158 [DOI: 10.11569/wcjd.v24.i20.3149] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
588 Ket SN, Palmer R, Travis S. Endoscopic Disease Activity in Inflammatory Bowel Disease. Curr Gastroenterol Rep 2015;17:50. [PMID: 26650939 DOI: 10.1007/s11894-015-0470-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
589 Rivera-nieves J. Strategies that target leukocyte traffic in inflammatory bowel diseases: recent developments. Current Opinion in Gastroenterology 2015;31:441-8. [DOI: 10.1097/mog.0000000000000218] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 3.5] [Reference Citation Analysis]
590 Song YD, Liu SX, Zhong YQ. Biological agents for treatment of inflammatory bowel disease: Research progress and associated risks. Shijie Huaren Xiaohua Zazhi 2016; 24(19): 2964-2973 [DOI: 10.11569/wcjd.v24.i19.2964] [Reference Citation Analysis]
591 Iskandar HN, Dhere T, Farraye FA. Ulcerative Colitis: Update on Medical Management. Curr Gastroenterol Rep. 2015;17:44. [PMID: 26386686 DOI: 10.1007/s11894-015-0466-9] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 3.2] [Reference Citation Analysis]
592 Stansfield C. Inflammatory bowel disease: current challenges and advances in treatment. British Journal of Healthcare Management 2016;22:300-3. [DOI: 10.12968/bjhc.2016.22.6.300] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
593 Sandborn WJ, Bhandari BR, Fogel R, Onken J, Yen E, Zhao X, Jiang Z, Ge D, Xin Y, Ye Z, French D, Silverman JA, Kanwar B, Subramanian GM, McHutchison JG, Lee SD, Shackelton LM, Pai RK, Levesque BG, Feagan BG. Randomised clinical trial: a phase 1, dose-ranging study of the anti-matrix metalloproteinase-9 monoclonal antibody GS-5745 versus placebo for ulcerative colitis. Aliment Pharmacol Ther 2016;44:157-69. [PMID: 27218676 DOI: 10.1111/apt.13653] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 6.3] [Reference Citation Analysis]
594 Atreya R, Bloom S, Scaldaferri F, Gerardi V, Admyre C, Karlsson Å, Knittel T, Kowalski J, Lukas M, Löfberg R, Nancey S, Petryka R, Rydzewska G, Schnabel R, Seidler U, Neurath MF, Hawkey C. Clinical Effects of a Topically Applied Toll-like Receptor 9 Agonist in Active Moderate-to-Severe Ulcerative Colitis. J Crohns Colitis 2016;10:1294-302. [PMID: 27208386 DOI: 10.1093/ecco-jcc/jjw103] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 6.5] [Reference Citation Analysis]
595 Fiorino G, Gilardi D, Danese S. The clinical potential of etrolizumab in ulcerative colitis: hypes and hopes. Therap Adv Gastroenterol 2016;9:503-12. [PMID: 27366219 DOI: 10.1177/1756283X16647935] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
596 Christophi GP, Rengarajan A, Ciorba MA. Rectal budesonide and mesalamine formulations in active ulcerative proctosigmoiditis: efficacy, tolerance, and treatment approach. Clin Exp Gastroenterol 2016;9:125-30. [PMID: 27274301 DOI: 10.2147/CEG.S80237] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
597 Mosli MH, Al-Harbi O, Feagan BG, Almadi MA. A Saudi Gastroenterology association position statement on the use of tumor necrosis factor-alfa antagonists for the treatment of inflammatory bowel disease. Saudi J Gastroenterol. 2015;21:185-197. [PMID: 26228361 DOI: 10.4103/1319-3767.161635] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
598 Yokomizo L, Limketkai B, Park KT. Cost-effectiveness of adalimumab, infliximab or vedolizumab as first-line biological therapy in moderate-to-severe ulcerative colitis. BMJ Open Gastroenterol 2016;3:e000093. [PMID: 27195130 DOI: 10.1136/bmjgast-2016-000093] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 5.5] [Reference Citation Analysis]
599 Raad MA, Chams NH, Sharara AI. New and Evolving Immunotherapy in Inflammatory Bowel Disease. Inflamm Intest Dis. 2016;1:85-95. [PMID: 29922662 DOI: 10.1159/000445986] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
600 Chen F, Yan CK. Recent progress in drug therapy of ulcerative colitis. Shijie Huaren Xiaohua Zazhi 2016; 24(12): 1840-1845 [DOI: 10.11569/wcjd.v24.i12.1840] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
601 Gibson PR, Feagan BG, Sandborn WJ, Marano C, Strauss R, Johanns J, Padgett L, Collins J, Tarabar D, Hebzda Z, Rutgeerts P, Reinisch W. Maintenance of Efficacy and Continuing Safety of Golimumab for Active Ulcerative Colitis: PURSUIT-SC Maintenance Study Extension Through 1 Year. Clin Transl Gastroenterol 2016;7:e168. [PMID: 27124701 DOI: 10.1038/ctg.2016.24] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 4.5] [Reference Citation Analysis]
602 McLean LP, Cross RK. Pharmacodynamic assessment of vedolizumab for the treatment of ulcerative colitis. Expert Opin Drug Metab Toxicol 2016;12:833-42. [PMID: 27096357 DOI: 10.1080/17425255.2016.1181171] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
603 Sofia MA, Rubin DT. Current approaches for optimizing the benefit of biologic therapy in ulcerative colitis. Therap Adv Gastroenterol 2016;9:548-59. [PMID: 27366223 DOI: 10.1177/1756283X16643242] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
604 Kawashima K, Ishihara S, Yuki T, Fukuba N, Oshima N, Kazumori H, Sonoyama H, Yamashita N, Tada Y, Kusunoki R, Oka A, Mishima Y, Moriyama I, Kinoshita Y. Fecal calprotectin level correlated with both endoscopic severity and disease extent in ulcerative colitis. BMC Gastroenterol 2016;16:47. [PMID: 27071448 DOI: 10.1186/s12876-016-0462-z] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 3.7] [Reference Citation Analysis]
605 Jauregui-Amezaga A, Vermeire S, Prenen H. Use of biologics and chemotherapy in patients with inflammatory bowel diseases and cancer. Ann Gastroenterol 2016;29:127-36. [PMID: 27065724 DOI: 10.20524/aog.2016.0004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
606 Feuerstein JD, Akbari M, Tapper EB, Cheifetz AS. Systematic review and meta-analysis of third-line salvage therapy with infliximab or cyclosporine in severe ulcerative colitis. Ann Gastroenterol 2016;29:341-7. [PMID: 27366036 DOI: 10.20524/aog.2016.0032] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
607 Karuppuchamy T, Behrens EH, González-Cabrera P, Sarkisyan G, Gima L, Boyer JD, Bamias G, Jedlicka P, Veny M, Clark D, Peach R, Scott F, Rosen H, Rivera-Nieves J. Sphingosine-1-phosphate receptor-1 (S1P1) is expressed by lymphocytes, dendritic cells, and endothelium and modulated during inflammatory bowel disease. Mucosal Immunol 2017;10:162-71. [PMID: 27049060 DOI: 10.1038/mi.2016.35] [Cited by in Crossref: 50] [Cited by in F6Publishing: 59] [Article Influence: 8.3] [Reference Citation Analysis]
608 Ungar B, Kopylov U. Advances in the development of new biologics in inflammatory bowel disease. Ann Gastroenterol. 2016;29:243-248. [PMID: 27366024 DOI: 10.20524/aog.2016.0027] [Cited by in Crossref: 10] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
609 Singh H, Grewal N, Arora E, Kumar H, Kakkar AK. Vedolizumab: A novel anti-integrin drug for treatment of inflammatory bowel disease. J Nat Sci Biol Med 2016;7:4-9. [PMID: 27003961 DOI: 10.4103/0976-9668.175016] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
610 Grinspan A, Kornbluth A. Positioning Therapy for Ulcerative Colitis. Curr Gastroenterol Rep 2015;17:29. [PMID: 26143627 DOI: 10.1007/s11894-015-0454-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
611 Scott FI, Lichtenstein GR. Advances in Therapeutic Drug Monitoring of Biologic Therapies in Inflammatory Bowel Disease: 2015 in Review. Curr Treat Options Gastroenterol 2016;14:91-102. [PMID: 26847358 DOI: 10.1007/s11938-016-0085-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
612 Petkau JM, Eksteen B. Selective biologics for ulcerative colitis and Crohn's disease - clinical utility of vedolizumab. Biologics 2016;10:33-52. [PMID: 27022240 DOI: 10.2147/BTT.S71679] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
613 Sifuentes-Dominguez L, Patel AS. Genetics and Therapeutics in Pediatric Ulcerative Colitis: the Past, Present and Future. F1000Res 2016;5:F1000 Faculty Rev-240. [PMID: 26973787 DOI: 10.12688/f1000research.7440.1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
614 Rosen MJ, Dhawan A, Saeed SA. Inflammatory Bowel Disease in Children and Adolescents. JAMA Pediatr. 2015;169:1053-1060. [PMID: 26414706 DOI: 10.1001/jamapediatrics.2015.1982] [Cited by in Crossref: 192] [Cited by in F6Publishing: 231] [Article Influence: 32.0] [Reference Citation Analysis]
615 Cintolo M, Costantino G, Pallio S, Fries W. Mucosal healing in inflammatory bowel disease: Maintain or de-escalate therapy. World J Gastrointest Pathophysiol 2016; 7(1): 1-16 [PMID: 26909224 DOI: 10.4291/wjgp.v7.i1.1] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
616 Murdoch T, O'Donnell S, Silverberg MS, Panaccione R. Biomarkers as potential treatment targets in inflammatory bowel disease: A systematic review. Can J Gastroenterol Hepatol 2015;29:203-8. [PMID: 25965441 DOI: 10.1155/2015/389548] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
617 Shah ED, Siegel CA, Chong K, Melmed GY. Evaluating Study Withdrawal Among Biologics and Immunomodulators in Treating Ulcerative Colitis: A Meta-analysis of Controlled Clinical Trials. Inflamm Bowel Dis 2016;22:933-9. [PMID: 26818417 DOI: 10.1097/MIB.0000000000000680] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
618 Ley K, Rivera-Nieves J, Sandborn WJ, Shattil S. Integrin-based therapeutics: biological basis, clinical use and new drugs. Nat Rev Drug Discov 2016;15:173-83. [PMID: 26822833 DOI: 10.1038/nrd.2015.10] [Cited by in Crossref: 206] [Cited by in F6Publishing: 224] [Article Influence: 34.3] [Reference Citation Analysis]
619 Löwenberg M, D’Haens G. Next-Generation Therapeutics for IBD. Curr Gastroenterol Rep. 2015;17:21. [PMID: 26031830 DOI: 10.1007/s11894-015-0444-2] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 4.8] [Reference Citation Analysis]
620 Dignass A, Akbar A, Hart A, Subramanian S, Bommelaer G, Baumgart DC, Grimaud JC, Cadiot G, Makins R, Hoque S, Bouguen G, Bonaz B. Safety and Efficacy of Granulocyte/Monocyte Apheresis in Steroid-Dependent Active Ulcerative Colitis with Insufficient Response or Intolerance to Immunosuppressants and/or Biologics [the ART Trial]: 12-week Interim Results. J Crohns Colitis. 2016;10:812-820. [PMID: 26818659 DOI: 10.1093/ecco-jcc/jjw032] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
621 Goldberg R, Prescott N, Lord GM, MacDonald TT, Powell N. The unusual suspects--innate lymphoid cells as novel therapeutic targets in IBD. Nat Rev Gastroenterol Hepatol 2015;12:271-83. [PMID: 25971811 DOI: 10.1038/nrgastro.2015.52] [Cited by in Crossref: 63] [Cited by in F6Publishing: 60] [Article Influence: 10.5] [Reference Citation Analysis]
622 Wei X, Kenny JR, Dickmann L, Maciuca R, Looney C, Tang MT. Assessment of Disease-Related Therapeutic Protein Drug-Drug Interaction for Etrolizumab in Patients With Moderately to Severely Active Ulcerative Colitis. J Clin Pharmacol. 2016;56:693-704. [PMID: 26412221 DOI: 10.1002/jcph.649] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
623 Jairath V, Zou G, Parker CE, Macdonald JK, Mosli MH, Khanna R, Shackelton LM, Vandervoort MK, AlAmeel T, Al Beshir M. Systematic Review and Meta-analysis: Placebo Rates in Induction and Maintenance Trials of Ulcerative Colitis. J Crohns Colitis. 2016;10:607-618. [PMID: 26746169 DOI: 10.1093/ecco-jcc/jjw004] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
624 Sandborn WJ, Colombel JF, Ghosh S, Sands BE, Dryden G, Hébuterne X, Leong RW, Bressler B, Ullman T, Lakatos PL, Reinisch W, Xu LA, Luo A. Eldelumab [Anti-IP-10] Induction Therapy for Ulcerative Colitis: A Randomised, Placebo-Controlled, Phase 2b Study. J Crohns Colitis 2016;10:418-28. [PMID: 26721935 DOI: 10.1093/ecco-jcc/jjv224] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 4.4] [Reference Citation Analysis]
625 Ben-Horin S, Mao R, Chen M. Optimizing biologic treatment in IBD: objective measures, but when, how and how often? BMC Gastroenterol. 2015;15:178. [PMID: 26678147 DOI: 10.1186/s12876-015-0408-x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 27] [Article Influence: 3.1] [Reference Citation Analysis]
626 Dulai PS, Mosli M, Khanna R, Levesque BG, Sandborn WJ, Feagan BG. Vedolizumab for the treatment of moderately to severely active ulcerative colitis. Pharmacotherapy 2015;35:412-23. [PMID: 25884529 DOI: 10.1002/phar.1561] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
627 Vivio EE, Kanuri N, Gilbertsen JJ, Monroe K, Dey N, Chen CH, Gutierrez AM, Ciorba MA. Vedolizumab Effectiveness and Safety Over the First Year of Use in an IBD Clinical Practice. J Crohns Colitis. 2016;10:402-409. [PMID: 26681763 DOI: 10.1093/ecco-jcc/jjv226] [Cited by in Crossref: 68] [Cited by in F6Publishing: 64] [Article Influence: 9.7] [Reference Citation Analysis]
628 Chaparro M, Gisbert JP. [New molecules in the treatment of inflammatory bowel disease]. Gastroenterol Hepatol 2016;39:411-23. [PMID: 26631943 DOI: 10.1016/j.gastrohep.2015.09.017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
629 Hirten R, Sultan K, Thomas A, Bernstein DE. Hepatic manifestations of non-steroidal inflammatory bowel disease therapy. World J Hepatol 2015; 7(27): 2716-2728 [PMID: 26644815 DOI: 10.4254/wjh.v7.i27.2716] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
630 Quetglas EG, Mujagic Z, Wigge S, Keszthelyi D, Wachten S, Masclee A, Reinisch W. Update on pathogenesis and predictors of response of therapeutic strategies used in inflammatory bowel disease. World J Gastroenterol 2015; 21(44): 12519-12543 [PMID: 26640330 DOI: 10.3748/wjg.v21.i44.12519] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
631 Danese S, Grisham M, Hodge J, Telliez JB. JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines. Am J Physiol Gastrointest Liver Physiol. 2016;310:G155-G162. [PMID: 26608188 DOI: 10.1152/ajpgi.00311.2015] [Cited by in Crossref: 97] [Cited by in F6Publishing: 88] [Article Influence: 13.9] [Reference Citation Analysis]
632 Dalakas MC. Future perspectives in target-specific immunotherapies of myasthenia gravis. Ther Adv Neurol Disord 2015;8:316-27. [PMID: 26600875 DOI: 10.1177/1756285615605700] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
633 Zoet ID, de Boer NK, de Meij TG. Successful Vedolizumab Therapy in a Sixteen-Year-Old Boy with Refractory Ulcerative Colitis. J Crohns Colitis 2016;10:373-4. [PMID: 26574489 DOI: 10.1093/ecco-jcc/jjv205] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
634 Akiho H, Yokoyama A, Abe S, Nakazono Y, Murakami M, Otsuka Y, Fukawa K, Esaki M, Niina Y, Ogino H. Promising biological therapies for ulcerative colitis: A review of the literature. World J Gastrointest Pathophysiol 2015; 6(4): 219-227 [PMID: 26600980 DOI: 10.4291/wjgp.v6.i4.219] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 28] [Article Influence: 4.4] [Reference Citation Analysis]
635 Khan HM, Mehmood F, Khan N. Optimal management of steroid-dependent ulcerative colitis. Clin Exp Gastroenterol. 2015;8:293-302. [PMID: 26648749 DOI: 10.2147/ceg.s57248] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
636 Habtezion A, Nguyen LP, Hadeiba H, Butcher EC. Leukocyte Trafficking to the Small Intestine and Colon. Gastroenterology 2016;150:340-54. [PMID: 26551552 DOI: 10.1053/j.gastro.2015.10.046] [Cited by in Crossref: 149] [Cited by in F6Publishing: 167] [Article Influence: 21.3] [Reference Citation Analysis]
637 Gómez-Gómez GJ, Masedo &, Yela C, Martínez-Montiel MDP, Casís B. Current stage in inflammatory bowel disease: What is next? World J Gastroenterol 2015; 21(40): 11282-11303 [PMID: 26525013 DOI: 10.3748/wjg.v21.i40.11282] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
638 Cleynen I, Boucher G, Jostins L, Schumm LP, Zeissig S, Ahmad T, Andersen V, Andrews JM, Annese V, Brand S, Brant SR, Cho JH, Daly MJ, Dubinsky M, Duerr RH, Ferguson LR, Franke A, Gearry RB, Goyette P, Hakonarson H, Halfvarson J, Hov JR, Huang H, Kennedy NA, Kupcinskas L, Lawrance IC, Lee JC, Satsangi J, Schreiber S, Théâtre E, van der Meulen-de Jong AE, Weersma RK, Wilson DC, Parkes M, Vermeire S, Rioux JD, Mansfield J, Silverberg MS, Radford-Smith G, McGovern DP, Barrett JC, Lees CW; International Inflammatory Bowel Disease Genetics Consortium. Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study. Lancet 2016;387:156-67. [PMID: 26490195 DOI: 10.1016/S0140-6736(15)00465-1] [Cited by in Crossref: 394] [Cited by in F6Publishing: 384] [Article Influence: 56.3] [Reference Citation Analysis]
639 Schreiber S. [Anti-TNF biosimilars in chronic inflammatory bowel disease. What can rheumatologists learn from it?]. Z Rheumatol 2015;74:689-94. [PMID: 26450434 DOI: 10.1007/s00393-014-1488-7] [Reference Citation Analysis]
640 Lord J, Chen J, Thirlby RC, Sherwood AM, Carlson CS. T-cell receptor sequencing reveals the clonal diversity and overlap of colonic effector and FOXP3+ T cells in ulcerative colitis. Inflamm Bowel Dis 2015;21:19-30. [PMID: 25437819 DOI: 10.1097/MIB.0000000000000242] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
641 Leppkes M, Ganslmayer M, Strauß R, Neurath MF. [Toxic megacolon]. Med Klin Intensivmed Notfmed 2015;110:500-5. [PMID: 26369529 DOI: 10.1007/s00063-015-0076-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
642 Park SC, Jeen YT. Current and emerging biologics for ulcerative colitis. Gut Liver 2015;9:18-27. [PMID: 25547087 DOI: 10.5009/gnl14226] [Cited by in Crossref: 71] [Cited by in F6Publishing: 64] [Article Influence: 10.1] [Reference Citation Analysis]
643 Bamias G, Pizarro TT, Cominelli F. Pathway-based approaches to the treatment of inflammatory bowel disease. Transl Res 2016;167:104-15. [PMID: 26408803 DOI: 10.1016/j.trsl.2015.09.002] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
644 Cherry LN, Yunker NS, Lambert ER, Vaughan D, Lowe DK. Vedolizumab: an α4β7 integrin antagonist for ulcerative colitis and Crohn's disease. Ther Adv Chronic Dis 2015;6:224-33. [PMID: 26336591 DOI: 10.1177/2040622315586970] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
645 Hussein HA, Walker LR, Abdel-Raouf UM, Desouky SA, Montasser AK, Akula SM. Beyond RGD: virus interactions with integrins. Arch Virol 2015;160:2669-81. [PMID: 26321473 DOI: 10.1007/s00705-015-2579-8] [Cited by in Crossref: 65] [Cited by in F6Publishing: 88] [Article Influence: 9.3] [Reference Citation Analysis]
646 Kaplan GG. The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol. 2015;12:720-727. [PMID: 26323879 DOI: 10.1038/nrgastro.2015.150] [Cited by in Crossref: 1021] [Cited by in F6Publishing: 974] [Article Influence: 145.9] [Reference Citation Analysis]
647 Kothari M, Mudireddy P, Swaminath A. Patient considerations in the management of ulcerative colitis - role of vedolizumab. Ther Clin Risk Manag 2015;11:1235-42. [PMID: 26316768 DOI: 10.2147/TCRM.S65650] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
648 Peyrin-biroulet L, Sandborn W, Sands BE, Reinisch W, Bemelman W, Bryant RV, D'haens G, Dotan I, Dubinsky M, Feagan B, Fiorino G, Gearry R, Krishnareddy S, Lakatos PL, Loftus EV, Marteau P, Munkholm P, Murdoch TB, Ordás I, Panaccione R, Riddell RH, Ruel J, Rubin DT, Samaan M, Siegel CA, Silverberg MS, Stoker J, Schreiber S, Travis S, Van Assche G, Danese S, Panes J, Bouguen G, O'donnell S, Pariente B, Winer S, Hanauer S, Colombel J-. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. American Journal of Gastroenterology 2015;110:1324-38. [DOI: 10.1038/ajg.2015.233] [Cited by in Crossref: 937] [Cited by in F6Publishing: 993] [Article Influence: 133.9] [Reference Citation Analysis]
649 Martínez-Montiel MP, Casis-Herce B, Gómez-Gómez GJ, Masedo-González A, Yela-San Bernardino C, Piedracoba C, Castellano-Tortajada G. Pharmacologic therapy for inflammatory bowel disease refractory to steroids. Clin Exp Gastroenterol 2015;8:257-69. [PMID: 26316792 DOI: 10.2147/CEG.S58152] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
650 Tanida S, Mizoshita T, Ozeki K, Katano T, Kataoka H, Kamiya T, Joh T. Advances in refractory ulcerative colitis treatment: A new therapeutic target, Annexin A2. World J Gastroenterol 2015; 21(29): 8776-8786 [PMID: 26269667 DOI: 10.3748/wjg.v21.i29.8776] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
651 Bürger M, Schmidt C, Teich N, Stallmach A. Medical Therapy of Active Ulcerative Colitis. Viszeralmedizin 2015;31:236-45. [PMID: 26557831 DOI: 10.1159/000436959] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
652 de Mattos BR, Garcia MP, Nogueira JB, Paiatto LN, Albuquerque CG, Souza CL, Fernandes LG, Tamashiro WM, Simioni PU. Inflammatory Bowel Disease: An Overview of Immune Mechanisms and Biological Treatments. Mediators Inflamm. 2015;2015:493012. [PMID: 26339135 DOI: 10.1155/2015/493012] [Cited by in Crossref: 83] [Cited by in F6Publishing: 93] [Article Influence: 11.9] [Reference Citation Analysis]
653 Hamilton MJ, Frei SM, Stevens RL. The multifaceted mast cell in inflammatory bowel disease. Inflamm Bowel Dis. 2014;20:2364-2378. [PMID: 25401721 DOI: 10.1097/MIB.0000000000000142] [Cited by in Crossref: 43] [Cited by in F6Publishing: 45] [Article Influence: 6.1] [Reference Citation Analysis]
654 Hirsch A, Colman RJ, Lang GD, Rubin DT. Successful Treatment of Ulcerative Colitis With Vedolizumab in a Patient With an Infliximab-Associated Psoriasiform Rash. ACG Case Rep J 2015;2:236-8. [PMID: 26203450 DOI: 10.14309/crj.2015.70] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
655 Greuter T, Biedermann L, Rogler G, Sauter B, Seibold F. Alicaforsen, an antisense inhibitor of ICAM-1, as treatment for chronic refractory pouchitis after proctocolectomy: A case series. United European Gastroenterol J 2016;4:97-104. [PMID: 26966529 DOI: 10.1177/2050640615593681] [Cited by in Crossref: 40] [Cited by in F6Publishing: 28] [Article Influence: 5.7] [Reference Citation Analysis]
656 Łodyga M, Eder P, Bartnik W, Gonciarz M, Kłopocka M, Linke K, Małecka-Panas E, Radwan P, Rydzewska G. New pharmaceuticals in inflammatory bowel disease. Prz Gastroenterol 2015;10:57-60. [PMID: 26557934 DOI: 10.5114/pg.2015.52702] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
657 Bressler B, Panaccione R, Fedorak RN, Seidman EG. Clinicians’ guide to the use of fecal calprotectin to identify and monitor disease activity in inflammatory bowel disease. Can J Gastroenterol Hepatol. 2015;29:369-372. [PMID: 26125109 DOI: 10.1155/2015/852723] [Cited by in Crossref: 44] [Cited by in F6Publishing: 37] [Article Influence: 6.3] [Reference Citation Analysis]
658 Seo GS, Chae SC. Biological therapy for ulcerative colitis: An update. World J Gastroenterol. 2014;20:13234-13238. [PMID: 25309060 DOI: 10.3748/wjg.v20.i37] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
659 Poole RM. Vedolizumab: first global approval. Drugs 2014;74:1293-303. [PMID: 24985716 DOI: 10.1007/s40265-014-0253-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
660 Sheth T, Pitchumoni CS, Das KM. Management of Musculoskeletal Manifestations in Inflammatory Bowel Disease. Gastroenterol Res Pract. 2015;2015:387891. [PMID: 26170832 DOI: 10.1155/2015/387891] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
661 Taxonera C, Barreiro-de Acosta M, Calvo M, Saro C, Bastida G, Martín-Arranz MD, Gisbert JP, García-Sánchez V, Marín-Jiménez I, Bermejo F, Chaparro M, Ponferrada Á, Martínez-Montiel MP, Pajares R, de Gracia C, Olivares D, Alba C, Mendoza JL, Fernández-Blanco I. Infliximab Dose Escalation as an Effective Strategy for Managing Secondary Loss of Response in Ulcerative Colitis. Dig Dis Sci 2015;60:3075-84. [PMID: 26044830 DOI: 10.1007/s10620-015-3735-4] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
662 Tilg H, Kaser A. Failure of interleukin 13 blockade in ulcerative colitis. Gut 2015;64:857-8. [PMID: 25804632 DOI: 10.1136/gutjnl-2015-309464] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
663 Jin Y, Lin Y, Lin LJ, Zheng CQ. Meta-analysis of the effectiveness and safety of vedolizumab for ulcerative colitis. World J Gastroenterol 2015; 21(20): 6352-6360 [PMID: 26034371 DOI: 10.3748/wjg.v21.i20.6352] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
664 Quetglas EG, Armuzzi A, Wigge S, Fiorino G, Barnscheid L, Froelich M, Danese S. Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment. Eur J Clin Pharmacol 2015;71:773-99. [PMID: 26008212 DOI: 10.1007/s00228-015-1862-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
665 Mei WQ, Hu HZ, Liu Y, Li ZC, Wang WG. Infliximab is superior to other biological agents for treatment of active ulcerative colitis: A meta-analysis. World J Gastroenterol 2015; 21(19): 6044-6051 [PMID: 26019471 DOI: 10.3748/wjg.v21.i19.6044] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
666 Dulai PS, Levesque BG, Feagan BG, D'Haens G, Sandborn WJ. Assessment of mucosal healing in inflammatory bowel disease: review. Gastrointest Endosc 2015;82:246-55. [PMID: 26005012 DOI: 10.1016/j.gie.2015.03.1974] [Cited by in Crossref: 41] [Cited by in F6Publishing: 52] [Article Influence: 5.9] [Reference Citation Analysis]
667 Bellaguarda E, Keyashian K, Pekow J, Rubin DT, Cohen RD, Sakuraba A. Prevalence of Antibodies Against JC Virus in Patients With Refractory Crohn's Disease and Effects of Natalizumab Therapy. Clin Gastroenterol Hepatol 2015;13:1919-25. [PMID: 26001336 DOI: 10.1016/j.cgh.2015.05.022] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
668 Palmela C, Torres J, Cravo M. New Trends in Inflammatory Bowel Disease. GE Port J Gastroenterol 2015;22:103-11. [PMID: 28868386 DOI: 10.1016/j.jpge.2015.03.009] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
669 Steinmann S, Scheibe K, Erlenbach-Wuensch K, Neufert C, Schneider-Stock R. Death-associated protein kinase: A molecule with functional antagonistic duality and a potential role in inflammatory bowel disease (Review). Int J Oncol 2015;47:5-15. [PMID: 25963636 DOI: 10.3892/ijo.2015.2998] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
670 Plugis NM, Khosla C. Therapeutic approaches for celiac disease. Best Pract Res Clin Gastroenterol. 2015;29:503-521. [PMID: 26060114 DOI: 10.1016/j.bpg.2015.04.005] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
671 Lin L, Liu X, Wang D, Zheng C. Efficacy and safety of antiintegrin antibody for inflammatory bowel disease: a systematic review and meta-analysis. Medicine (Baltimore). 2015;94:e556. [PMID: 25761174 DOI: 10.1097/md.0000000000000556] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
672 Nalle SC, Turner JR. Intestinal barrier loss as a critical pathogenic link between inflammatory bowel disease and graft-versus-host disease. Mucosal Immunol 2015;8:720-30. [PMID: 25943273 DOI: 10.1038/mi.2015.40] [Cited by in Crossref: 71] [Cited by in F6Publishing: 75] [Article Influence: 10.1] [Reference Citation Analysis]
673 Monaco MC, Major EO. Immune System Involvement in the Pathogenesis of JC Virus Induced PML: What is Learned from Studies of Patients with Underlying Diseases and Therapies as Risk Factors. Front Immunol 2015;6:159. [PMID: 25972864 DOI: 10.3389/fimmu.2015.00159] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 4.3] [Reference Citation Analysis]
674 Wendt E, Keshav S. CCR9 antagonism: potential in the treatment of Inflammatory Bowel Disease. Clin Exp Gastroenterol 2015;8:119-30. [PMID: 25897254 DOI: 10.2147/CEG.S48305] [Cited by in Crossref: 8] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
675 Rothlin CV, Leighton JA, Ghosh S. Tyro3, Axl, and Mertk receptor signaling in inflammatory bowel disease and colitis-associated cancer. Inflamm Bowel Dis. 2014;20:1472-1480. [PMID: 24846720 DOI: 10.1097/mib.0000000000000050] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
676 Ananthakrishnan AN, Kane SV. The Toronto consensus guidelines for nonhospitalized ulcerative colitis: a welcome update but not the end of the story. Gastroenterology 2015;148:877-80. [PMID: 25805424 DOI: 10.1053/j.gastro.2015.03.025] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
677 Wang MC, Zhang LY, Han W, Shao Y, Chen M, Ni R, Wang GN, Wei FX, Zhang YW, Xu XD. PRISMA--efficacy and safety of vedolizumab for inflammatory bowel diseases: a systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2014;93:e326. [PMID: 25526490 DOI: 10.1097/md.0000000000000326] [Cited by in Crossref: 45] [Cited by in F6Publishing: 42] [Article Influence: 6.4] [Reference Citation Analysis]
678 Amiot A, Peyrin-Biroulet L. Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases. Therap Adv Gastroenterol. 2015;8:66-82. [PMID: 25729432 DOI: 10.1177/1756283x14558193] [Cited by in Crossref: 89] [Cited by in F6Publishing: 83] [Article Influence: 12.7] [Reference Citation Analysis]
679 Ho EY, Cominelli F, Katz J. Ulcerative Colitis: What is the Optimal Treatment Goal and How Do We Achieve It? Curr Treat Options Gastroenterol. 2015;13:130-142. [PMID: 25619458 DOI: 10.1007/s11938-014-0044-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
680 Ali AH, Carey EJ, Lindor KD. Current research on the treatment of primary sclerosing cholangitis. Intractable Rare Dis Res. 2015;4:1-6. [PMID: 25674381 DOI: 10.5582/irdr.2014.01018] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.1] [Reference Citation Analysis]
681 Brand S. Für jedes Stadium und Befallsmuster die passende Therapie wählen. MMW - Fortschritte der Medizin 2015;157:45-50. [DOI: 10.1007/s15006-015-2648-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
682 Danese S, Rudziński J, Brandt W, Dupas JL, Peyrin-Biroulet L, Bouhnik Y, Kleczkowski D, Uebel P, Lukas M, Knutsson M, Erlandsson F, Hansen MB, Keshav S. Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study. Gut 2015;64:243-9. [PMID: 25304132 DOI: 10.1136/gutjnl-2014-308004] [Cited by in Crossref: 107] [Cited by in F6Publishing: 105] [Article Influence: 15.3] [Reference Citation Analysis]
683 McNamee EN, Masterson JC, Veny M, Collins CB, Jedlicka P, Byrne FR, Ng GY, Rivera-Nieves J. Chemokine receptor CCR7 regulates the intestinal TH1/TH17/Treg balance during Crohn's-like murine ileitis. J Leukoc Biol. 2015;97:1011-1022. [PMID: 25637591 DOI: 10.1189/jlb.3hi0614-303r] [Cited by in Crossref: 31] [Cited by in F6Publishing: 39] [Article Influence: 4.4] [Reference Citation Analysis]
684 Sheridan C. First integrin inhibitor since Tysabri nears approval for IBD. Nat Biotechnol 2014;32:205-7. [PMID: 24727756 DOI: 10.1038/nbt0314-205] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
685 Park KT, Crandall WV, Fridge J, Leibowitz IH, Tsou M, Dykes DM, Hoffenberg EJ, Kappelman MD, Colletti RB. Implementable strategies and exploratory considerations to reduce costs associated with anti-TNF therapy in inflammatory bowel disease. Inflamm Bowel Dis 2014;20:946-51. [PMID: 24451222 DOI: 10.1097/01.MIB.0000441349.40193.aa] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
686 Wyant T, Yang L, Fedyk E. In vitro assessment of the effects of vedolizumab binding on peripheral blood lymphocytes. MAbs 2013;5:842-50. [PMID: 24492340 DOI: 10.4161/mabs.26392] [Cited by in Crossref: 37] [Cited by in F6Publishing: 43] [Article Influence: 5.3] [Reference Citation Analysis]
687 Jiang XL, Wang HH, Cui HF. Combined diosmectite and mesalazine treatment for mild-to-moderate ulcerative colitis: a randomized, placebo-controlled study. Med Sci Monit 2015;21:163-70. [PMID: 25582578 DOI: 10.12659/MSM.891400] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
688 Fausel R, Afzali A. Biologics in the management of ulcerative colitis - comparative safety and efficacy of TNF-α antagonists. Ther Clin Risk Manag 2015;11:63-73. [PMID: 25609972 DOI: 10.2147/TCRM.S55506] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
689 Eksteen B. Targeting of gut specific leucocyte recruitment in IBD by vedolizumab. Gut 2015;64:8-10. [PMID: 24946955 DOI: 10.1136/gutjnl-2014-307397] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
690 Wyant T, Leach T, Sankoh S, Wang Y, Paolino J, Pasetti MF, Feagan BG, Parikh A. Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results. Gut 2015;64:77-83. [PMID: 24763133 DOI: 10.1136/gutjnl-2014-307127] [Cited by in Crossref: 108] [Cited by in F6Publishing: 104] [Article Influence: 15.4] [Reference Citation Analysis]
691 Krupka N, Baumgart DC. Designing biologic selectivity for inflammatory bowel disease--role of vedolizumab. Drug Des Devel Ther. 2014;9:147-154. [PMID: 25552903 DOI: 10.2147/dddt.s50348] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
692 Bernstein CN. Treatment of IBD: where we are and where we are going. Am J Gastroenterol. 2015;110:114-126. [PMID: 25488896 DOI: 10.1038/ajg.2014.357] [Cited by in Crossref: 111] [Cited by in F6Publishing: 119] [Article Influence: 13.9] [Reference Citation Analysis]
693 Arseneau KO, Cominelli F. Targeting leukocyte trafficking for the treatment of inflammatory bowel disease. Clin Pharmacol Ther 2015;97:22-8. [PMID: 25670380 DOI: 10.1002/cpt.6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
694 Mosli M, Al Beshir M, Al-Judaibi B, Al-Ameel T, Saleem A, Bessissow T, Ghosh S, Almadi M. Advances in the diagnosis and management of inflammatory bowel disease: challenges and uncertainties. Saudi J Gastroenterol 2014;20:81-101. [PMID: 24705146 DOI: 10.4103/1319-3767.129473] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
695 Weintraub Y, Mimouni FB, Cohen S. Temporal trends in inflammatory bowel disease publications over a 19-years period. World J Gastroenterol 2014; 20(44): 16745-16749 [PMID: 25469047 DOI: 10.3748/wjg.v20.i44.16745] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
696 Byrareddy SN, Kallam B, Arthos J, Cicala C, Nawaz F, Hiatt J, Kersh EN, McNicholl JM, Hanson D, Reimann KA, Brameier M, Walter L, Rogers K, Mayne AE, Dunbar P, Villinger T, Little D, Parslow TG, Santangelo PJ, Villinger F, Fauci AS, Ansari AA. Targeting α4β7 integrin reduces mucosal transmission of simian immunodeficiency virus and protects gut-associated lymphoid tissue from infection. Nat Med 2014;20:1397-400. [PMID: 25419708 DOI: 10.1038/nm.3715] [Cited by in Crossref: 112] [Cited by in F6Publishing: 110] [Article Influence: 14.0] [Reference Citation Analysis]
697 Mitroulis I, Alexaki VI, Kourtzelis I, Ziogas A, Hajishengallis G, Chavakis T. Leukocyte integrins: role in leukocyte recruitment and as therapeutic targets in inflammatory disease. Pharmacol Ther 2015;147:123-35. [PMID: 25448040 DOI: 10.1016/j.pharmthera.2014.11.008] [Cited by in Crossref: 128] [Cited by in F6Publishing: 146] [Article Influence: 16.0] [Reference Citation Analysis]
698 Raine T. Vedolizumab for inflammatory bowel disease: Changing the game, or more of the same? United European Gastroenterol J 2014;2:333-44. [PMID: 25360311 DOI: 10.1177/2050640614550672] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
699 Arora Z, Shen B. Biological therapy for ulcerative colitis. Gastroenterol Rep (Oxf) 2015;3:103-9. [PMID: 25344680 DOI: 10.1093/gastro/gou070] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
700 Cheng FK, McLean LP, Cross RK. What is the role of vedolizumab in the era of anti-TNF agents? Ann Transl Med 2014;2:4. [PMID: 25332980 DOI: 10.3978/j.issn.2305-5839.2013.10.01] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
701 Seo GS, Chae SC. Biological therapy for ulcerative colitis: An update. World J Gastroenterol 2014; 20(37): 13234-13238 [PMID: 25309060 DOI: 10.3748/wjg.v20.i37.13234] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
702 Guerra I, Bermejo F. Management of inflammatory bowel disease in poor responders to infliximab. Clin Exp Gastroenterol 2014;7:359-67. [PMID: 25258548 DOI: 10.2147/CEG.S45297] [Cited by in Crossref: 7] [Cited by in F6Publishing: 18] [Article Influence: 0.9] [Reference Citation Analysis]
703 Kempster SL, Kaser A. α4β7 integrin: beyond T cell trafficking. Gut 2014;63:1377-9. [PMID: 24334217 DOI: 10.1136/gutjnl-2013-305967] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
704 Sarlos P, Kovesdi E, Magyari L, Banfai Z, Szabo A, Javorhazy A, Melegh B. Genetic update on inflammatory factors in ulcerative colitis: Review of the current literature. World J Gastrointest Pathophysiol 2014; 5(3): 304-321 [PMID: 25133031 DOI: 10.4291/wjgp.v5.i3.304] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
705 Aceituno M, Zabana Y, Esteve M. [Treatment of severe ulcerative colitis flares]. Gastroenterol Hepatol 2014;37:471-9. [PMID: 25015428 DOI: 10.1016/j.gastrohep.2014.05.005] [